BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W;  National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966. [PMID: 17452677 DOI: 10.1200/jco.2006.07.9525] [Cited by in Crossref: 2630] [Cited by in F6Publishing: 2897] [Article Influence: 164.4] [Reference Citation Analysis]
Number Citing Articles
1 Liu Q, Li S, Qiu Y, Zhang J, Rios FJ, Zou Z, Touyz RM. Cardiovascular toxicity of tyrosine kinase inhibitors during cancer treatment: Potential involvement of TRPM7. Front Cardiovasc Med 2023;10. [DOI: 10.3389/fcvm.2023.1002438] [Reference Citation Analysis]
2 Xu T, Schulga A, Konovalova E, Rinne SS, Zhang H, Vorontsova O, Orlova A, Deyev SM, Tolmachev V, Vorobyeva A. Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin–Toxin Fusion in a Pancreatic Cancer Xenograft Model. IJMS 2023;24:2838. [DOI: 10.3390/ijms24032838] [Reference Citation Analysis]
3 Chan Y, Tan H, Lu Y, Zhang C, Cheng C, Wu J, Wang N, Feng Y. Pancreatic melatonin enhances anti-tumor immunity in pancreatic adenocarcinoma through regulating tumor-associated neutrophils infiltration and NETosis. Acta Pharmaceutica Sinica B 2023. [DOI: 10.1016/j.apsb.2023.01.020] [Reference Citation Analysis]
4 Gordon ER, Wright CA, James M, Cooper SJ. Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance.. [DOI: 10.21203/rs.3.rs-2444404/v1] [Reference Citation Analysis]
5 Zhan G, Hu J, Da S, Weng J, Zhou C, Wen F, Liu S, Fang F, Shen E, Zhou Q, Luo P, Xu M, Zhan D, Su Y. A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer. Front Endocrinol (Lausanne) 2023;14:1110624. [PMID: 36742383 DOI: 10.3389/fendo.2023.1110624] [Reference Citation Analysis]
6 von den Driesch J, Flöttmann J, Prall F, Mullins CS, Linnebacher M, Bürtin F. HROP68: A rare case of medullary pancreatic cancer—characterization and chemosensitivity of the first patient-derived cell line. Front Oncol 2023;12. [DOI: 10.3389/fonc.2022.1082927] [Reference Citation Analysis]
7 Shaya J, Kato S, Adashek JJ, Patel H, Fanta PT, Botta GP, Sicklick JK, Kurzrock R. Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis. NPJ Genom Med 2023;8:1. [PMID: 36670111 DOI: 10.1038/s41525-022-00346-5] [Reference Citation Analysis]
8 Jenner AL, Kelly W, Dallaston M, Araujo R, Parfitt I, Steinitz D, Pooladvand P, Kim PS, Wade SJ, Vine KL. Examining the efficacy of localised gemcitabine therapy for the treatment of pancreatic cancer using a hybrid agent-based model. PLoS Comput Biol 2023;19:e1010104. [PMID: 36649330 DOI: 10.1371/journal.pcbi.1010104] [Reference Citation Analysis]
9 Arora S, Kumar R. FDA approved six-membered ring fused pyrimidine-based derivatives. Fused Pyrimidine-Based Drug Discovery 2023. [DOI: 10.1016/b978-0-443-18616-5.00011-9] [Reference Citation Analysis]
10 Javadi S, Fleming JB, Javle M, Lee JH, Bhosale PR. Cystic Pancreatic Lesions. Oncologic Imaging : a Multidisciplinary Approach 2023. [DOI: 10.1016/b978-0-323-69538-1.00013-6] [Reference Citation Analysis]
11 Jiang Y, Sohal DPS. Pancreatic Adenocarcinoma Management. JCO Oncol Pract 2023;19:19-32. [PMID: 36137253 DOI: 10.1200/OP.22.00328] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Hara K, Horikoshi Y, Morimoto M, Nakaso K, Sunaguchi T, Kurashiki T, Nakayama Y, Hanaki T, Yamamoto M, Sakamoto T, Fujiwara Y, Matsura T. TYRO3 promotes chemoresistance via increased LC3 expression in pancreatic cancer. Transl Oncol 2023;28:101608. [PMID: 36577166 DOI: 10.1016/j.tranon.2022.101608] [Reference Citation Analysis]
13 Yang J, Li Y, Han X, Pei X, Lin Z, Li C. The antitumor effect of the novel agent MCL/ACT001 in pancreatic ductal adenocarcinoma. J Cancer Res Clin Oncol 2022. [DOI: 10.1007/s00432-022-04542-9] [Reference Citation Analysis]
14 Hegewisch-becker S, Kratz-albers K, Wierecky J, Gerhardt S, Reschke D, Borchardt J, Reichelt R, Friedrich F. Current treatment landscape of pancreatic cancer patients in a network of office-based oncologists in Germany. Future Oncology 2022. [DOI: 10.2217/fon-2022-0141] [Reference Citation Analysis]
15 Ricci V, Fabozzi T, Bareschino MA, Barletta E, Germano D, Paciolla I, Tinessa V, Grimaldi AM. Pancreatic Cancer: Beyond Brca Mutations. J Pers Med 2022;12. [PMID: 36556296 DOI: 10.3390/jpm12122076] [Reference Citation Analysis]
16 Hosen SMZ, Uddin MN, Xu Z, Buckley BJ, Perera C, Pang TCY, Mekapogu AR, Moni MA, Notta F, Gallinger S, Pirola R, Wilson J, Ranson M, Goldstein D, Apte M. Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU). Front Immunol 2022;13:1060957. [PMID: 36591282 DOI: 10.3389/fimmu.2022.1060957] [Reference Citation Analysis]
17 Haensel D, Gaddam S, Li NY, Gonzalez F, Patel T, Cloutier JM, Sarin KY, Tang JY, Rieger KE, Aasi SZ, Oro AE. LY6D marks pre-existing resistant basosquamous tumor subpopulations. Nat Commun 2022;13:7520. [PMID: 36473848 DOI: 10.1038/s41467-022-35020-y] [Reference Citation Analysis]
18 Mugiyanto E, Adikusuma W, Irham LM, Huang W, Chang W, Kuo C. Integrated genomic analysis to identify druggable targets for pancreatic cancer. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.989077] [Reference Citation Analysis]
19 Arya JS, Joseph MM, Murali VP, Vidyalekshmi MS, Maiti KK. Targeted Delivery Polymeric Nanosystem Reinforced by Synergism of Embilin and RPI-1 for Therapeutics of Pancreatic Cancer. ACS Appl Nano Mater 2022. [DOI: 10.1021/acsanm.2c04400] [Reference Citation Analysis]
20 Nag S, Mandal A, Joshi A, Jain N, Srivastava RS, Singh S, Khattri A. Sialyltransferases and Neuraminidases: Potential Targets for Cancer Treatment. Diseases 2022;10. [PMID: 36547200 DOI: 10.3390/diseases10040114] [Reference Citation Analysis]
21 Nishiwada S, Shimura T, Yamamura K, Nakagawa K, Nagai M, Nakamura K, Terai T, Yamada S, Fujii T, Kodera Y, Sho M, Goel A. Clinical significance and functional role of adhesion G-protein-coupled receptors in human pancreatic ductal adenocarcinoma. Br J Cancer 2022. [DOI: 10.1038/s41416-022-02057-1] [Reference Citation Analysis]
22 Rémond MS, Pellat A, Brezault C, Dhooge M, Coriat R. Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma? ESMO Open 2022;7:100638. [PMID: 36399952 DOI: 10.1016/j.esmoop.2022.100638] [Reference Citation Analysis]
23 Gillies RJ, Ibrahim-hashim A, Ordway B, Gatenby RA. Back to basic: Trials and tribulations of alkalizing agents in cancer. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.981718] [Reference Citation Analysis]
24 Shi X, Wang M, Zhang Y, Guo X, Liu M, Zhou Z, Zhao Y, He R, Gao Y, Liu Y, Pan S, Zhou M, Zhao C, Yin T, Li X, Wang H, Yang J, Zhu F, Li M, Qin R. Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition. EBioMedicine 2022;86:104352. [PMID: 36371988 DOI: 10.1016/j.ebiom.2022.104352] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Zhang W, Zhang J, Liang X, Ding J. Research advances and treatment perspectives of pancreatic adenosquamous carcinoma. Cell Oncol 2022. [DOI: 10.1007/s13402-022-00732-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Elshami M, Ahmed FA, Kakish H, Hue JJ, Hoehn RS, Rothermel LD, Bajor D, Mohamed A, Selfridge JE, Ammori JB, Hardacre JM, Winter JM, Ocuin LM. Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenocarcinoma. HPB (Oxford) 2022;24:1878-87. [PMID: 35961931 DOI: 10.1016/j.hpb.2022.07.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
27 Seufferlein T, Mayerle J, Böck S, Brunner T, Ettrich TJ, Grenacher L, Gress TM, Hackert T, Heinemann V, Kestler A, Sinn M, Tannapfel A, Wedding U, Uhl W. S3-Leitlinie zum exokrinen Pankreaskarzinom – Langversion 2.0 – Dezember 2021 – AWMF-Registernummer: 032/010OL. Z Gastroenterol 2022;60:e812-909. [PMID: 36368658 DOI: 10.1055/a-1856-7346] [Reference Citation Analysis]
28 Ge X, Peng Y, Tu D. A generalized single‐index linear threshold model for identifying treatment‐sensitive subsets based on multiple covariates and longitudinal measurements. Can J Statistics. [DOI: 10.1002/cjs.11737] [Reference Citation Analysis]
29 Liu GH, Chen T, Zhang X, Ma XL, Shi HS. Small molecule inhibitors targeting the cancers. MedComm (2020) 2022;3:e181. [PMID: 36254250 DOI: 10.1002/mco2.181] [Reference Citation Analysis]
30 Li X, Jiang W, Dong S, Li W, Zhu W, Zhou W. STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer. Biomolecules 2022;12:1450. [PMID: 36291659 DOI: 10.3390/biom12101450] [Reference Citation Analysis]
31 Wu CP, Hsieh YJ, Tseng HY, Huang YH, Li YQ, Hung TH, Wang SP, Wu YS. The WD repeat-containing protein 5 (WDR5) antagonist WDR5-0103 restores the efficacy of cytotoxic drugs in multidrug-resistant cancer cells overexpressing ABCB1 or ABCG2. Biomed Pharmacother 2022;154:113663. [PMID: 36081287 DOI: 10.1016/j.biopha.2022.113663] [Reference Citation Analysis]
32 Yamakawa K, Koyanagi-aoi M, Machinaga A, Kakiuchi N, Hirano T, Kodama Y, Aoi T. Blockage of retinoic acid signaling via RARγ suppressed the proliferation of pancreatic cancer cells by arresting the cell cycle progression of the G1-S phase.. [DOI: 10.21203/rs.3.rs-2084078/v1] [Reference Citation Analysis]
33 . Pancreatic Cancer. Fundamentals of Cancer Detection, Treatment, and Prevention 2022. [DOI: 10.1002/9783527838561.ch15] [Reference Citation Analysis]
34 Yang J, Li Y, Han X, Pei X, Lin Z, Li C. The anti-tumor effect of a novel agent MCL/ACT001 in pancreatic ductal adenocarcinoma.. [DOI: 10.21203/rs.3.rs-2085698/v1] [Reference Citation Analysis]
35 Rehman M, Khaled A, Noel M. Cytotoxic Chemotherapy in Advanced Pancreatic Cancer. Hematol Oncol Clin North Am 2022:S0889-8588(22)00074-0. [PMID: 36154782 DOI: 10.1016/j.hoc.2022.07.006] [Reference Citation Analysis]
36 Maneenet J, Tawila AM, Omar AM, Phan ND, Ojima C, Kuroda M, Sato M, Mizoguchi M, Takahashi I, Awale S. Chemical Constituents of Callistemon subulatus and Their Anti-Pancreatic Cancer Activity against Human PANC-1 Cell Line. Plants 2022;11:2466. [DOI: 10.3390/plants11192466] [Reference Citation Analysis]
37 Liu T, Cheng S, Xu Q, Wang Z. Management of Advanced Pancreatic Cancer through Stromal Depletion and Immune Modulation. Medicina (Kaunas) 2022;58:1298. [PMID: 36143975 DOI: 10.3390/medicina58091298] [Reference Citation Analysis]
38 Hintzen G, Dulat HJ, Rajkovic E. Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling. Front Oncol 2022;12:892212. [DOI: 10.3389/fonc.2022.892212] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Turpin A, Neuzillet C, Colle E, Dusetti N, Nicolle R, Cros J, de Mestier L, Bachet JB, Hammel P. Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies. Ther Adv Med Oncol 2022;14:17588359221118019. [PMID: 36090800 DOI: 10.1177/17588359221118019] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Reddy AK, Scott JT, Joshua Stephens B, Patel A, Checketts JX, Stotler WM, Hawkins BJ, Vassar M. Evaluation of Proposed Protocol Changing Statistical Significance From 0.05 to 0.005 in Foot and Ankle Randomized Controlled Trials. J Foot Ankle Surg 2022;61:925-6. [PMID: 35367112 DOI: 10.1053/j.jfas.2022.03.005] [Reference Citation Analysis]
41 Lin Q, Shen S, Qian Z, Rasam SS, Serratore A, Jusko WJ, Kandel ES, Qu J, Straubinger RM. Comparative Proteomic Analysis Identifies Key Metabolic Regulators of Gemcitabine Resistance in Pancreatic Cancer. Mol Cell Proteomics 2022;21:100409. [PMID: 36084875 DOI: 10.1016/j.mcpro.2022.100409] [Reference Citation Analysis]
42 Capula M, Perán M, Xu G, Donati V, Yee D, Gregori A, Assaraf YG, Giovannetti E, Deng D. Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance. Drug Resist Updat 2022;64:100864. [PMID: 36115181 DOI: 10.1016/j.drup.2022.100864] [Reference Citation Analysis]
43 Zhang C, Atri P, Nallasamy P, Parte S, Rauth S, Nimmakayala RK, Marimuthu S, Chirravuri-venkata R, Bhatia R, Halder S, Shah A, Cox JL, Smith L, Kumar S, Foster JM, Kukreja R, Seshacharyulu P, Ponnusamy MP, Batra SK. Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215922] [Reference Citation Analysis]
44 Rudloff U. Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma. Expert Opin Emerg Drugs 2022;27:345-68. [PMID: 36250721 DOI: 10.1080/14728214.2022.2134346] [Reference Citation Analysis]
45 Song L, Xu C, Zhang T, Chen S, Shi Z, Hu S, Cheng B, Tong H, Wei G, Li X. Development and validation of a competing risk model for second primary pancreatic ductal adenocarcinoma: A population-based study. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.934148] [Reference Citation Analysis]
46 Striefler JK, Stieler JM, Neumann CCM, Geisel D, Ghadjar P, Sinn M, Malinka T, Pratschke J, Stintzing S, Oettle H, Riess H, Pelzer U. Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer-The CONKO-008 Phase I Investigation. J Clin Med 2022;11:4905. [PMID: 36013144 DOI: 10.3390/jcm11164905] [Reference Citation Analysis]
47 Cui J, Jiao F, Li Q, Wang Z, Fu D, Liang J, Liang H, Xia T, Zhang T, Zhang Y, Dai G, Zhang Z, Wang J, Bai Y, Bai Y, Bi F, Chen D, Cao D, Chen J, Fang W, Gao Y, Guo J, Hao J, Hua H, Huang X, Liu W, Liu X, Li D, Li J, Li E, Li Z, Pan H, Shen L, Sun Y, Tao M, Wang C, Wang F, Xiong J, Zhang T, Zhang X, Zhan X, Zheng L, Ren G, Zhang T, Zhou J, Ma Q, Qin S, Hao C, Wang L. Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer. Journal of the National Cancer Center 2022. [DOI: 10.1016/j.jncc.2022.08.006] [Reference Citation Analysis]
48 Thouvenin J, Van Marcke C, Decoster L, Raicevic G, Punie K, Vandenbulcke M, Salgado R, Van Valckenborgh E, Maes B, Joris S, Steichel DV, Vranken K, Jacobs S, Dedeurwaerdere F, Martens G, Devos H, Duhoux FP, Rasschaert M, Pauwels P, Geboes K, Collignon J, Tejpar S, Canon JL, Peeters M, Rutten A, Van de Mooter T, Vermeij J, Schrijvers D, Demey W, Lybaert W, Van Huysse J, Mebis J, Awada A, Claes KBM, Hebrant A, Van der Meulen J, Delafontaine B, Bempt IV, Maetens J, de Hemptinne M, Rottey S, Aftimos P, De Grève J. PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment. ESMO Open 2022;7:100524. [PMID: 35970014 DOI: 10.1016/j.esmoop.2022.100524] [Reference Citation Analysis]
49 Heinemann V, Boeck S, Westphalen CB. Therapie des metastasierten Pankreaskarzinoms. Innere Medizin 2022;63:851-862. [DOI: 10.1007/s00108-022-01334-8] [Reference Citation Analysis]
50 Xiao Y, Xu G, Cloyd JM, Du S, Mao Y, Pawlik TM. Predicting Novel Drug Candidates for Pancreatic Neuroendocrine Tumors via Gene Signature Comparison and Connectivity Mapping. J Gastrointest Surg 2022;26:1670-8. [PMID: 35508682 DOI: 10.1007/s11605-022-05337-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Gyawali B, Booth CM. Defining clinically important overall survival thresholds: lessons from quality of life. Nat Rev Clin Oncol 2022. [PMID: 35896739 DOI: 10.1038/s41571-022-00667-5] [Reference Citation Analysis]
52 Gupta P, Makkar TK, Goel L, Pahuja M. Role of inflammation and oxidative stress in chemotherapy-induced neurotoxicity. Immunol Res 2022. [PMID: 35859244 DOI: 10.1007/s12026-022-09307-7] [Reference Citation Analysis]
53 Lu S, Ke S, Wang C, Xu Y, Li Z, Song K, Bai M, Zhou M, Yu H, Yin B, Li X, Feng Z, Hua Y, Pan S, Jiang H, Li L, Wu Y, Ma Y. NNMT promotes the progression of intrahepatic cholangiocarcinoma by regulating aerobic glycolysis via the EGFR-STAT3 axis. Oncogenesis 2022;11:39. [PMID: 35851575 DOI: 10.1038/s41389-022-00415-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Wang X, Zhang CS, Dong XY, Hu Y, Duan BJ, Bai J, Wu YY, Fan L, Liao XH, Kang Y, Zhang P, Li MY, Xu J, Mao ZJ, Liu HT, Zhang XL, Tian LF, Li EX. Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma. World J Gastrointest Oncol 2022; 14(7): 1252-1264 [DOI: 10.4251/wjgo.v14.i7.1252] [Reference Citation Analysis]
55 Sorbara M, Cordelier P, Bery N. Antibody-Based Approaches to Target Pancreatic Tumours. Antibodies 2022;11:47. [DOI: 10.3390/antib11030047] [Reference Citation Analysis]
56 Kobayashi S, Ueno M, Ishii H, Furuse J. Management of elderly patients with unresectable pancreatic cancer. Jpn J Clin Oncol 2022:hyac101. [PMID: 35789391 DOI: 10.1093/jjco/hyac101] [Reference Citation Analysis]
57 Luo D, Liao S, Li Q, Lin Y, Wei J, Li Y, Liao X. Case Report: A Case of Locally Advanced Pancreatic Cancer Which Achieved Progression Free for Over 12 Months by Subsequent Therapy with Anlotinib Hydrochloride Plus Tegafur-Gimeracil-Oteracil Potassium (TS-1). Front Oncol 2022;12:862600. [DOI: 10.3389/fonc.2022.862600] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Casolino R, Corbo V, Beer P, Hwang C, Paiella S, Silvestri V, Ottini L, Biankin AV. Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care. Cancers 2022;14:3239. [DOI: 10.3390/cancers14133239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Mahmood T, Ved A, Siddiqui MH, Ahsan F, Shamim A, Ansari VA, Ahmad A, Kashyap MK. An in-Depth Analysis of Ovarian Cancer: Pathogenesis and Clinical Manifestation. Drug Res (Stuttg) 2022. [PMID: 35760337 DOI: 10.1055/a-1867-4654] [Reference Citation Analysis]
60 Midorikawa Y. Treatment of biliary tract carcinoma over the last 30 years. Biosci Trends 2022. [PMID: 35732436 DOI: 10.5582/bst.2022.01267] [Reference Citation Analysis]
61 Ulanja MB, Moody AE, Beutler BD, Antwi-Amoabeng D, Rahman GA, Alese OB. Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival. Oncotarget 2022;13:828-41. [PMID: 35720978 DOI: 10.18632/oncotarget.28242] [Reference Citation Analysis]
62 Liu Q, Song C, Li J, Liu M, Fu L, Jiang J, Zeng Z, Zhu H. E2F2 enhances the chemoresistance of pancreatic cancer to gemcitabine by regulating the cell cycle and upregulating the expression of RRM2. Med Oncol 2022;39:124. [PMID: 35716217 DOI: 10.1007/s12032-022-01715-x] [Reference Citation Analysis]
63 Mortazavi M, Moosavi F, Martini M, Giovannetti E, Firuzi O. Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer. Crit Rev Oncol Hematol 2022;:103749. [PMID: 35728737 DOI: 10.1016/j.critrevonc.2022.103749] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
64 Huff SE, Winter JM, Dealwis CG. Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present. Biomolecules 2022;12:815. [PMID: 35740940 DOI: 10.3390/biom12060815] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
65 Sun W, Zhang Y, Ren X, Cui L, Wang J, Ni X. In Silico Studies, Biological Activities, and Anti-human Pancreatic Cancer Potential of 6-Hydroxy-4-methylcoumarin and 2,5-Dihydroxyacetophenone as Flavonoid Compounds. J Oleo Sci 2022;71:853-61. [PMID: 35661067 DOI: 10.5650/jos.ess22021] [Reference Citation Analysis]
66 Lin H, Liang T, Chang Y, Liu D, Fan J, Roffler SR, Lin S. Development of Irinotecan Liposome Armed with Dual-Target Anti-Epidermal Growth Factor Receptor and Anti-Fibroblast Activation Protein-Specific Antibody for Pancreatic Cancer Treatment. Pharmaceutics 2022;14:1202. [DOI: 10.3390/pharmaceutics14061202] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Seufferlein T, Mayerle J, Böck S, Brunner T, Ettrich TJ, Grenacher L, Gress TM, Hackert T, Heinemann V, Kestler A, Sinn M, Tannapfel A, Wedding U, Uhl W. S3-Leitlinie zum exokrinen Pankreaskarzinom – Kurzversion 2.0 – Dezember 2021, AWMF-Registernummer: 032/010OL. Z Gastroenterol 2022;60:991-1037. [PMID: 35671996 DOI: 10.1055/a-1771-6811] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
68 Yamakawa K, Koyanagi-aoi M, Uehara K, Masuda A, Yanagimoto H, Toyama H, Fukumoto T, Kodama Y, Aoi T. Increased expression of SPRR1A is associated with a poor prognosis in pancreatic ductal adenocarcinoma. PLoS ONE 2022;17:e0266620. [DOI: 10.1371/journal.pone.0266620] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Chakrabarti S, Kamgar M, Mahipal A. Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities. Cancers (Basel) 2022;14:2588. [PMID: 35681565 DOI: 10.3390/cancers14112588] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
70 Tarannum M, Vivero-Escoto JL. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment. Adv Drug Deliv Rev 2022;187:114357. [PMID: 35605679 DOI: 10.1016/j.addr.2022.114357] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
71 Alausa A, Lawal KA, Babatunde OA, Obiwulu ENO, Oladokun OC, Fadahunsi OS, Celestine UO, Moses EU, Rejoice AI, Adegbola PI. Overcoming Immunotherapeutic Resistance in PDAC: SIRPα-CD47 blockade. Pharmacol Res 2022;:106264. [PMID: 35597384 DOI: 10.1016/j.phrs.2022.106264] [Reference Citation Analysis]
72 Koltai T, Reshkin SJ, Carvalho TMA, Di Molfetta D, Greco MR, Alfarouk KO, Cardone RA. Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review. Cancers (Basel) 2022;14:2486. [PMID: 35626089 DOI: 10.3390/cancers14102486] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
73 John S. Immunotherapy for patients with pancreatic adenocarcinoma. Onkologie 2022;16:127-129. [DOI: 10.36290/xon.2022.025] [Reference Citation Analysis]
74 He X, Hikiba Y, Suzuki Y, Nakamori Y, Kanemaru Y, Sugimori M, Sato T, Nozaki A, Chuma M, Maeda S. EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells. Sci Rep 2022;12:8007. [PMID: 35568782 DOI: 10.1038/s41598-022-12076-w] [Reference Citation Analysis]
75 Kim EY, Lee SH, Hong TH. Palliative laparoscopic Roux-en-Y choledochojejunostomy as a feasible treatment option for malignant distal biliary obstruction. Surg Today 2022. [PMID: 35536400 DOI: 10.1007/s00595-022-02513-8] [Reference Citation Analysis]
76 Zhu M, Zhou L, Hu S, Miao Q, Gong J, Zhang N, Zhang G, Wang M, Wang J, He H, Wang Y. Rational Design and Systemic Appraisal of an EGFR-Targeting Antibody-Drug Conjugate LR-DM1 for Pancreatic Cancer. J Med Chem 2022. [PMID: 35522590 DOI: 10.1021/acs.jmedchem.1c01920] [Reference Citation Analysis]
77 Principe DR, Aissa AF, Kumar S, Pham TND, Underwood PW, Nair R, Ke R, Rana B, Trevino JG, Munshi HG, Benevolenskaya EV, Rana A. Calcium channel blockers potentiate gemcitabine chemotherapy  in pancreatic cancer. Proc Natl Acad Sci U S A 2022;119:e2200143119. [PMID: 35476525 DOI: 10.1073/pnas.2200143119] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
78 Zhou T, Chen T, Lai B, Zhang W, Luo X, Xia D, Fu W, Xu J. FBXW2 inhibits prostate cancer proliferation and metastasis via promoting EGFR ubiquitylation and degradation. Cell Mol Life Sci 2022;79:268. [PMID: 35499593 DOI: 10.1007/s00018-022-04320-3] [Reference Citation Analysis]
79 Liermann J, Munter M, Naumann P, Abdollahi A, Krempien R, Debus J. Cetuximab, gemcitabine and radiotherapy in locally advanced pancreatic cancer: Long-term results of the randomized controlled phase II PARC trial. Clinical and Translational Radiation Oncology 2022;34:15-22. [DOI: 10.1016/j.ctro.2022.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
80 Neuenschwander B, Roychoudhury S, Wandel S, Natarajan K, Zuber E. The Predictive Individual Effect for Survival Data. Ther Innov Regul Sci 2022;56:492-500. [PMID: 35294767 DOI: 10.1007/s43441-022-00386-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Losurdo G, Gravina AG, Maroni L, Gabrieletto EM, Ianiro G, Ferrarese A; Young Investigator group of SIGE, the Italian Society of Gastroenterology. Future challenges in gastroenterology and hepatology, between innovations and unmet needs: A SIGE Young Editorial Board's perspective. Dig Liver Dis 2022;54:583-97. [PMID: 34509394 DOI: 10.1016/j.dld.2021.08.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Malvi D, Vasuri F, Maloberti T, Sanza V, De Leo A, Fornelli A, Masetti M, Benini C, Lombardi R, Offi MF, Di Marco M, Ravaioli M, Fiorino S, Franceschi E, Brandes AA, Jovine E, D’errico A, Tallini G, de Biase D. Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene Panel. Diagnostics 2022;12:1058. [DOI: 10.3390/diagnostics12051058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Jenner AL, Kelly W, Dallaston M, Araujo R, Parfitt I, Steinitz D, Pooladvand P, Kim PS, Wade SJ, Vine KL. Examining the efficacy of localised gemcitabine therapy for the treatment of pancreatic cancer using a hybrid agent-based model.. [DOI: 10.1101/2022.04.18.488716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Papadimitriou K, Kiss-Bodolay D, Hedjoudje A, Millan DS, Simonin A, Fournier JY, Huscher K. Late metachronous cerebral metastasis of pancreatic adenocarcinoma of the tail of the pancreas: a case report. J Med Case Rep 2022;16:144. [PMID: 35379334 DOI: 10.1186/s13256-022-03314-w] [Reference Citation Analysis]
85 Wei K, Zhu H, Qin G, Zhu Z, Tu D. Multiply robust subgroup analysis based on a single-index threshold linear marginal model for longitudinal data with dropouts. Stat Med 2022. [PMID: 35347738 DOI: 10.1002/sim.9386] [Reference Citation Analysis]
86 Selvanesan BC, Chandra D, Quispe-Tintaya W, Jahangir A, Patel A, Meena K, Alves Da Silva RA, Friedman M, Gabor L, Khouri O, Libutti SK, Yuan Z, Li J, Siddiqui S, Beck A, Tesfa L, Koba W, Chuy J, McAuliffe JC, Jafari R, Entenberg D, Wang Y, Condeelis J, DesMarais V, Balachandran V, Zhang X, Lin K, Gravekamp C. Listeria delivers tetanus toxoid protein to pancreatic tumors and induces cancer cell death in mice. Sci Transl Med 2022;14:eabc1600. [PMID: 35320003 DOI: 10.1126/scitranslmed.abc1600] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
87 Knoche SM, Larson AC, Brumfield GL, Cate S, Hildebrand WH, Solheim JC. Major histocompatibility complex class I molecule expression by pancreatic cancer cells is regulated by activation and inhibition of the epidermal growth factor receptor. Immunol Res 2022. [PMID: 35303241 DOI: 10.1007/s12026-022-09262-3] [Reference Citation Analysis]
88 Halfdanarson TR, Foster NR, Kim GP, Haddock MG, Dakhil SR, Behrens RJ, Alberts SR. N064A (Alliance): Phase II Study of Panitumumab, Chemotherapy, and External Beam Radiation in Patients with Locally Advanced Pancreatic Adenocarcinoma. Oncologist 2022;27:534-e546. [PMID: 35285484 DOI: 10.1093/oncolo/oyac002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Nisar M, Paracha RZ, Gul A, Arshad I, Ejaz S, Murad D, Khan S, Mustansar Z. Interaction Analysis of Adenovirus L5 Protein With Pancreatic Cancer Cell Surface Receptor to Analyze Its Affinity for Oncolytic Virus Therapy. Front Oncol 2022;12:832277. [DOI: 10.3389/fonc.2022.832277] [Reference Citation Analysis]
90 Zou N, Han A. Application of Pyrrolobenzodiazepines in Antibody Drug Conjugates. In: Huang X, Aslanian RG, Tang WH, editors. Contemporary Accounts in Drug Discovery and Development. Wiley; 2022. pp. 293-339. [DOI: 10.1002/9781119627784.ch13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Furukawa T. Genome analyses of pancreatic ductal adenocarcinoma: Current status and future perspectives. Journal of the Japan Pancreas Society 2022;37:40-46. [DOI: 10.2958/suizo.37.40] [Reference Citation Analysis]
92 Chitturi KR, Burns EA, Muhsen IN, Anand K, Trachtenberg BH. Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy. Curr Oncol Rep 2022. [PMID: 35192115 DOI: 10.1007/s11912-022-01215-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Khandakar GI, Satoh R, Takasaki T, Fujitani K, Tanabe G, Sakai K, Nishio K, Sugiura R. ACAGT-007a, an ERK MAPK Signaling Modulator, in Combination with AKT Signaling Inhibition Induces Apoptosis in KRAS Mutant Pancreatic Cancer T3M4 and MIA-Pa-Ca-2 Cells. Cells 2022;11:702. [DOI: 10.3390/cells11040702] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Robatel S, Schenk M. Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment. Cancers 2022;14:985. [DOI: 10.3390/cancers14040985] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
95 Tang H, Xue Y, Li B, Xu X, Zhang F, Guo J, Li Q, Yuan T, Chen Y, Pan Y, Ping Y, Li D. Membrane-camouflaged supramolecular nanoparticles for co-delivery of chemotherapeutic and molecular-targeted drugs with siRNA against patient-derived pancreatic carcinoma. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.02.007] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
96 Hirt CK, Booij TH, Grob L, Simmler P, Toussaint NC, Keller D, Taube D, Ludwig V, Goryachkin A, Pauli C, Lenggenhager D, Stekhoven DJ, Stirnimann CU, Endhardt K, Ringnalda F, Villiger L, Siebenhüner A, Karkampouna S, De Menna M, Beshay J, Klett H, Kruithof-de Julio M, Schüler J, Schwank G. Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label therapy. Cell Genomics 2022;2:100095. [DOI: 10.1016/j.xgen.2022.100095] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
97 Ando T, Sakumura M, Mihara H, Fujinami H, Yasuda I. A Review of Potential Role of Capsule Endoscopy in the Work-Up for Chemotherapy-Induced Diarrhea. Healthcare 2022;10:218. [DOI: 10.3390/healthcare10020218] [Reference Citation Analysis]
98 Sinha S, Vegesna R, Dhruba SR, Wu W, Kerr DL, Stroganov OV, Grishagin I, Aldape KD, Blakely CM, Jiang P, Thomas CJ, Bivona TG, Schäffer AA, Ruppin E. Predicting patient treatment response and resistance via single-cell transcriptomics of their tumors.. [DOI: 10.1101/2022.01.11.475728] [Reference Citation Analysis]
99 Wooten DJ, Sinha I, Sinha R. Selenium Induces Pancreatic Cancer Cell Death Alone and in Combination with Gemcitabine. Biomedicines 2022;10:149. [DOI: 10.3390/biomedicines10010149] [Reference Citation Analysis]
100 Takumoto Y, Sasahara Y, Narimatsu H, Akazawa M. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis. JAMA Netw Open 2022;5:e2145515. [PMID: 35099549 DOI: 10.1001/jamanetworkopen.2021.45515] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
101 Sturm N, Ettrich TJ, Perkhofer L. The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy. Cancers (Basel) 2022;14:217. [PMID: 35008381 DOI: 10.3390/cancers14010217] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
102 Leung D, Khushman M, Junck L. Neurological complications of GI cancers. Neurological Complications of Systemic Cancer and Antineoplastic Therapy 2022. [DOI: 10.1016/b978-0-12-821976-8.00006-2] [Reference Citation Analysis]
103 Liang H, Williamson S. Nonsurgical Management of Pancreatic Adenocarcinoma. Hepato-Pancreato-Biliary Malignancies 2022. [DOI: 10.1007/978-3-030-41683-6_31] [Reference Citation Analysis]
104 Aguilar-company J, Ruiz-camps I. Cell-Surface Receptors: EGFR- and VEGFR-Targeted Agents. Infectious Complications in Biologic and Targeted Therapies 2022. [DOI: 10.1007/978-3-031-11363-5_8] [Reference Citation Analysis]
105 Yamada Y, Sasaki T, Takeda T, Okamoto T, Takamatsu M, Mori C, Mie T, Furukawa T, Kasuga A, Matsuyama M, Ozaka M, Igarashi Y, Sasahira N. A Case of Multiple Gastric Metastases after Distal Pancreatectomy for Pancreatic Cancer. Intern Med . [DOI: 10.2169/internalmedicine.8848-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Lee HS, Park SW, Song SY. Chemotherapy in Pancreatic Ductal Adenocarcinoma. The IASGO Textbook of Multi-Disciplinary Management of Hepato-Pancreato-Biliary Diseases 2022. [DOI: 10.1007/978-981-19-0063-1_20] [Reference Citation Analysis]
107 Mizrahi JD, Wolff RA. Management of Locally Advanced/Metastatic Disease: Medical Oncology. Pancreatic Cancer: A Multidisciplinary Approach 2022. [DOI: 10.1007/978-3-031-05724-3_9] [Reference Citation Analysis]
108 Thunshelle CP, Koay EJ, Hill C, Alfano CM, Herman JM. Patient Reported Outcomes and Quality of Life. Pancreatic Cancer: A Multidisciplinary Approach 2022. [DOI: 10.1007/978-3-031-05724-3_28] [Reference Citation Analysis]
109 Dane F, Demircan NC. Systemic Therapies for Pancreatic Cancer. The IASGO Textbook of Multi-Disciplinary Management of Hepato-Pancreato-Biliary Diseases 2022. [DOI: 10.1007/978-981-19-0063-1_23] [Reference Citation Analysis]
110 Domadia K, Goel V, Koyyala VPB, Patnaik N, Chaudhari K, Raina S, Doval DC, Talwar V. Study of Gemcitabine Plus Nab-Paclitaxel-Based Chemotherapy Regimen as First-Line Treatment in Metastatic Pancreatic Carcinoma. South Asian J Cancer. [DOI: 10.1055/s-0041-1735956] [Reference Citation Analysis]
111 Lundy J, Harris M, Zalcberg J, Zimet A, Goldstein D, Gebski V, Borsaru A, Desmond C, Swan M, Jenkins BJ, Croagh D. EUS-FNA Biopsies to Guide Precision Medicine in Pancreatic Cancer: Results of a Pilot Study to Identify KRAS Wild-Type Tumours for Targeted Therapy. Front Oncol 2021;11:770022. [PMID: 34956889 DOI: 10.3389/fonc.2021.770022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
112 Caglevic C, Mahave M, Sanhueza C, Ubillos L. Current Systemic Treatment Options for Metastatic and Unresectable Pancreatic Cancer. Challenges in Pancreatic Cancer 2021. [DOI: 10.5772/intechopen.93225] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
113 Mulder J, van Rossum T, Mariz S, Magrelli A, de Boer A, Pasmooij AMG, Stoyanova-beninska V. Orphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan Designation. Front Oncol 2021;11. [DOI: 10.3389/fonc.2021.809035] [Reference Citation Analysis]
114 Nussinov R, Tsai CJ, Jang H. Anticancer drug resistance: An update and perspective. Drug Resist Updat 2021;:100796. [PMID: 34953682 DOI: 10.1016/j.drup.2021.100796] [Cited by in Crossref: 24] [Cited by in F6Publishing: 31] [Article Influence: 12.0] [Reference Citation Analysis]
115 Cura Daball P, Tröger H, Daum S. [Long-term response in advanced pancreatic adenocarcinoma - a case report and literature review]. Z Gastroenterol 2021. [PMID: 34905798 DOI: 10.1055/a-1695-3528] [Reference Citation Analysis]
116 Lin L, Miao L, Lin H, Cheng J, Li M, Zhuo Z, He J. Targeting RAS in neuroblastoma: Is it possible? Pharmacol Ther 2021;236:108054. [PMID: 34915055 DOI: 10.1016/j.pharmthera.2021.108054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
117 van Roey R, Brabletz T, Stemmler MP, Armstark I. Deregulation of Transcription Factor Networks Driving Cell Plasticity and Metastasis in Pancreatic Cancer. Front Cell Dev Biol 2021;9:753456. [PMID: 34888306 DOI: 10.3389/fcell.2021.753456] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
118 Poels TT, Vuijk FA, de Geus-Oei LF, Vahrmeijer AL, Oprea-Lager DE, Swijnenburg RJ. Molecular Targeted Positron Emission Tomography Imaging and Radionuclide Therapy of Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;13:6164. [PMID: 34944781 DOI: 10.3390/cancers13246164] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
119 Scirocco E, Cellini F, Zamagni A, Macchia G, Deodato F, Cilla S, Strigari L, Buwenge M, Rizzo S, Cammelli S, Morganti AG. Clinical Studies on Ultrafractionated Chemoradiation: A Systematic Review. Front Oncol 2021;11:748200. [PMID: 34868948 DOI: 10.3389/fonc.2021.748200] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
120 Barros AG, Pulido CF, Machado M, Brito MJ, Couto N, Sousa O, Melo SA, Mansinho H. Treatment optimization of locally advanced and metastatic pancreatic cancer (Review). Int J Oncol 2021;59:110. [PMID: 34859257 DOI: 10.3892/ijo.2021.5290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
121 Ouyang G, Wu Y, Liu Z, Lu W, Li S, Hao S, Pan G. Efficacy and safety of gemcitabine-capecitabine combination therapy for pancreatic cancer. Medicine 2021;100:e27870. [DOI: 10.1097/md.0000000000027870] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
122 Wenning AS, Ryser CO, Andreou A, Gloor B, Berger MD. Neues zur Therapie des Pankreaskarzinoms: Hoffnung am Horizont? Schweiz Gastroenterol 2021;2:138-147. [DOI: 10.1007/s43472-021-00054-y] [Reference Citation Analysis]
123 Raufi AG, Liguori NR, Carlsen L, Parker C, Hernandez Borrero L, Zhang S, Tian X, Louie A, Zhou L, Seyhan AA, El-deiry WS. Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma. Front Pharmacol 2021;12:751568. [DOI: 10.3389/fphar.2021.751568] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
124 Chiu TJ, Su YY, Yang SH, Li CP, Bai LY, Chiang NJ, Chuang SC, Shan YS, Chan DC, Chen LT, Yen CJ, Peng CM, Chen YY, Chen JS, Chou WC. Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study. Ther Adv Med Oncol 2021;13:17588359211058255. [PMID: 34819998 DOI: 10.1177/17588359211058255] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
125 Sankarasubramanian S, Pfohl U, Regenbrecht CRA, Reinhard C, Wedeken L. Context Matters-Why We Need to Change From a One Size Fits all Approach to Made-to-Measure Therapies for Individual Patients With Pancreatic Cancer. Front Cell Dev Biol 2021;9:760705. [PMID: 34805167 DOI: 10.3389/fcell.2021.760705] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
126 Schnog JB, Samson MJ, Gans ROB, Duits AJ. An urgent call to raise the bar in oncology. Br J Cancer 2021;125:1477-85. [PMID: 34400802 DOI: 10.1038/s41416-021-01495-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
127 Connor AA, Gallinger S. Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data. Nat Rev Cancer 2021. [PMID: 34789870 DOI: 10.1038/s41568-021-00418-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
128 Miquel M, Zhang S, Pilarsky C. Pre-clinical Models of Metastasis in Pancreatic Cancer. Front Cell Dev Biol 2021;9:748631. [PMID: 34778259 DOI: 10.3389/fcell.2021.748631] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
129 Słotwiński R, Lech G, Słotwińska SM. Molecular aspects of pancreatic cancer: focus on reprogrammed metabolism in a nutrient-deficient environment and potential therapeutic targets. Cent Eur J Immunol 2021;46:258-63. [PMID: 34764796 DOI: 10.5114/ceji.2021.107027] [Reference Citation Analysis]
130 Liu D, Sharbeen G, Phillips P, Ford CE; Australian Pancreatic Cancer Genome Initiative. ROR1 and ROR2 expression in pancreatic cancer. BMC Cancer 2021;21:1199. [PMID: 34763666 DOI: 10.1186/s12885-021-08952-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
131 Huang X, Li M, Hou S, Tian B. Role of the microbiome in systemic therapy for pancreatic ductal adenocarcinoma (Review). Int J Oncol 2021;59:101. [PMID: 34738624 DOI: 10.3892/ijo.2021.5281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
132 Kang BW, Chau I. Emerging agents for metastatic pancreatic cancer: spotlight on early phase clinical trials. Expert Opin Investig Drugs 2021;:1-19. [PMID: 34727804 DOI: 10.1080/13543784.2021.1995354] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
133 Alausa A, Victor UC, Celestine UO, Eweje IA, Balogun TA, Adeyemi R, Olatinwo M, Ogunlana AT, Oladipo O, Olaleke B. Phytochemical based sestrin2 pharmacological modulators in the treatment of adenocarcinomas. Phytomedicine Plus 2021;1:100133. [DOI: 10.1016/j.phyplu.2021.100133] [Reference Citation Analysis]
134 Wenzel P, von Figura G. Diagnostik und Therapie des Pankreaskarzinoms. Onkologische Welt 2021;12:265-271. [DOI: 10.1055/a-1641-5787] [Reference Citation Analysis]
135 Wenzel P, von Figura G. Diagnostik und Therapie des Pankreaskarzinoms. TumorDiagnostik & Therapie 2021;42:655-661. [DOI: 10.1055/a-1631-6377] [Reference Citation Analysis]
136 Hu HF, Ye Z, Qin Y, Xu XW, Yu XJ, Zhuo QF, Ji SR. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. Acta Pharmacol Sin 2021;42:1725-41. [PMID: 33574569 DOI: 10.1038/s41401-020-00584-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
137 Kordbacheh F, Farah CS. Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma. Cancers (Basel) 2021;13:5471. [PMID: 34771633 DOI: 10.3390/cancers13215471] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
138 Carter CJ, Mekkawy AH, Morris DL. Role of human nucleoside transporters in pancreatic cancer and chemoresistance. World J Gastroenterol 2021; 27(40): 6844-6860 [PMID: 34790010 DOI: 10.3748/wjg.v27.i40.6844] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
139 Wang G, Yang L, Gao J, Mu H, Song Y, Jiang X, Chen B, Cui R. Identification of Candidate Biomarker ASXL2 and Its Predictive Value in Pancreatic Carcinoma. Front Oncol 2021;11:736694. [PMID: 34692512 DOI: 10.3389/fonc.2021.736694] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
140 Jain A, Bhardwaj V. Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities. World J Gastroenterol 2021; 27(39): 6527-6550 [PMID: 34754151 DOI: 10.3748/wjg.v27.i39.6527] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
141 Ettrich TJ, Seufferlein T. Systemic Therapy for Metastatic Pancreatic Cancer. Curr Treat Options Oncol 2021;22:106. [PMID: 34665339 DOI: 10.1007/s11864-021-00895-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
142 Vasyuk YA, Gendlin GE, Emelina EI, Shupenina EY, Ballyuzek MF, Barinova IV, Vitsenya MV, Davydkin IL, Dundua DP, Duplyakov DV, Zateishchikov DA, Zolotovskaya IA, Konradi AO, Lopatin YM, Moiseeva OM, Nedogoda SV, Nedoshivin AO, Nikitin IG, Poltavskaya MG, Potievskaya VI, Repin AN, Sumin АN, Zotova LA, Tumyan GS, Shlyakhto EV, Khatkov IE, Yakushin SS, Belenkov YN. Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. Russ J Cardiol 2021;26:4703. [DOI: 10.15829/1560-4071-2021-4703] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
143 Zhang X, Zhu H, Qu X, Yu Z, Zhang J. Suppressing LncRNA HOXA-AS3 by CRISPR-dCas9 inhibits pancreatic cancer development. J Cancer 2021;12:6439-44. [PMID: 34659534 DOI: 10.7150/jca.62631] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
144 Jiang Y, Zeng Z, Zeng J, Liu C, Qiu J, Li Y, Tang J, Mo N, Du L, Ma J. Efficacy and Safety of First-Line Chemotherapies for Patients With Advanced Biliary Tract Carcinoma: A Systematic Review and Network Meta-Analysis. Front Oncol 2021;11:736113. [PMID: 34650920 DOI: 10.3389/fonc.2021.736113] [Reference Citation Analysis]
145 Narita Y, Muragaki Y, Kagawa N, Asai K, Nagane M, Matsuda M, Ueki K, Kuroda J, Date I, Kobayashi H, Kumabe T, Beppu T, Kanamori M, Kasai S, Nishimura Y, Xiong H, Ocampo C, Yamada M, Mishima K. Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial. Cancer Sci 2021;112:5020-33. [PMID: 34609773 DOI: 10.1111/cas.15153] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
146 Schlick K, Kiem D, Greil R. Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy-A Review of the Literature. Biomolecules 2021;11:1469. [PMID: 34680101 DOI: 10.3390/biom11101469] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
147 Low RRJ, Lim WW, Nguyen PM, Lee B, Christie M, Burgess AW, Gibbs P, Grimmond SM, Hollande F, Putoczki TL. The Diverse Applications of Pancreatic Ductal Adenocarcinoma Organoids. Cancers (Basel) 2021;13:4979. [PMID: 34638463 DOI: 10.3390/cancers13194979] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
148 Tang D, Kroemer G, Kang R. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges. Mol Cancer 2021;20:128. [PMID: 34607583 DOI: 10.1186/s12943-021-01422-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
149 Sakai Y, Sugiyama H, Kawaguchi Y, Kawashima Y, Hirata N, Nakaji S, Natsui M, Shioji K, Nakahara K, Tsuyuguchi T, Kato N. Uncovered versus covered metallic stents for the management of unresectable malignant distal biliary obstruction: a randomized multicenter trial. Scand J Gastroenterol 2021;56:1229-35. [PMID: 34375164 DOI: 10.1080/00365521.2021.1938207] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
150 Pook H, Pauklin S. Mechanisms of Cancer Cell Death: Therapeutic Implications for Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;13:4834. [PMID: 34638318 DOI: 10.3390/cancers13194834] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
151 Blomstrand H, Batra A, Cheung WY, Elander NO. Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer. World J Clin Oncol 2021; 12(9): 787-799 [PMID: 34631442 DOI: 10.5306/wjco.v12.i9.787] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
152 Xu H, Chen R, Shen Q, Yang D, Peng H, Tong J, Fu Q. Overexpression of Circular RNA circ_0013587 Reverses Erlotinib Resistance in Pancreatic Cancer Cells Through Regulating the miR-1227/E-Cadherin Pathway. Front Oncol 2021;11:754146. [PMID: 34552882 DOI: 10.3389/fonc.2021.754146] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
153 KalantarMotamedi Y, Choi RJ, Koh SB, Bramhall JL, Fan TP, Bender A. Prediction and identification of synergistic compound combinations against pancreatic cancer cells. iScience 2021;24:103080. [PMID: 34585118 DOI: 10.1016/j.isci.2021.103080] [Reference Citation Analysis]
154 Bittoni A, Giampieri R, Pecci F, Pinterpe G, Mandolesi A, Del Prete M, Zizzi A, Crocetti S, Liguori C, Mentrasti G, Cantini L, Pellei C, Bisonni R, Scarpelli M, Berardi R. Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients. Curr Oncol 2021;28:3525-36. [PMID: 34590611 DOI: 10.3390/curroncol28050303] [Reference Citation Analysis]
155 Reese M, Dhayat SA. Small extracellular vesicle non-coding RNAs in pancreatic cancer: molecular mechanisms and clinical implications. J Hematol Oncol 2021;14:141. [PMID: 34496946 DOI: 10.1186/s13045-021-01149-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
156 Pappalardo A, Giunta EF, Tirino G, Pompella L, Federico P, Daniele B, De Vita F, Petrillo A. Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting. Front Oncol 2021;11:695627. [PMID: 34485130 DOI: 10.3389/fonc.2021.695627] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
157 Applications of Constrained Helices. Cyclized Helical Peptides 2021. [DOI: 10.1002/9783527343430.ch4] [Reference Citation Analysis]
158 Go SI, Lee SC, Bae WK, Zang DY, Lee HW, Jang JS, Ji JH, Kim JH, Park S, Sym SJ, Yang Y, Jeon SY, Hwang IG, Oh SY, Kang JH. Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3). Eur J Cancer 2021;157:21-30. [PMID: 34464782 DOI: 10.1016/j.ejca.2021.08.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
159 Mahajan UM, Li Q, Alnatsha A, Maas J, Orth M, Maier SH, Peterhansl J, Regel I, Sendler M, Wagh PR, Mishra N, Xue Y, Allawadhi P, Beyer G, Kühn JP, Marshall T, Appel B, Lämmerhirt F, Belka C, Müller S, Weiss FU, Lauber K, Lerch MM, Mayerle J. Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models. Gastroenterology 2021;161:996-1010.e1. [PMID: 34097885 DOI: 10.1053/j.gastro.2021.05.055] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
160 Wu CP, Li YQ, Chi YC, Huang YH, Hung TH, Wu YS. The Second-Generation PIM Kinase Inhibitor TP-3654 Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs. Int J Mol Sci 2021;22:9440. [PMID: 34502348 DOI: 10.3390/ijms22179440] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
161 Shiozaki A, Konishi T, Kosuga T, Kudou M, Kurashima K, Inoue H, Shoda K, Arita T, Konishi H, Morimura R, Komatsu S, Ikoma H, Toma A, Kubota T, Fujiwara H, Okamoto K, Otsuji E. Roles of voltage‑gated potassium channels in the maintenance of pancreatic cancer stem cells. Int J Oncol 2021;59:76. [PMID: 34414448 DOI: 10.3892/ijo.2021.5256] [Reference Citation Analysis]
162 Dujardin P, Baginska AK, Urban S, Grüner BM. Unraveling Tumor Heterogeneity by Using DNA Barcoding Technologies to Develop Personalized Treatment Strategies in Advanced-Stage PDAC. Cancers (Basel) 2021;13:4187. [PMID: 34439341 DOI: 10.3390/cancers13164187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
163 Oar A, Lee M, Le H, Wilson K, Aiken C, Chantrill L, Simes J, Nguyen N, Barbour A, Samra J, Sjoquist KM, Moore A, Espinoza D, Gebski V, Yip S, Chu J, Kneebone A, Goldstein D. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. BMC Cancer 2021;21:936. [PMID: 34412605 DOI: 10.1186/s12885-021-08666-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
164 Vucetic M, Daher B, Cassim S, Parks S, Pouyssegur J. Overcoming Therapeutic Challenges for Pancreatic Ductal Adenocarcinoma with xCT Inhibitors. Adv Exp Med Biol 2021;1301:7-24. [PMID: 34370285 DOI: 10.1007/978-3-030-62026-4_2] [Reference Citation Analysis]
165 Fujii H, Koda M, Sadaka S, Ohata K, Kato-Hayashi H, Iihara H, Kobayashi R, Ishihara T, Uemura S, Iwashita T, Hayashi H, Sugiyama T, Shimizu M, Suzuki A. Anorexia, pain and peripheral neuropathy are associated with a decrease in quality of life in patients with advanced pancreatic cancer receiving outpatient chemotherapy - a retrospective observational study. J Pharm Health Care Sci 2021;7:27. [PMID: 34334136 DOI: 10.1186/s40780-021-00210-1] [Reference Citation Analysis]
166 Tewari M, Swain JR, Mahendran R. Update on Management Periampullary/Pancreatic Head Cancer. Indian J Surg 2021;83:654-664. [DOI: 10.1007/s12262-019-02053-5] [Reference Citation Analysis]
167 Takeda T, Sasaki T, Mie T, Furukawa T, Yamada Y, Kasuga A, Matsuyama M, Ozaka M, Sasahira N. Improved prognosis of pancreatic cancer patients with peritoneal metastasis. Pancreatology 2021;21:903-11. [PMID: 33766484 DOI: 10.1016/j.pan.2021.03.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
168 Yang HH, Liu JW, Lee JH, Harn HJ, Chiou TW. Pancreatic Adenocarcinoma Therapeutics Targeting RTK and TGF Beta Receptor. Int J Mol Sci 2021;22:8125. [PMID: 34360896 DOI: 10.3390/ijms22158125] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
169 Lim SH, Yun J, Lee MY, Kim HJ, Kim KH, Kim SH, Lee SC, Bae SB, Kim CK, Lee N, Lee KT, Park SK, Lee YN, Moon JH. Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial. Yonsei Med J 2021;62:671-8. [PMID: 34296544 DOI: 10.3349/ymj.2021.62.8.671] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
170 Chen K, Zhang Y, Qian L, Wang P. Emerging strategies to target RAS signaling in human cancer therapy. J Hematol Oncol 2021;14:116. [PMID: 34301278 DOI: 10.1186/s13045-021-01127-w] [Cited by in Crossref: 23] [Cited by in F6Publishing: 31] [Article Influence: 11.5] [Reference Citation Analysis]
171 Gopal S, Kwon SJ, Ku B, Lee DW, Kim J, Dordick JS. 3D tumor spheroid microarray for high-throughput, high-content natural killer cell-mediated cytotoxicity. Commun Biol 2021;4:893. [PMID: 34290356 DOI: 10.1038/s42003-021-02417-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
172 Wu CP, Murakami M, Wu YS, Chi YC, Hsiao SH, Huang YH, Hung TH, Ambudkar SV. Branebrutinib (BMS-986195), a Bruton's Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents. Front Cell Dev Biol 2021;9:699571. [PMID: 34350184 DOI: 10.3389/fcell.2021.699571] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
173 Islam MM, Goertzen A, Singh PK, Saha R. Exploring the metabolic landscape of pancreatic ductal adenocarcinoma cells using genome-scale metabolic modeling.. [DOI: 10.1101/2021.07.14.452356] [Reference Citation Analysis]
174 Di Federico A, Tateo V, Parisi C, Formica F, Carloni R, Frega G, Rizzo A, Ricci D, Di Marco M, Palloni A, Brandi G. Hacking Pancreatic Cancer: Present and Future of Personalized Medicine. Pharmaceuticals (Basel) 2021;14:677. [PMID: 34358103 DOI: 10.3390/ph14070677] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
175 Principe DR, Underwood PW, Korc M, Trevino JG, Munshi HG, Rana A. The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. Front Oncol 2021;11:688377. [PMID: 34336673 DOI: 10.3389/fonc.2021.688377] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
176 Peng X, Chen L, Jiao Y, Wang Y, Hao Z, Zhan X. Application of natural killer cells in pancreatic cancer. Oncol Lett 2021;22:647. [PMID: 34386069 DOI: 10.3892/ol.2021.12908] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
177 Lellouche L, Palmieri LJ, Dermine S, Brezault C, Chaussade S, Coriat R. Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives. Ther Adv Med Oncol 2021;13:17588359211018539. [PMID: 34285720 DOI: 10.1177/17588359211018539] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
178 Trunk A, Miotke L, Nevala-Plagemann C, Verdaguer H, Macarulla T, Garrido-Laguna I. Emerging Treatment Strategies in Pancreatic Cancer. Pancreas 2021;50:773-87. [PMID: 34398070 DOI: 10.1097/MPA.0000000000001845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
179 Imaoka H, Sasaki M, Hashimoto Y, Watanabe K, Miyazawa S, Shibuki T, Mitsunaga S, Ikeda M. Impact of Endoscopic Ultrasound-Guided Tissue Acquisition on Decision-Making in Precision Medicine for Pancreatic Cancer: Beyond Diagnosis. Diagnostics (Basel) 2021;11:1195. [PMID: 34209310 DOI: 10.3390/diagnostics11071195] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
180 Gupta VK, Banerjee S, Saluja AK. New Pharmacological Approaches for Pancreatic Cancer Therapy. Clinical Pancreatology for Practising Gastroenterologists and Surgeons 2021. [DOI: 10.1002/9781119570097.ch69] [Reference Citation Analysis]
181 Fuentes R, Serrano JJ, Rodríguez M, Carrato A. Chemotherapy for Nonresectable Pancreatic Cancer. Clinical Pancreatology for Practising Gastroenterologists and Surgeons 2021. [DOI: 10.1002/9781119570097.ch65] [Reference Citation Analysis]
182 Cai H, Chen Y, Xu L, Zou Y, Zhou X, Liang G, Wang D, Tao Z. Differently PEGylated Polymer Nanoparticles for Pancreatic Cancer Delivery: Using a Novel Near-Infrared Emissive and Biodegradable Polymer as the Fluorescence Tracer. Front Bioeng Biotechnol 2021;9:699610. [PMID: 34268300 DOI: 10.3389/fbioe.2021.699610] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
183 Yokoyama T. Current Status of Treatment for Pancreatic Cancer in Japan and Prospects for the Future. Nihon Ika Daigaku Igakkai Zasshi 2021;17:98-107. [DOI: 10.1272/manms.17.98] [Reference Citation Analysis]
184 Davis HW, Kaynak A, Vallabhapurapu SD, Qi X. Targeting of elevated cell surface phosphatidylserine with saposin C-dioleoylphosphatidylserine nanodrug as individual or combination therapy for pancreatic cancer. World J Gastrointest Oncol 2021; 13(6): 550-559 [PMID: 34163572 DOI: 10.4251/wjgo.v13.i6.550] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
185 Montemagno C, Cassim S, De Leiris N, Durivault J, Faraggi M, Pagès G. Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine? Int J Mol Sci 2021;22:6413. [PMID: 34203923 DOI: 10.3390/ijms22126413] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
186 Xelwa N, Candy GP, Devar J, Omoshoro-Jones J, Smith M, Nweke EE. Targeting Growth Factor Signaling Pathways in Pancreatic Cancer: Towards Inhibiting Chemoresistance. Front Oncol 2021;11:683788. [PMID: 34195085 DOI: 10.3389/fonc.2021.683788] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
187 Wishart G, Gupta P, Nisbet A, Velliou E, Schettino G. Novel Anticancer and Treatment Sensitizing Compounds against Pancreatic Cancer. Cancers (Basel) 2021;13:2940. [PMID: 34208295 DOI: 10.3390/cancers13122940] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
188 Cui J, Yang H, Liu J, Chen D, Hu J, Zhang H, Wang Y, Han T, Mao T, Jiao F, Biskup E, Pan Y, Liu M, Wang L. A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma. BMC Cancer 2021;21:672. [PMID: 34098895 DOI: 10.1186/s12885-021-08375-6] [Reference Citation Analysis]
189 Vidovic D, Simms GA, Pasternak S, Walsh M, Peltekian K, Stein J, Helyer LK, Giacomantonio CA. Case Report: Combined Intra-Lesional IL-2 and Topical Imiquimod Safely and Effectively Clears Multi-Focal, High Grade Cutaneous Squamous Cell Cancer in a Combined Liver and Kidney Transplant Patient. Front Immunol 2021;12:678028. [PMID: 34122442 DOI: 10.3389/fimmu.2021.678028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
190 Ji X, Zhao Y, He C, Han S, Zhu X, Shen Z, Chen C, Chu X. Clinical Effects of Stereotactic Body Radiation Therapy Targeting the Primary Tumor of Liver-Only Oligometastatic Pancreatic Cancer. Front Oncol 2021;11:659987. [PMID: 34123818 DOI: 10.3389/fonc.2021.659987] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
191 Muyinda IJ, Park JG, Jang EJ, Yoo BC. KRAS, A Prime Mediator in Pancreatic Lipid Synthesis through Extra Mitochondrial Glutamine and Citrate Metabolism. Int J Mol Sci 2021;22:5070. [PMID: 34064761 DOI: 10.3390/ijms22105070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
192 Kemski S, Molitor V, Steffens M, Nümm TJ, Herrmann N, Hornung T, Bieber T, Schumann C, Kächele V, Seufferlein T, Heinemann V, Scholl C, Stingl JC. Association between miRNA signatures in serum samples from epidermal growth factor inhibitor treated patients and skin toxicity. Oncotarget 2021;12:982-95. [PMID: 34012511 DOI: 10.18632/oncotarget.27953] [Reference Citation Analysis]
193 Cherri S, Noventa S, Zaniboni A. Pancreatic adenocarcinoma: Beyond first line, where are we? World J Gastroenterol 2021; 27(17): 1847-1863 [PMID: 34007126 DOI: 10.3748/wjg.v27.i17.1847] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
194 Heinemann V, Westphalen CB, Böck S. Systemische Therapie des duktalen Pankreaskarzinoms. InFo Hämatol Onkol 2021;24:37-47. [DOI: 10.1007/s15004-021-8653-3] [Reference Citation Analysis]
195 Park JK, Lee JH, Noh DH, Park JK, Lee KT, Lee JK, Lee KH, Jang KT, Cho J. Factors of Endoscopic Ultrasound-Guided Tissue Acquisition for Successful Next-Generation Sequencing in Pancreatic Ductal Adenocarcinoma. Gut Liver 2020;14:387-94. [PMID: 31581388 DOI: 10.5009/gnl19011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
196 Ren H, Mai G, Liu Y, Xiang R, Yang C, Su W. Eukaryotic Translation Initiation Factor 3 Subunit B Is a Promoter in the Development and Progression of Pancreatic Cancer. Front Oncol 2021;11:644156. [PMID: 33996561 DOI: 10.3389/fonc.2021.644156] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
197 Lin H, Hu C, Zheng S, Zhang X, Chen R, Zhou Q. A novel gene signature for prognosis prediction and chemotherapy response in patients with pancreatic cancer. Aging (Albany NY) 2021;13:12493-513. [PMID: 33901011 DOI: 10.18632/aging.202922] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
198 Zdrazil B, Ecker GF. Cancer Drug Resistance – Targets and Therapies. Burger's Medicinal Chemistry and Drug Discovery 2021. [DOI: 10.1002/0471266949.bmc215.pub2] [Reference Citation Analysis]
199 Alzhrani R, Alsaab HO, Vanamal K, Bhise K, Tatiparti K, Barari A, Sau S, Iyer AK. Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes. Adv Ther (Weinh) 2021;4:2000262. [PMID: 34212073 DOI: 10.1002/adtp.202000262] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
200 Rabia E, Garambois V, Hubert J, Bruciamacchie M, Pirot N, Delpech H, Broyon M, Theillet C, Colombo PE, Vie N, Tosi D, Gongora C, Khellaf L, Jarlier M, Radosevic-Robin N, Chardès T, Pèlegrin A, Larbouret C. Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models. MAbs 2021;13:1914883. [PMID: 33876707 DOI: 10.1080/19420862.2021.1914883] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
201 Rossi G, Simoni N, Paiella S, Rossi R, Venezia M, Micera R, Malleo G, Salvia R, Giuliani T, Di Gioia A, Auriemma A, Milella M, Guariglia S, Cavedon C, Bassi C, Mazzarotto R. Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer. Front Oncol 2021;11:662205. [PMID: 33959509 DOI: 10.3389/fonc.2021.662205] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
202 Sun J, Chen L, Dong M. MiR-338-5p Inhibits EGF-Induced EMT in Pancreatic Cancer Cells by Targeting EGFR/ERK Signaling. Front Oncol 2021;11:616481. [PMID: 33937024 DOI: 10.3389/fonc.2021.616481] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
203 Du J, Gu J, Li J. Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels. Biosci Rep 2020;40:BSR20200401. [PMID: 32677676 DOI: 10.1042/BSR20200401] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
204 Mancinelli G, Torres C, Krett N, Bauer J, Castellanos K, McKinney R, Dawson D, Guzman G, Hwang R, Grimaldo S, Grippo P, Jung B. Role of stromal activin A in human pancreatic cancer and metastasis in mice. Sci Rep 2021;11:7986. [PMID: 33846512 DOI: 10.1038/s41598-021-87213-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
205 Arias-Pinilla GA, Modjtahedi H. Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities. Cancers (Basel) 2021;13:1781. [PMID: 33917882 DOI: 10.3390/cancers13081781] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
206 Elsayed M, Abdelrahim M. The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies. Biomedicines 2021;9:389. [PMID: 33917380 DOI: 10.3390/biomedicines9040389] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
207 Puri A, Chang J, Tanner N, Lucente P, Desiongco J, Dragovich T, Naraev B, Kundranda M. Skeletal metastases in advanced pancreatic ductal adenocarcinoma: a retrospective analysis. J Gastrointest Oncol 2021;12:455-63. [PMID: 34012639 DOI: 10.21037/jgo-20-361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
208 Kasi A, McGinnis T, Naik G, Handa S, Williams G, Paluri R. Efficacy and tolerability of the combination of nano-liposomal irinotecan and 5-fluorouracil/leucovorin in advanced pancreatic adenocarcinoma: post-approval clinic experience. J Gastrointest Oncol 2021;12:464-73. [PMID: 34012640 DOI: 10.21037/jgo-20-338] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
209 Wu CP, Hung TH, Lusvarghi S, Chu YH, Hsiao SH, Huang YH, Chang YT, Ambudkar SV. The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. Biochem Pharmacol 2021;188:114516. [PMID: 33713643 DOI: 10.1016/j.bcp.2021.114516] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
210 Wishart G, Gupta P, Schettino G, Nisbet A, Velliou E. 3d tissue models as tools for radiotherapy screening for pancreatic cancer. Br J Radiol 2021;94:20201397. [PMID: 33684308 DOI: 10.1259/bjr.20201397] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
211 Kim ST, Hong JY, Lee J, Park JO, Lim HY, Kang WK, Park YS. Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study. Target Oncol 2020;15:67-73. [PMID: 31820199 DOI: 10.1007/s11523-019-00691-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
212 Perkhofer L, Gout J, Roger E, Kude de Almeida F, Baptista Simões C, Wiesmüller L, Seufferlein T, Kleger A. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. Gut 2021;70:606-17. [PMID: 32855305 DOI: 10.1136/gutjnl-2019-319984] [Cited by in Crossref: 67] [Cited by in F6Publishing: 67] [Article Influence: 33.5] [Reference Citation Analysis]
213 Purohit D, Pandey P. Role of Erlotinib in Influencing the Quality of Life of Cancer Patients. CCAND 2021;8:1-9. [DOI: 10.2174/2212697x07999200820162006] [Reference Citation Analysis]
214 Hamada T, Nakai Y, Isayama H, Koike K. Antireflux metal stent for biliary obstruction: Any benefits? Dig Endosc 2021;33:310-20. [PMID: 32250476 DOI: 10.1111/den.13679] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
215 Uwagawa T, Sakamoto T, Yasuda J, Shiozaki H, Furukawa K, Onda S, Gocho T, Shiba H, Yanaga K. Phase II Study of Adjuvant Chemotherapy With Gemcitabine and Nafamostat Mesilate for Pancreatic Cancer. Pancreas 2021;50:313-6. [PMID: 33835961 DOI: 10.1097/MPA.0000000000001767] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
216 Busch E, Werft W, Bougatf N, Hackert T, Jäger D, Springfeld C, Berger AK. Metastatic Acinar Cell Carcinoma of the Pancreas: A Retrospective Cohort Study on Systemic Chemotherapy and Review of the Literature. Pancreas 2021;50:300-5. [PMID: 33835959 DOI: 10.1097/MPA.0000000000001765] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
217 Yamamoto T, Satoi S, Yamaki S, Hashimoto D, Sakaguchi T, Hirooka S, Sekimoto M. Adjuvant therapy for patients with resectable pancreatic ductal adenocarcinoma. Journal of the Japan Pancreas Society 2021;36:12-19. [DOI: 10.2958/suizo.36.12] [Reference Citation Analysis]
218 Okada Y, Takahashi N, Takayama T, Goel A. LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma. Carcinogenesis 2021;42:546-56. [PMID: 33624791 DOI: 10.1093/carcin/bgab011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
219 Luo J. KRAS mutation in pancreatic cancer. Semin Oncol 2021:S0093-7754(21)00008-7. [PMID: 33676749 DOI: 10.1053/j.seminoncol.2021.02.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
220 Wenzel P, von Figura G. [Diagnostics and therapy of pancreatic carcinoma]. Dtsch Med Wochenschr 2021;146:246-52. [PMID: 33592660 DOI: 10.1055/a-1221-7306] [Reference Citation Analysis]
221 Zheng-Lin B, O'Reilly EM. Pancreatic ductal adenocarcinoma in the era of precision medicine. Semin Oncol 2021:S0093-7754(21)00005-1. [PMID: 33637355 DOI: 10.1053/j.seminoncol.2021.01.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
222 Reißig T, Siveke J. Duktales Adenokarzinom des Pankreas – Entstehung, Diagnostik, Therapie. Gastroenterologe 2021;16:41-50. [DOI: 10.1007/s11377-020-00493-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
223 Samatiwat P, Tabtimmai L, Suphakun P, Jiwacharoenchai N, Toviwek B, Kukongviriyapan V, Gleeson MP, Choowongkomon K. The Effect of the EGFR - Targeting Compound 3-[(4-Phenylpyrimidin-2-yl) Amino] Benzene-1-Sulfonamide (13f) against Cholangiocarcinoma Cell Lines. Asian Pac J Cancer Prev 2021;22:381-90. [PMID: 33639651 DOI: 10.31557/APJCP.2021.22.2.381] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
224 Zhang X, Detering L, Sultan D, Luehmann H, Li L, Heo GS, Zhang X, Lou L, Grierson PM, Greco S, Ruzinova M, Laforest R, Dehdashti F, Lim KH, Liu Y. CC Chemokine Receptor 2-Targeting Copper Nanoparticles for Positron Emission Tomography-Guided Delivery of Gemcitabine for Pancreatic Ductal Adenocarcinoma. ACS Nano 2021;15:1186-98. [PMID: 33406361 DOI: 10.1021/acsnano.0c08185] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
225 He X, Sun Y, Fan R, Sun J, Zou D, Yuan Y. Knockdown of the DJ-1 (PARK7) gene sensitizes pancreatic cancer to erlotinib inhibition. Mol Ther Oncolytics 2021;20:364-72. [PMID: 33614917 DOI: 10.1016/j.omto.2021.01.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
226 Otsuka T, Shirakawa T, Shimokawa M, Koga F, Kawaguchi Y, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Okabe Y, Makiyama A, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Mizuta T, Mitsugi K, Ureshino N. A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study. Int J Clin Oncol 2021;26:941-50. [PMID: 33483857 DOI: 10.1007/s10147-021-01859-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
227 Fleming Martinez AK, Döppler HR, Bastea LI, Edenfield B, Patel T, Leitges M, Liou GY, Storz P. Dysfunctional EGFR and oxidative stress-induced PKD1 signaling drive formation of DCLK1+ pancreatic stem cells. iScience 2021;24:102019. [PMID: 33521594 DOI: 10.1016/j.isci.2020.102019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
228 Umemoto K, Takahashi H, Morizane C, Yamada I, Shimizu S, Shioji K, Yoshida Y, Motoya M, Mizuno N, Kojima Y, Terashima T, Uesugi K, Ueno M, Furuse J, Akimoto T, Ikeda M. FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study. Cancer Chemother Pharmacol 2021;87:397-404. [PMID: 33386925 DOI: 10.1007/s00280-020-04206-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
229 Lu L, Li M. Strategies and methods for selecting suitable combined interventional therapy for pancreatic carcinoma. Integrative Pancreatic Intervention Therapy 2021. [DOI: 10.1016/b978-0-12-819402-7.00025-5] [Reference Citation Analysis]
230 Satoi S, Yamamoto T, Hashimoto D, Yamaki S, Hirooka S, Sakaguchi T, Ryota H, Ishida M, Sekimoto M. Treatment Approach for Pancreatic Cancer with Peritoneal Dissemination. Management of Pancreatic Cancer and Cholangiocarcinoma 2021. [DOI: 10.1007/978-981-16-2870-2_16] [Reference Citation Analysis]
231 Han B, Kim BJ, Kim HS, Choi DR, Shim BY, Lee KH, Kim JW, Kim JH, Song H, Kim JH, Park CK, Lee JW, Kim MJ, Zang DY. A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer. J Cancer 2021;12:912-7. [PMID: 33403047 DOI: 10.7150/jca.50514] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
232 Fanale D, Madonia G, Galvano A, Peeters M, ten Tije AJ, Iovanna JL, Russo A. Cancer of Exocrine Pancreas. Practical Medical Oncology Textbook 2021. [DOI: 10.1007/978-3-030-56051-5_40] [Reference Citation Analysis]
233 O'Rourke CJ, Munoz-Garrido P, Andersen JB. Molecular Targets in Cholangiocarcinoma. Hepatology 2021;73 Suppl 1:62-74. [PMID: 32304327 DOI: 10.1002/hep.31278] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
234 Ansari D, Andersson R. Biomarkers in Pancreatic Cancer. Textbook of Pancreatic Cancer 2021. [DOI: 10.1007/978-3-030-53786-9_31] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
235 Liu R, Yin L. Interventional therapy combined with molecular-targeted therapy for pancreatic cancer. Integrative Pancreatic Intervention Therapy 2021. [DOI: 10.1016/b978-0-12-819402-7.00024-3] [Reference Citation Analysis]
236 Su BB, Bai DS, Yu JQ, Zhang C, Jin SJ, Zhou BH, Jiang GQ. Can Patients with Pancreatic Cancer and Liver Metastases Obtain Survival Benefit from Surgery? A Population-Based Study. J Cancer 2021;12:539-52. [PMID: 33391450 DOI: 10.7150/jca.51218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
237 Zhao Y, Wang D, Xia W, Chen W, Liu Z. Internal medicine treatment of pancreatic lesions. Integrative Pancreatic Intervention Therapy 2021. [DOI: 10.1016/b978-0-12-819402-7.00004-8] [Reference Citation Analysis]
238 Nagy B, Lamarca A, Mcnamara MG, Hubner RA, Valle JW. Chemotherapy for Advanced Pancreatic Cancer: Available Drugs, Mechanisms and Toxicity. Textbook of Pancreatic Cancer 2021. [DOI: 10.1007/978-3-030-53786-9_44] [Reference Citation Analysis]
239 Murray EJ, Caniglia EC, Petito LC. Causal survival analysis: A guide to estimating intention-to-treat and per-protocol effects from randomized clinical trials with non-adherence. Research Methods in Medicine & Health Sciences 2021;2:39-49. [DOI: 10.1177/2632084320961043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
240 Zuzak T, Seiler R, Ostermann T, Heusser P, Schwermer M, Längler A. Use of supportive anthroposophic medicine in a German integrative paediatric oncology centre. Der Merkurstab 2021;74:472-477. [DOI: 10.14271/dms-21425-en] [Reference Citation Analysis]
241 Alm M, Andresen V, Ell C, Fibbe C, Fischbach W, Keller J, Frank Kipp P, May A, Miehlke S, Porschen R, Stallmach A, Weinke T, Aehling N, Alm M, Andresen V, Baumgart DC, Bertram F, Böhlig A, Bullmann C, Carstensen J, de Greck M, Ellerbeck W, Enders G, Fibbe C, Fischbach W, Fritz K, Gaus A, Gottschalk L, Grandt KD, Henniges U, Herta T, Jasper D, Keller J, Kschowak N, Lang K, Lange A, Layer P, Liedtke N, Luttermann J, Mancke L, Meier VS, Melle U, Menge D, Michaelis S, Nader S, Niedergassel T, Pachmann C, Porschen R, Rose S, Rosien U, Rössle M, Schellhorn M, Schnell O, Schulz S, Siegel J, Stein A, Szuba J, Teising S, Thiel S, Thomas-morr J, Tillmann H, Todt F, Veelken R, von Schassen H, Wölfel M, Wolf S, Wolgast V, Wübbolding C, Zimmermann K. Pankreas. Facharztwissen Gastroenterologie und Hepatologie 2021. [DOI: 10.1016/b978-3-437-21252-9.00013-4] [Reference Citation Analysis]
242 Uddin MH, Azmi AS, Mohammad RM. Potential of PAR-4 as a Therapeutic Target for Pancreatic Cancer. Tumor Suppressor Par-4 2021. [DOI: 10.1007/978-3-030-80558-6_10] [Reference Citation Analysis]
243 Zheng-lin B, O’reilly EM. Immune Landscape of Pancreas Ductal Adenocarcinoma: Current Therapeutic Strategies and Future Perspective. Cancer Immunotherapy 2021. [DOI: 10.1007/13905_2021_8] [Reference Citation Analysis]
244 Ceniceros L, Prados S, Alvarez Gallego R. Jaundice in Pancreatic Cancer. Textbook of Pancreatic Cancer 2021. [DOI: 10.1007/978-3-030-53786-9_78] [Reference Citation Analysis]
245 Guo Z, Yu H. Arterial infusion and arterial chemoembolization for pancreatic cancer. Integrative Pancreatic Intervention Therapy 2021. [DOI: 10.1016/b978-0-12-819402-7.00011-5] [Reference Citation Analysis]
246 Liang H, Williamson S. Nonsurgical Management of Pancreatic Adenocarcinoma. Hepato-Pancreato-Biliary Malignancies 2021. [DOI: 10.1007/978-3-030-37482-2_31-1] [Reference Citation Analysis]
247 Zhang X, Li M. Molecular-targeted therapy of pancreatic carcinoma and its progress. Integrative Pancreatic Intervention Therapy 2021. [DOI: 10.1016/b978-0-12-819402-7.00020-6] [Reference Citation Analysis]
248 van Duijneveldt G, Griffin MDW, Putoczki TL. Emerging roles for the IL-6 family of cytokines in pancreatic cancer. Clin Sci (Lond) 2020;134:2091-115. [PMID: 32808663 DOI: 10.1042/CS20191211] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
249 Moskvicheva LI, Bolotina LV. Possibilities of palliative chemotherapy in patients with locally advanced and metastatic pancreatic cancer. Issled prakt med (Print) 2020;7:118-134. [DOI: 10.17709/2409-2231-2020-7-4-10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
250 Rong Y, Gao J, Kuang T, Chen J, Li JA, Huang Y, Xin H, Fang Y, Han X, Sun LQ, Deng YZ, Li Z, Lou W. DIAPH3 promotes pancreatic cancer progression by activating selenoprotein TrxR1-mediated antioxidant effects. J Cell Mol Med 2021;25:2163-75. [PMID: 33345387 DOI: 10.1111/jcmm.16196] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
251 Zong Y, Peng Z, Wang X, Lu M, Shen L, Zhou J. Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma. Cancer Manag Res 2020;12:12657-66. [PMID: 33328763 DOI: 10.2147/CMAR.S263773] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
252 Dogra P, Ramírez JR, Peláez MJ, Wang Z, Cristini V, Parasher G, Rawat M. Mathematical Modeling to Address Challenges in Pancreatic Cancer. Curr Top Med Chem 2020;20:367-76. [PMID: 31893993 DOI: 10.2174/1568026620666200101095641] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
253 Doleschal B. Tackling DNA damage repair mechanisms—a promising molecular informed therapeutic approach in pancreatic ductal adenocarcinoma. memo 2020;13:380-384. [DOI: 10.1007/s12254-020-00658-1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
254 Iovanna J. Implementing biological markers as a tool to guide clinical care of patients with pancreatic cancer. Transl Oncol 2021;14:100965. [PMID: 33248412 DOI: 10.1016/j.tranon.2020.100965] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
255 Rehman H, Chi J, Hakim N, Goyal SP, Olazagasti C, Jose J, Moriarty L, Saif MW. Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic cancer. Therap Adv Gastroenterol 2020;13:1756284820974912. [PMID: 33281939 DOI: 10.1177/1756284820974912] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
256 Britain CM, Bhalerao N, Silva AD, Chakraborty A, Buchsbaum DJ, Crowley MR, Crossman DK, Edwards YJK, Bellis SL. Glycosyltransferase ST6Gal-I promotes the epithelial to mesenchymal transition in pancreatic cancer cells. J Biol Chem 2021;296:100034. [PMID: 33148698 DOI: 10.1074/jbc.RA120.014126] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
257 De Simoni O, Scarpa M, Tonello M, Pilati P, Tolin F, Spolverato Y, Gruppo M. Oligometastatic Pancreatic Cancer to the Liver in the Era of Neoadjuvant Chemotherapy: Which Role for Conversion Surgery? A Systematic Review and Meta-Analysis. Cancers (Basel) 2020;12:E3402. [PMID: 33213022 DOI: 10.3390/cancers12113402] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
258 Grbovic-Huezo O, Pitter KL, Lecomte N, Saglimbeni J, Askan G, Holm M, Melchor JP, Chandwani R, Joshi S, Haglund C, Iacobuzio-Donahue CA, Chiosis G, Tammela T, Leach SD. Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma. Proc Natl Acad Sci U S A 2020;117:30670-8. [PMID: 33199632 DOI: 10.1073/pnas.1920240117] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
259 Ciecielski KJ, Berninger A, Algül H. Precision Therapy of Pancreatic Cancer: From Bench to Bedside. Visc Med 2020;36:373-80. [PMID: 33178734 DOI: 10.1159/000509232] [Reference Citation Analysis]
260 Li J, Yuan S, Norgard RJ, Yan F, Sun YH, Kim IK, Merrell AJ, Sela Y, Jiang Y, Bhanu NV, Garcia BA, Vonderheide RH, Blanco A, Stanger BZ. Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer. Cancer Discov 2021;11:736-53. [PMID: 33158848 DOI: 10.1158/2159-8290.CD-20-0519] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
261 Bijou I, Wang J. Evolving trends in pancreatic cancer therapeutic development. Ann Pancreat Cancer 2019;2:17. [PMID: 33089149 DOI: 10.21037/apc.2019.09.01] [Reference Citation Analysis]
262 Yin N, Yu H, Zhang X, Lv X. Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib. Drug Des Devel Ther 2020;14:4465-75. [PMID: 33122890 DOI: 10.2147/DDDT.S270303] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
263 Saito K, Nakai Y, Takahara N, Ishigaki K, Suzuki Y, Inokuma A, Noguchi K, Kanai S, Sato T, Hakuta R, Saito T, Hamada T, Mizuno S, Kogure H, Ijichi H, Tateishi K, Koike K. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel. Invest New Drugs 2021;39:605-13. [PMID: 33094362 DOI: 10.1007/s10637-020-01022-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
264 Khan T, Seddon AM, Dalgleish AG, Khelwatty S, Ioannou N, Mudan S, Modjtahedi H. Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer. Oncol Rep 2020;44:2581-94. [PMID: 33125153 DOI: 10.3892/or.2020.7822] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
265 Qian Y, Gong Y, Fan Z, Luo G, Huang Q, Deng S, Cheng H, Jin K, Ni Q, Yu X, Liu C. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. J Hematol Oncol 2020;13:130. [PMID: 33008426 DOI: 10.1186/s13045-020-00958-3] [Cited by in Crossref: 64] [Cited by in F6Publishing: 72] [Article Influence: 21.3] [Reference Citation Analysis]
266 Reißig T, Siveke J. Duktales Adenokarzinom des Pankreas – Entstehung, Diagnostik, Therapie. Onkologe 2020;26:977-985. [DOI: 10.1007/s00761-020-00813-7] [Reference Citation Analysis]
267 Cheng C, Sui B, Wang M, Hu X, Shi S, Xu P. Carrier-Free Nanoassembly of Curcumin-Erlotinib Conjugate for Cancer Targeted Therapy. Adv Healthc Mater 2020;9:e2001128. [PMID: 32893507 DOI: 10.1002/adhm.202001128] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
268 Zhong A, Cheng CS, Kai J, Lu R, Guo L. Clinical Significance of Glucose to Lymphocyte Ratio (GLR) as a Prognostic Marker for Patients With Pancreatic Cancer. Front Oncol 2020;10:520330. [PMID: 33117673 DOI: 10.3389/fonc.2020.520330] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
269 Iede K, Yamada T, Kato R, Ueda M, Tsuda Y, Nakashima S, Ohta K, Matsuyama J, Ikenaga M, Tominaga S. Predictive implications of decreased CA19-9 at 8 weeks during nab-paclitaxel plus gemcitabine for the induction of second-line chemotherapy for patients with advanced pancreatic cancer. Cancer Rep (Hoboken) 2020;3:e1289. [PMID: 32969199 DOI: 10.1002/cnr2.1289] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
270 Katayama ES, Hue JJ, Bajor DL, Ocuin LM, Ammori JB, Hardacre JM, Winter JM. A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike? Oncotarget 2020;11:3489-501. [PMID: 33014285 DOI: 10.18632/oncotarget.27727] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
271 Wang Y, Lakoma A, Zogopoulos G. Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities. Genes (Basel) 2020;11:E1098. [PMID: 32967105 DOI: 10.3390/genes11091098] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
272 Sharma N, Bhushan A, He J, Kaushal G, Bhardwaj V. Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase. Cancer Metab 2020;8:19. [PMID: 32974013 DOI: 10.1186/s40170-020-00226-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
273 Cheng J, Cashman JR. Pancreatic cancer drug-sensitivity predicted by synergy of p53-Activator Wnt Inhibitor-2 (PAWI-2) and protein biomarker expression. Invest New Drugs 2021;39:131-41. [PMID: 32915418 DOI: 10.1007/s10637-020-00998-z] [Reference Citation Analysis]
274 Kouzy R, Abi Jaoude J, Lin D, Nguyen ND, El Alam MB, Ludmir EB, Taniguchi CM. Patient-Reported Outcome Measures in Pancreatic Cancer Receiving Radiotherapy. Cancers (Basel) 2020;12:E2487. [PMID: 32887363 DOI: 10.3390/cancers12092487] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
275 Chen X, Tian J, Su GH, Lin J. Blocking IL-6/GP130 Signaling Inhibits Cell Viability/Proliferation, Glycolysis, and Colony Forming Activity in Human Pancreatic Cancer Cells. Curr Cancer Drug Targets 2019;19:417-27. [PMID: 29714141 DOI: 10.2174/1568009618666180430123939] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
276 Ishido K, Hakamada K, Kimura N, Miura T, Wakiya T. Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg 2021;5:7-23. [PMID: 33532676 DOI: 10.1002/ags3.12379] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
277 Korolkova OY, Widatalla SE, Williams SD, Whalen DS, Beasley HK, Ochieng J, Grewal T, Sakwe AM. Diverse Roles of Annexin A6 in Triple-Negative Breast Cancer Diagnosis, Prognosis and EGFR-Targeted Therapies. Cells 2020;9:E1855. [PMID: 32784650 DOI: 10.3390/cells9081855] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
278 Le Large TY, Mantini G, Meijer LL, Pham TV, Funel N, van Grieken NC, Kok B, Knol J, van Laarhoven HW, Piersma SR, Jimenez CR, Kazemier G, Giovannetti E, Bijlsma MF. Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets. JCI Insight 2020;5:138290. [PMID: 32634123 DOI: 10.1172/jci.insight.138290] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
279 Suzuki S, Yamamoto M, Sanomachi T, Togashi K, Sugai A, Seino S, Okada M, Yoshioka T, Kitanaka C. Doxazosin, a Classic Alpha 1-Adrenoceptor Antagonist, Overcomes Osimertinib Resistance in Cancer Cells via the Upregulation of Autophagy as Drug Repurposing. Biomedicines 2020;8:E273. [PMID: 32764319 DOI: 10.3390/biomedicines8080273] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
280 Wang C, Zhang T, Liao Q, Dai M, Guo J, Yang X, Tan W, Lin D, Wu C, Zhao Y. Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulation. Protein Cell. 2021;12:128-144. [PMID: 32737864 DOI: 10.1007/s13238-020-00760-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
281 Sung MJ, Bang S. Updates of Chemotherapy and Radiotherapy for Pancreatic Cancer. Korean J Pancreas Biliary Tract 2020;25:72-82. [DOI: 10.15279/kpba.2020.25.2.72] [Reference Citation Analysis]
282 Strapcova S, Takacova M, Csaderova L, Martinelli P, Lukacikova L, Gal V, Kopacek J, Svastova E. Clinical and Pre-Clinical Evidence of Carbonic Anhydrase IX in Pancreatic Cancer and Its High Expression in Pre-Cancerous Lesions. Cancers (Basel) 2020;12:E2005. [PMID: 32707920 DOI: 10.3390/cancers12082005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
283 Christenson ES, Jaffee E, Azad NS. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future. Lancet Oncol. 2020;21:e135-e145. [PMID: 32135117 DOI: 10.1016/s1470-2045(19)30795-8] [Cited by in Crossref: 93] [Cited by in F6Publishing: 104] [Article Influence: 31.0] [Reference Citation Analysis]
284 Grossberg AJ, Chu LC, Deig CR, Fishman EK, Hwang WL, Maitra A, Marks DL, Mehta A, Nabavizadeh N, Simeone DM, Weekes CD, Thomas CR Jr. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin 2020;70:375-403. [PMID: 32683683 DOI: 10.3322/caac.21626] [Cited by in Crossref: 100] [Cited by in F6Publishing: 109] [Article Influence: 33.3] [Reference Citation Analysis]
285 Iede K, Yamada T, Kato R, Ueda M, Tsuda Y, Nakashima S, Ohta K, Matsuyama J, Ikenaga M, Tominaga S. Efficacy of S-1 in second-line chemotherapy after nab-paclitaxel plus gemcitabine for patients with advanced pancreatic cancer. Cancer Rep (Hoboken) 2020;3:e1215. [PMID: 32672000 DOI: 10.1002/cnr2.1215] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
286 Zhang Y, Xu G, Chen M, Wei Q, Zhou T, Chen Z, Shen M, Wang P. Stage IA Patients With Pancreatic Ductal Adenocarcinoma Cannot Benefit From Chemotherapy: A Propensity Score Matching Study. Front Oncol 2020;10:1018. [PMID: 32766130 DOI: 10.3389/fonc.2020.01018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
287 Kubo H, Murakami T, Matsuyama R, Yabushita Y, Tsuchiya N, Sawada Y, Homma Y, Kumamoto T, Endo I. Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection. World J Surg 2019;43:3153-60. [PMID: 31549202 DOI: 10.1007/s00268-019-05159-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
288 Cheng J, Cashman JR. PAWI-2: A novel inhibitor for eradication of cancer. Med Chem Res 2020;29:1147-1159. [DOI: 10.1007/s00044-020-02575-8] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
289 Hagerty BL, Pegna GJ, Xu J, Tai CH, Alewine C. Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors. Biomolecules 2020;10:E973. [PMID: 32605175 DOI: 10.3390/biom10070973] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
290 Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov 2020;19:533-52. [PMID: 32528145 DOI: 10.1038/s41573-020-0068-6] [Cited by in Crossref: 279] [Cited by in F6Publishing: 308] [Article Influence: 93.0] [Reference Citation Analysis]
291 Selvanesan BC, Meena K, Beck A, Meheus L, Lara O, Rooman I, Gravekamp C. Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice.. [DOI: 10.1101/2020.06.02.129809] [Reference Citation Analysis]
292 Deng Y, Zhou T, Wu J, Chen Y, Shen C, Zeng M, Chen T, Zhang X. The impact of molecular classification based on the transcriptome of pancreatic cancer: from bench to bedside. Chin J Acad Radiol 2020;3:67-75. [DOI: 10.1007/s42058-020-00037-z] [Reference Citation Analysis]
293 Glatzer M, Horber D, Montemurro M, Winterhalder R, Inauen R, Berger MD, Pestalozzi B, Pederiva S, Pless M, Putora PM. Choice of first line systemic treatment in pancreatic cancer among national experts. Pancreatology 2020;20:686-90. [PMID: 32299764 DOI: 10.1016/j.pan.2020.03.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
294 Wang X, Gao X, Tian J, Zhang R, Qiao Y, Hua X, Shi G. TSPAN1 promotes human pancreatic cancer cells proliferation by modulating CDK1 via Akt.. [DOI: 10.1101/2020.05.29.123091] [Reference Citation Analysis]
295 Wu CP, Hung TH, Hsiao SH, Huang YH, Hung LC, Yu YJ, Chang YT, Wang SP, Wu YS. Erdafitinib Resensitizes ABCB1-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs. Cancers (Basel) 2020;12:E1366. [PMID: 32466597 DOI: 10.3390/cancers12061366] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
296 Vena F, Bayle S, Nieto A, Quereda V, Aceti M, Frydman SM, Sansil SS, Grant W, Monastyrskyi A, McDonald P, Roush WR, Teng M, Duckett D. Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase. Mol Cancer Ther. 2020;19:1623-1635. [PMID: 32430484 DOI: 10.1158/1535-7163.mct-19-0997] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
297 Hedegger K, Algül H, Lesina M, Blutke A, Schmid RM, Schneider MR, Dahlhoff M. Unraveling ERBB network dynamics upon betacellulin signaling in pancreatic ductal adenocarcinoma in mice. Mol Oncol 2020;14:1653-69. [PMID: 32335999 DOI: 10.1002/1878-0261.12699] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
298 Damanakis AI, Gebauer F, Bruns CJ. [Molecular predictors for the course of disease and individualized therapy in pancreatic cancer]. Chirurg 2020;91:642-9. [PMID: 32405728 DOI: 10.1007/s00104-020-01172-0] [Reference Citation Analysis]
299 Devis-Jauregui L, Eritja N, Davis ML, Matias-Guiu X, Llobet-Navàs D. Autophagy in the physiological endometrium and cancer. Autophagy 2021;17:1077-95. [PMID: 32401642 DOI: 10.1080/15548627.2020.1752548] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 11.0] [Reference Citation Analysis]
300 Awad S, Alkashash AM, Amin M, Baker SJ, Rose JB. Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Front Oncol 2020;10:620. [PMID: 32477933 DOI: 10.3389/fonc.2020.00620] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
301 Madamsetty VS, Pal K, Dutta SK, Wang E, Mukhopadhyay D. Targeted Dual Intervention-Oriented Drug-Encapsulated (DIODE) Nanoformulations for Improved Treatment of Pancreatic Cancer. Cancers (Basel) 2020;12:E1189. [PMID: 32397114 DOI: 10.3390/cancers12051189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
302 Milton CK, Self AJ, Clarke PA, Banerji U, Piccioni F, Root DE, Whittaker SR. A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer. Mol Cancer Ther 2020;19:1423-35. [PMID: 32371585 DOI: 10.1158/1535-7163.MCT-19-1131] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
303 Dhayat SA, Yang Z. Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas. J Cancer Res Clin Oncol 2020;146:1625-45. [PMID: 32338295 DOI: 10.1007/s00432-020-03219-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
304 Zaborowska-Szmit M, Krzakowski M, Kowalski DM, Szmit S. Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer. J Clin Med 2020;9:E1268. [PMID: 32349387 DOI: 10.3390/jcm9051268] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
305 Cutmore LC, Brown NF, Raj D, Chauduri S, Wang P, Maher J, Wang Y, Lemoine NR, Marshall JF. Pancreatic Cancer UK Grand Challenge: Developments and challenges for effective CAR T cell therapy for pancreatic ductal adenocarcinoma. Pancreatology 2020;20:394-408. [PMID: 32173257 DOI: 10.1016/j.pan.2020.02.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
306 Koujima T, Tazawa H, Ieda T, Araki H, Fushimi T, Shoji R, Kuroda S, Kikuchi S, Yoshida R, Umeda Y, Teraishi F, Urata Y, Mizuguchi H, Fujiwara T. Oncolytic Virus-Mediated Targeting of the ERK Signaling Pathway Inhibits Invasive Propensity in Human Pancreatic Cancer. Mol Ther Oncolytics 2020;17:107-17. [PMID: 32322667 DOI: 10.1016/j.omto.2020.03.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
307 Kandimalla R, Tomihara H, Banwait JK, Yamamura K, Singh G, Baba H, Goel A. A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 2020;26:3641-8. [PMID: 32234757 DOI: 10.1158/1078-0432.CCR-19-4044] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
308 Gromisch C, Qadan M, Machado MA, Liu K, Colson Y, Grinstaff MW. Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease. Cancer Res 2020;80:3179-92. [PMID: 32220831 DOI: 10.1158/0008-5472.CAN-19-2731] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
309 Cleary JM, Calvo E, Moreno V, Juric D, Shapiro GI, Vanderwal CA, Hu B, Gifford M, Barch D, Roberts-Rapp L, Ansell PJ, Xiong H, Ocampo C, Tolcher AW. A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR. Invest New Drugs 2020;38:1483-94. [PMID: 32189093 DOI: 10.1007/s10637-020-00908-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
310 Miller AL, Garcia PL, Yoon KJ. Developing effective combination therapy for pancreatic cancer: An overview. Pharmacol Res 2020;155:104740. [PMID: 32135247 DOI: 10.1016/j.phrs.2020.104740] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
311 Petito LC, García-Albéniz X, Logan RW, Howlader N, Mariotto AB, Dahabreh IJ, Hernán MA. Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked Database. JAMA Netw Open 2020;3:e200452. [PMID: 32134464 DOI: 10.1001/jamanetworkopen.2020.0452] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
312 Skipworth JR, Pereira SP. Tumours of the pancreas. Oxford Textbook of Medicine 2020. [DOI: 10.1093/med/9780198746690.003.0337] [Reference Citation Analysis]
313 John S. Current perspective on the treatment of advanced pancreatic adenocarcinoma. Onkologie 2020;14:37-39. [DOI: 10.36290/xon.2020.010] [Reference Citation Analysis]
314 Furuse J, Ioka T, Fukutomi A, Mizuno N, Ozaka M, Okusaka T. Chemotherapy for patients with unresesctable pancreatic cancer is recommended in the Clinical Practice Guidelines for Pancreatic Cancer 2019. Journal of the Japan Pancreas Society 2020;35:69-74. [DOI: 10.2958/suizo.35.69] [Reference Citation Analysis]
315 Kieler M, Unseld M, Bianconi D, Schindl M, Kornek GV, Scheithauer W, Prager GW. Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients. J Clin Med. 2020;9. [PMID: 32121198 DOI: 10.3390/jcm9030648] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
316 Westphalen CB, Kukiolka T, Garlipp B, Hahn L, Fuchs M, Malfertheiner P, Reiser M, Kütting F, Heinemann V, Beringer A, Waldschmidt DT. Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib - results from a non-interventional multi-center study. BMC Cancer 2020;20:155. [PMID: 32093649 DOI: 10.1186/s12885-020-6636-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
317 Cho IR, Kang H, Jo JH, Lee HS, Chung MJ, Park JY, Park SW, Song SY, An C, Park MS, Bang S. FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study. World J Gastrointest Oncol 2020; 12(2): 182-194 [PMID: 32104549 DOI: 10.4251/wjgo.v12.i2.182] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
318 Feldmann G. Medikamentöse Therapie des Pankreaskarzinoms. Internist 2020;61:226-232. [DOI: 10.1007/s00108-020-00750-y] [Reference Citation Analysis]
319 Bhat AA, Ahamad B, Rehman MU, Ahmad P. Impact of ethanolic extract of Equisetum arvense (EA1) on pancreatic carcinoma AsPC-1 cells. Saudi J Biol Sci 2020;27:1260-4. [PMID: 32346333 DOI: 10.1016/j.sjbs.2020.01.029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
320 Sakaguchi T, Satoi S, Yamamoto T, Yamaki S, Sekimoto M. The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma. Surg Today 2020;50:335-43. [PMID: 31993761 DOI: 10.1007/s00595-020-01963-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
321 Serda M, Malarz K, Mrozek-Wilczkiewicz A, Wojtyniak M, Musioł R, Curley SA. Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment. Sci Rep 2020;10:260. [PMID: 31937861 DOI: 10.1038/s41598-019-57155-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
322 Li P, Cao G, Zhang Y, Shi J, Cai K, Zhen L, He X, Zhou Y, Li Y, Zhu Y, Xiong M, Wu Y. FHL3 promotes pancreatic cancer invasion and metastasis through preventing the ubiquitination degradation of EMT associated transcription factors. Aging (Albany NY) 2020;12:53-69. [PMID: 31935687 DOI: 10.18632/aging.102564] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
323 Wu CP, Hsiao SH, Huang YH, Hung LC, Yu YJ, Chang YT, Hung TH, Wu YS. Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs. Cancers (Basel) 2020;12:E195. [PMID: 31941029 DOI: 10.3390/cancers12010195] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
324 Rao L, Giannico D, Leone P, Solimando AG, Maiorano E, Caporusso C, Duda L, Tamma R, Mallamaci R, Susca N, Buonavoglia A, Da Vià MC, Ribatti D, De Re V, Vacca A, Racanelli V. HB-EGF-EGFR Signaling in Bone Marrow Endothelial Cells Mediates Angiogenesis Associated with Multiple Myeloma. Cancers (Basel) 2020;12:E173. [PMID: 31936715 DOI: 10.3390/cancers12010173] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
325 Tang S, Li Z, Yang L, Shen L, Wang Y. A potential new role of ATM inhibitor in radiotherapy: suppressing ionizing Radiation-Activated EGFR. Int J Radiat Biol 2020;96:461-8. [PMID: 31859574 DOI: 10.1080/09553002.2020.1707325] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
326 Li Z, Wang M, Yao X, Luo W, Qu Y, Yu D, Li X, Fang J, Huang C. Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy. Target Oncol 2019;14:93-105. [PMID: 30635821 DOI: 10.1007/s11523-018-0616-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
327 Jain R, Vijayvergia N, Devarajan K, Lewis B, Denlinger CS, Cohen SJ, Dotan E. Chemotherapy use and survival in older adults with metastatic pancreatic cancer in the combination therapy era. J Geriatr Oncol 2020;11:640-6. [PMID: 31917116 DOI: 10.1016/j.jgo.2019.12.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
328 Pansare R, Nagasaka M, Sukari A. Dermatological Toxicities of Targeted Therapy. Handbook of Cancer Treatment-Related Symptons and Toxicities 2020. [DOI: 10.1016/b978-0-323-67241-2.00015-x] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
329 McCleary-Wheeler AL, Carr RM, Palmer SR, Smyrk TC, Allred JB, Almada LL, Tolosa EJ, Lamberti MJ, Marks DL, Borad MJ, Molina JR, Qi Y, Lingle WL, Grothey A, Pitot HC, Jatoi A, Northfelt DW, Bryce AH, McWilliams RR, Okuno SH, Haluska P, Kim GP, Colon-Otero G, Lowe VJ, Callstrom MR, Ma WW, Bekaii-Saab T, Hung MC, Erlichman C, Fernandez-Zapico ME. Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. Pancreatology 2020;20:101-9. [PMID: 31787526 DOI: 10.1016/j.pan.2019.11.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
330 De Jesus-acosta A, Narang A, Mauro L, Herman J, Jaffee EM, Laheru DA. Carcinoma of the Pancreas. Abeloff's Clinical Oncology 2020. [DOI: 10.1016/b978-0-323-47674-4.00078-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
331 Chowdhury T, Sukari A, Nagasaka M. Gastrointestinal Toxicities of Targeted Therapy. Handbook of Cancer Treatment-Related Symptons and Toxicities 2020. [DOI: 10.1016/b978-0-323-67241-2.00013-6] [Reference Citation Analysis]
332 Jamshed MB, Munir F, Shahid N, Sadiq U, Muhammad SA, Ghanem NB, Zhong H, Li X, Zhang Q. Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer. Am J Physiol Gastrointest Liver Physiol 2020;318:G109-19. [PMID: 31736340 DOI: 10.1152/ajpgi.00130.2019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
333 Okusaka T, Furuse J. Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. J Gastroenterol 2020;55:369-82. [PMID: 31997007 DOI: 10.1007/s00535-020-01666-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
334 Usami M, Kikuchi S, Takada K, Ono M, Sugama Y, Arihara Y, Hayasaka N, Nakamura H, Ikeda Y, Hirakawa M, Yoshida M, Miyanishi K, Kobune M, Kato J. FOXO3a Activation by HDAC Class IIa Inhibition Induces Cell Cycle Arrest in Pancreatic Cancer Cells. Pancreas 2020;49:135-42. [PMID: 31856089 DOI: 10.1097/MPA.0000000000001462] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
335 Deperalta DK, Frakes J, Mahipal A, Saeed N, Almhanna K, Kim R, Anaya DA. Multidisciplinary Management of Liver, Pancreatic, and Gastric Malignancies in Older Adults. Geriatric Oncology 2020. [DOI: 10.1007/978-3-319-57415-8_28] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
336 Hüser N, Aßfalg V, Hartmann D, Friess H. Pancreatic Ductal Adenocarinoma. Encyclopedia of Gastroenterology 2020. [DOI: 10.1016/b978-0-12-801238-3.65874-9] [Reference Citation Analysis]
337 Khitrova AN, Bolotina LV, Kornietskaya AL, Moskvicheva LI. High-intensity focused ultrasound therapy as part of combined treatment for inoperable pancreatic cancer. Onkol Z im P A Gercena 2020;9:50. [DOI: 10.17116/onkolog2020901150] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
338 Chen Z, Wu J, Xu H, Yu X, Wang K. In silico analysis of the prognostic value of FAS mRNA in malignancies. J Cancer 2020;11:542-50. [PMID: 31942177 DOI: 10.7150/jca.35614] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
339 Hakim N, Patel R, Devoe C, Saif MW. Why HALO 301 Failed and Implications for Treatment of Pancreatic Cancer. Pancreas (Fairfax) 2019;3:e1-4. [PMID: 32030361 DOI: 10.17140/POJ-3-e010] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 10.8] [Reference Citation Analysis]
340 Ni F, Tang H, Wang C, Zhang H, Zheng C, Zhang N, Chen B, Sun L. Baohuoside I Inhibits the Proliferation of Pancreatic Cancer Cells via mTOR/S6K1-Caspases/Bcl2/Bax Apoptotic Signaling. Cancer Manag Res 2019;11:10609-21. [PMID: 31908533 DOI: 10.2147/CMAR.S228926] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
341 Rutkowska A, Stoczyńska-Fidelus E, Janik K, Włodarczyk A, Rieske P. EGFRvIII: An Oncogene with Ambiguous Role. J Oncol 2019;2019:1092587. [PMID: 32089685 DOI: 10.1155/2019/1092587] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
342 Li K, Yang J, Chen J, Shi Y, Zhang Z, Chen W. High mobility group AT-hook 2 and c-MYC as potential prognostic factors in pancreatic ductal adenocarcinoma. Oncol Lett 2020;19:1584-92. [PMID: 31966084 DOI: 10.3892/ol.2019.11205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
343 Grapa CM, Mocan T, Gonciar D, Zdrehus C, Mosteanu O, Pop T, Mocan L. Epidermal Growth Factor Receptor and Its Role in Pancreatic Cancer Treatment Mediated by Nanoparticles. Int J Nanomedicine. 2019;14:9693-9706. [PMID: 31849462 DOI: 10.2147/ijn.s226628] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
344 Patel H, Okamura R, Fanta P, Patel C, Lanman RB, Raymond VM, Kato S, Kurzrock R. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. J Hematol Oncol. 2019;12:130. [PMID: 31801585 DOI: 10.1186/s13045-019-0824-4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 9.5] [Reference Citation Analysis]
345 Kumarasamy V, Ruiz A, Nambiar R, Witkiewicz AK, Knudsen ES. Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer. Oncogene 2020;39:1831-45. [PMID: 31745297 DOI: 10.1038/s41388-019-1102-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
346 Liu L, Wang E, Li L, Chen D, Peng K, Wang M, Han G. As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib. Can J Gastroenterol Hepatol 2019;2019:2576349. [PMID: 31815114 DOI: 10.1155/2019/2576349] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
347 Ma WW, Xie H, Fetterly G, Pitzonka L, Whitworth A, LeVea C, Wilton J, Mantione K, Schihl S, Dy GK, Boland P, Iyer R, Tan W, Brady W, Straubinger RM, Adjei AA. A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. Am J Clin Oncol 2019;42:184-9. [PMID: 30418178 DOI: 10.1097/COC.0000000000000492] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
348 Affram KO, Smith T, Ofori E, Krishnan S, Underwood P, Trevino JG, Agyare E. Cytotoxic effects of gemcitabine-loaded solid lipid nanoparticles in pancreatic cancer cells. J Drug Deliv Sci Technol 2020;55:101374. [PMID: 31903101 DOI: 10.1016/j.jddst.2019.101374] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
349 Lin KI, Yang JL, Lin YC, Chou CY, Chen JH, Hung CC. Network Meta-Analysis of Efficacy and Safety of Chemotherapy and Target Therapy in the First-Line Setting of Advanced Pancreatic Cancer. Cancers (Basel) 2019;11:E1746. [PMID: 31703359 DOI: 10.3390/cancers11111746] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
350 Kim J, Jo YH, Jang M, Nguyen NNY, Yun HR, Ko SH, Shin Y, Lee JS, Kang I, Ha J, Choi TG, Kim SS. PAC-5 Gene Expression Signature for Predicting Prognosis of Patients with Pancreatic Adenocarcinoma. Cancers (Basel) 2019;11:E1749. [PMID: 31703415 DOI: 10.3390/cancers11111749] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
351 Abbassi R, Schmid RM. Evolving Treatment Paradigms for Pancreatic Cancer. Visc Med 2019;35:362-72. [PMID: 31934585 DOI: 10.1159/000503797] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
352 Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci 2020;77:1745-70. [PMID: 31690961 DOI: 10.1007/s00018-019-03351-7] [Cited by in Crossref: 422] [Cited by in F6Publishing: 468] [Article Influence: 105.5] [Reference Citation Analysis]
353 Wen CL, Huang K, Jiang LL, Lu XX, Dai YT, Shi MM, Tang XM, Wang QB, Zhang XD, Wang PH, Li HT, Ruan XX, Wang LW, Wang XJ, Wang Q, Lu W, Xiang XQ, Sun X, Xu YH, Lai LH, Zhan Q, Li HW, Peng CH, Chen J, Huang JY, Ye DY, Chen SJ, Chen Z, Li M, Fang Y, Shen BY, Zhou L. An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A 2019;116:23264-73. [PMID: 31662475 DOI: 10.1073/pnas.1914557116] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
354 Chawla A, Ferrone CR. Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shift. Front Oncol 2019;9:1085. [PMID: 31681614 DOI: 10.3389/fonc.2019.01085] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
355 Sanomachi T, Suzuki S, Togashi K, Sugai A, Seino S, Okada M, Yoshioka T, Kitanaka C, Yamamoto M. Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs. Cancers (Basel) 2019;11:E1550. [PMID: 31614999 DOI: 10.3390/cancers11101550] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
356 Fenocchio E, Filippi R, Lombardi P, Quarà V, Milanesio M, Aimar G, Leone F, Aglietta M. Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer? Cancers (Basel) 2019;11:E1547. [PMID: 31614884 DOI: 10.3390/cancers11101547] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
357 Renz BW, D'haese JG, Werner J. Maligne Tumoren der Bauchspeicheldrüse. CME 2019;16:57-71. [DOI: 10.1007/s11298-019-7095-9] [Reference Citation Analysis]
358 Chen M, Yang S, Fan L, Wu L, Chen R, Chang J, Hu J. Combined Antiangiogenic Therapy and Immunotherapy Is Effective for Pancreatic Cancer With Mismatch Repair Proficiency but High Tumor Mutation Burden: A Case Report. Pancreas 2019;48:1232-6. [PMID: 31609933 DOI: 10.1097/MPA.0000000000001398] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
359 Fang Y, Pu N, Zhang L, Wu W, Lou W. Chemoradiotherapy is associated with improved survival for resected pancreatic adenosquamous carcinoma: a retrospective cohort study from the SEER database. Ann Transl Med. 2019;7:522. [PMID: 31807504 DOI: 10.21037/atm.2019.10.12] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
360 Lambert A, Schwarz L, Borbath I, Henry A, Van Laethem JL, Malka D, Ducreux M, Conroy T. An update on treatment options for pancreatic adenocarcinoma. Ther Adv Med Oncol 2019;11:1758835919875568. [PMID: 31598142 DOI: 10.1177/1758835919875568] [Cited by in Crossref: 85] [Cited by in F6Publishing: 96] [Article Influence: 21.3] [Reference Citation Analysis]
361 Rawat M, Kadian K, Gupta Y, Kumar A, Chain PSG, Kovbasnjuk O, Kumar S, Parasher G. MicroRNA in Pancreatic Cancer: From Biology to Therapeutic Potential. Genes (Basel) 2019;10:E752. [PMID: 31557962 DOI: 10.3390/genes10100752] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 12.0] [Reference Citation Analysis]
362 Sahai V, Saif MW, Kalyan A, Philip PA, Rocha-Lima CM, Ocean A, Ondovik MS, Simeone DM, Banerjee S, Bhore R, Louis CU, Picozzi V. A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients with Metastatic Pancreatic Cancer. J Pancreat Cancer 2019;5:35-42. [PMID: 31559379 DOI: 10.1089/pancan.2019.0012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
363 Scheithauer W, Putora PM, Grünberger B, Eisterer W, Wöll E, Prager G, Schaberl-Moser R, Greil R, Glatzer M. Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine. Therap Adv Gastroenterol 2019;12:1756284819877635. [PMID: 31579123 DOI: 10.1177/1756284819877635] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
364 Gharaibeh M, McBride A, Alberts DS, Erstad B, Slack M, Alsaid N, Bootman JL, Abraham I. Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. Pharmacoeconomics 2018;36:1333-43. [PMID: 29981004 DOI: 10.1007/s40273-018-0684-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
365 Gallmeier E, Gress TM. [Pancreatic ductal adenocarcinoma]. Internist (Berl). 2018;59:805-822. [PMID: 29980819 DOI: 10.1007/s00108-018-0460-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
366 Lu Z, Weniger M, Jiang K, Boeck S, Zhang K, Bazhin A, Miao Y, Werner J, D'Haese JG. Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis. Target Oncol 2018;13:447-59. [PMID: 30062609 DOI: 10.1007/s11523-018-0578-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
367 Er JL, Goh PN, Lee CY, Tan YJ, Hii LW, Mai CW, Chung FF, Leong CO. Identification of inhibitors synergizing gemcitabine sensitivity in the squamous subtype of pancreatic ductal adenocarcinoma (PDAC). Apoptosis 2018;23:343-55. [PMID: 29740790 DOI: 10.1007/s10495-018-1459-6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 7.3] [Reference Citation Analysis]
368 Isacoff WH, Reber HA, Bedford R, Hoos W, Rahib L, Upfill-Brown A, Donahue T, Hines OJ. Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis. Target Oncol 2018;13:461-8. [PMID: 29882102 DOI: 10.1007/s11523-018-0572-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
369 Parameswaran N, Bartel CA, Hernandez-Sanchez W, Miskimen KL, Smigiel JM, Khalil AM, Jackson MW. A FAM83A Positive Feed-back Loop Drives Survival and Tumorigenicity of Pancreatic Ductal Adenocarcinomas. Sci Rep 2019;9:13396. [PMID: 31527715 DOI: 10.1038/s41598-019-49475-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
370 Brunner M, Wu Z, Krautz C, Pilarsky C, Grützmann R, Weber GF. Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions. Int J Mol Sci 2019;20:E4543. [PMID: 31540286 DOI: 10.3390/ijms20184543] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 9.8] [Reference Citation Analysis]
371 Aigner KR, Gailhofer S, Selak E, Aigner K. Intra-arterial infusion chemotherapy versus isolated upper abdominal perfusion for advanced pancreatic cancer: a retrospective cohort study on 454 patients. J Cancer Res Clin Oncol 2019;145:2855-62. [PMID: 31506738 DOI: 10.1007/s00432-019-03019-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
372 Kordes M, Yu J, Malgerud O, Gustafsson Liljefors M, Löhr J-. Survival Benefits of Chemotherapy for Patients with Advanced Pancreatic Cancer in A Clinical Real-World Cohort. Cancers (Basel) 2019;11:E1326. [PMID: 31500236 DOI: 10.3390/cancers11091326] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
373 Fong CYK, Burke E, Cunningham D, Starling N. Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma. Gastroenterol Res Pract 2019;2019:7135437. [PMID: 31582971 DOI: 10.1155/2019/7135437] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
374 Tian C, Clauser KR, Öhlund D, Rickelt S, Huang Y, Gupta M, Mani DR, Carr SA, Tuveson DA, Hynes RO. Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells. Proc Natl Acad Sci U S A 2019;116:19609-18. [PMID: 31484774 DOI: 10.1073/pnas.1908626116] [Cited by in Crossref: 139] [Cited by in F6Publishing: 150] [Article Influence: 34.8] [Reference Citation Analysis]
375 Gilles ME, Hao L, Brown K, Lim J, Bhatia SN, Slack FJ. Tumor penetrating nanomedicine targeting both an oncomiR and an oncogene in pancreatic cancer. Oncotarget 2019;10:5349-58. [PMID: 31523393 DOI: 10.18632/oncotarget.27160] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
376 Thomas R, Weihua Z. Rethink of EGFR in Cancer With Its Kinase Independent Function on Board. Front Oncol 2019;9:800. [PMID: 31508364 DOI: 10.3389/fonc.2019.00800] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 16.8] [Reference Citation Analysis]
377 Wei AC, Ou FS, Shi Q, Carrero X, O'Reilly EM, Meyerhardt J, Wolff RA, Kindler HL, Evans DB, Deshpande V, Misdraji J, Tamm E, Sahani D, Moore M, Newman E, Merchant N, Berlin J, Goff LW, Pisters P, Posner MC. Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Ann Surg Oncol 2019;26:4489-97. [PMID: 31418130 DOI: 10.1245/s10434-019-07685-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
378 Carnevale I, Capula M, Giovannetti E, Schmidt T, Coppola S. A mechanical memory of pancreatic cancer cells.. [DOI: 10.1101/730960] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
379 Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C, Schnurr M, Lauber K. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol 2019;14:141. [PMID: 31395068 DOI: 10.1186/s13014-019-1345-6] [Cited by in Crossref: 152] [Cited by in F6Publishing: 160] [Article Influence: 38.0] [Reference Citation Analysis]
380 Parkin A, Man J, Timpson P, Pajic M. Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy. FEBS J 2019;286:3510-39. [PMID: 31330086 DOI: 10.1111/febs.15011] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
381 Imaoka H, Sasaki M, Hashimoto Y, Watanabe K, Ikeda M. New Era of Endoscopic Ultrasound-Guided Tissue Acquisition: Next-Generation Sequencing by Endoscopic Ultrasound-Guided Sampling for Pancreatic Cancer. J Clin Med 2019;8:E1173. [PMID: 31387310 DOI: 10.3390/jcm8081173] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
382 Sinn M, Heinemann V. Systemtherapie des metastasierten Pankreaskarzinoms: Aktuelle Standards und Perspektiven. Onkologe 2019;25:696-703. [DOI: 10.1007/s00761-019-0569-2] [Reference Citation Analysis]
383 Abbassi R, Algül H. Palliative chemotherapy in pancreatic cancer-treatment sequences. Transl Gastroenterol Hepatol 2019;4:56. [PMID: 31559337 DOI: 10.21037/tgh.2019.06.09] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
384 Azar I, Virk G, Esfandiarifard S, Wazir A, Mehdi S. Treatment and survival rates of stage IV pancreatic cancer at VA hospitals: a nation-wide study. J Gastrointest Oncol 2019;10:703-11. [PMID: 31392051 DOI: 10.21037/jgo.2018.07.08] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
385 Wang J, Chan DKW, Sen A, Ma WW, Straubinger RM. Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model. Mol Cancer Ther 2019;18:2074-84. [PMID: 31363010 DOI: 10.1158/1535-7163.MCT-18-0354] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
386 Lee JS, Park SS, Lee YK, Norton JA, Jeffrey SS. Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA. Mol Oncol 2019;13:1623-50. [PMID: 31243883 DOI: 10.1002/1878-0261.12537] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 10.5] [Reference Citation Analysis]
387 Davis SL, Cardin DB, Shahda S, Lenz HJ, Dotan E, O'Neil BH, Kapoun AM, Stagg RJ, Berlin J, Messersmith WA, Cohen SJ. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Invest New Drugs 2020;38:821-30. [PMID: 31338636 DOI: 10.1007/s10637-019-00824-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
388 Fernandes GDS, Pereira A. Development of new therapies for metastatic pancreatic cancer: are they better than FOLFIRINOX? ESMO Open 2019;4:e000537. [PMID: 31354965 DOI: 10.1136/esmoopen-2019-000537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
389 Zhou X, Shi K, Hao Y, Yang C, Zha R, Yi C, Qian Z. Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy. Asian J Pharm Sci 2020;15:26-41. [PMID: 32175016 DOI: 10.1016/j.ajps.2019.06.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
390 Cardin DB, Thota R, Goff LW, Berlin JD, Jones CM, Ayers GD, Whisenant JG, Chan E. A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer. Am J Clin Oncol 2018;41:772-6. [PMID: 28301350 DOI: 10.1097/COC.0000000000000377] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
391 Beutel AK, Perkhofer L, Seufferlein TTW. Aktuelle Strategien für die palliative Sequenztherapie. Im Focus Onkologie 2019;22:14-18. [DOI: 10.1007/s15015-019-0103-9] [Reference Citation Analysis]
392 Madurantakam Royam M, Ramesh R, Shanker R, Sabarimurugan S, Kumarasamy C, Ramesh N, Gothandam KM, Baxi S, Gupta A, Krishnan S, Jayaraj R. miRNA Predictors of Pancreatic Cancer Chemotherapeutic Response: A Systematic Review and Meta-Analysis. Cancers (Basel) 2019;11:E900. [PMID: 31252688 DOI: 10.3390/cancers11070900] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
393 Gbenedio OM, Bonnans C, Grun D, Wang CY, Hatch AJ, Mahoney MR, Barras D, Matli M, Miao Y, Garcia KC, Tejpar S, Delorenzi M, Venook AP, Nixon AB, Warren RS, Roose JP, Depeille P. RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer. JCI Insight 2019;5:127552. [PMID: 31237864 DOI: 10.1172/jci.insight.127552] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
394 Chen L, Xu X, Wen X, Xu S, Wang L, Lu W, Jiang M, Huang J, Yang D, Wang J, Zheng M, Zhou XZ, Lu KP, Liu H. Targeting PIN1 exerts potent antitumor activity in pancreatic ductal carcinoma via inhibiting tumor metastasis. Cancer Sci 2019;110:2442-55. [PMID: 31148345 DOI: 10.1111/cas.14085] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
395 Halbrook CJ, Crawford HC. Hiding in plain sight. Science 2019;364:1132-3. [PMID: 31221844 DOI: 10.1126/science.aax9341] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
396 Babiker HM, Karass M, Recio-Boiles A, Chandana SR, McBride A, Mahadevan D. Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). Expert Opin Investig Drugs 2019;28:583-92. [PMID: 31215251 DOI: 10.1080/13543784.2019.1632289] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
397 Wu LW, Zhang JK, Rao M, Zhang ZY, Zhu HJ, Zhang C. Harmine suppresses the proliferation of pancreatic cancer cells and sensitizes pancreatic cancer to gemcitabine treatment. Onco Targets Ther 2019;12:4585-93. [PMID: 31354292 DOI: 10.2147/OTT.S205097] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
398 Brunetti O, Badalamenti G, De Summa S, Calabrese A, Argentiero A, Fucci L, Longo V, Galetta D, Perrotti PMS, Pinto R, Petriella D, Danza K, Tommasi S, Leonetti F, Silvestris N. Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy. Cancers (Basel) 2019;11:E749. [PMID: 31146476 DOI: 10.3390/cancers11060749] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
399 消化器がん. Nippon Jibiinkoka Gakkai Kaiho 2019;122:717-723. [DOI: 10.3950/jibiinkoka.122.717] [Reference Citation Analysis]
400 Lee SH, Chang PH, Chen PT, Lu CH, Hung YS, Tsang NM, Hung CY, Chen JS, Hsu HC, Chen YY, Chou WC. Association of time interval between cancer diagnosis and initiation of palliative chemotherapy with overall survival in patients with unresectable pancreatic cancer. Cancer Med 2019;8:3471-8. [PMID: 31099160 DOI: 10.1002/cam4.2254] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
401 Primavesi F, Stättner S, Schlick K, Kiesslich T, Mayr C, Klieser E, Urbas R, Neureiter D. Pancreatic cancer in young adults: changes, challenges, and solutions. Onco Targets Ther 2019;12:3387-400. [PMID: 31118690 DOI: 10.2147/OTT.S176700] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
402 Wood LD, Yurgelun MB, Goggins MG. Genetics of Familial and Sporadic Pancreatic Cancer. Gastroenterology 2019;156:2041-55. [PMID: 30660730 DOI: 10.1053/j.gastro.2018.12.039] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 9.8] [Reference Citation Analysis]
403 Harano Y, Babazono A, Fujita T, Jiang P. Efficacy of S-1 monotherapy for older patients with unresectable pancreatic cancer: A retrospective cohort study. Journal of Geriatric Oncology 2019;10:420-6. [DOI: 10.1016/j.jgo.2018.09.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
404 van Mackelenbergh MG, Stroes CI, Spijker R, van Eijck CHJ, Wilmink JW, Bijlsma MF, van Laarhoven HWM. Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel). 2019;11. [PMID: 31035512 DOI: 10.3390/cancers11050588] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
405 Cavanna L, Stroppa EM, Citterio C, Mordenti P, Di Nunzio C, Peveri S, Orlandi E, Vecchia S. Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience. Onco Targets Ther. 2019;12:3077-3085. [PMID: 31118666 DOI: 10.2147/ott.s200754] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
406 Ostwal V, Sahu A, Zanwar S, Nayak L, Shrikhande SV, Shetty N, Gupta S, Ramaswamy A. Experience with non-cremophor-based paclitaxel-gemcitabine regimen in advanced pancreatic cancer: Results from a single tertiary cancer centre.Indian J Med Res. 2018;148:284-290. [PMID: 30425218 DOI: 10.4103/ijmr.IJMR_249_17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
407 Lai HL, Chen YY, Lu CH, Hung CY, Kuo YC, Chen JS, Hsu HC, Chen PT, Chang PH, Hung YS, Chou WC. Effect of S-1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7-year multicenter observational cohort study in Taiwan. Cancer Med 2019;8:2085-94. [PMID: 31001907 DOI: 10.1002/cam4.2094] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
408 Lin T, Ren Q, Zuo W, Jia R, Xie L, Lin R, Zhao H, Chen J, Lei Y, Wang P, Dong H, Huang L, Cai J, Peng Y, Yu Z, Tan J, Wang S. Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs. J Exp Clin Cancer Res 2019;38:150. [PMID: 30961642 DOI: 10.1186/s13046-019-1160-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
409 Fagman JB, Ljungman D, Falk P, Iresjö BM, Engström C, Naredi P, Lundholm K. EGFR, but not COX-2, protein in resected pancreatic ductal adenocarcinoma is associated with poor survival. Oncol Lett 2019;17:5361-8. [PMID: 31186753 DOI: 10.3892/ol.2019.10224] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
410 Selvanesan BC, Chandra D, Quispe-tintaya W, Jahangir A, Patel A, Meena K, Alves Da Silva RA, Friedman M, Libutti SK, Yuan Z, Li J, Siddiqui S, Beck A, Tesfa L, Koba W, Chuy J, Mcauliffe JC, Jafari R, Entenberg D, Wang Y, Condeelis J, Desmarais V, Balachandran V, Zhang X, Gravekamp C. Tumor-targeted delivery of childhood vaccine recall antigens by attenuated Listeria reduces pancreatic cancer.. [DOI: 10.1101/600106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
411 Sasaki T, Kanata R, Yamada I, Matsuyama M, Ozaka M, Sasahira N. Improvement of Treatment Outcomes for Metastatic Pancreatic Cancer: A Real-world Data Analysis. In Vivo 2019;33:271-6. [PMID: 30587635 DOI: 10.21873/invivo.11471] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
412 Sonbol MB, Firwana BM, Hilal T, Murad MH. How to read a published clinical trial: A practical guide for clinicians. Avicenna J Med 2020;10:68-75. [PMID: 32500045 DOI: 10.4103/ajm.ajm_186_19] [Reference Citation Analysis]
413 Conway JR, Herrmann D, Evans TJ, Morton JP, Timpson P. Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Gut 2019;68:742-58. [PMID: 30396902 DOI: 10.1136/gutjnl-2018-316822] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 10.5] [Reference Citation Analysis]
414 Poteet E, Liu D, Liang Z, Van Buren G, Chen C, Yao Q. Mesothelin and TGF-α predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment with trametinib. PLoS One 2019;14:e0213294. [PMID: 30921351 DOI: 10.1371/journal.pone.0213294] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
415 Lee HH, Wang YN, Hung MC. Functional roles of the human ribonuclease A superfamily in RNA metabolism and membrane receptor biology. Mol Aspects Med 2019;70:106-16. [PMID: 30902663 DOI: 10.1016/j.mam.2019.03.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
416 Singh RR, Goldberg J, Varghese AM, Yu KH, Park W, O'Reilly EM. Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review. Cancer Treat Rev 2019;75:27-38. [PMID: 30927677 DOI: 10.1016/j.ctrv.2019.03.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
417 Chou WC, Chen YY, Hung CY, Chen JS, Lu CH, Chang PH. Evolution of the chemotherapeutic landscape and survival outcome in patients with metastatic pancreatic cancer: a four-institute cohort study in Taiwan, 2010-2016. Cancer Manag Res 2019;11:2119-27. [PMID: 30936744 DOI: 10.2147/CMAR.S196300] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
418 Gallmeier E, Gress TM. Duktales Adenokarzinom des Pankreas. Gastroenterologe 2019;14:131-148. [DOI: 10.1007/s11377-019-0340-7] [Reference Citation Analysis]
419 Giuliani J, Bonetti A. FOLFIRINOX is a cost-effective combination chemotherapy in first-line for advanced pancreatic Cancer. Pancreatology 2019;19:325-30. [PMID: 30704852 DOI: 10.1016/j.pan.2019.01.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
420 Wang D, Bi Y, Hu L, Luo Y, Ji J, Mao AZ, Logsdon CD, Li E, Abbruzzese JL, Li Z, Yang VW, Lu W. Obesogenic high-fat diet heightens aerobic glycolysis through hyperactivation of oncogenic KRAS. Cell Commun Signal 2019;17:19. [PMID: 30819189 DOI: 10.1186/s12964-019-0333-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
421 Madani Tonekaboni SA, Soltan Ghoraie L, Manem VSK, Haibe-Kains B. Predictive approaches for drug combination discovery in cancer. Brief Bioinform 2018;19:263-76. [PMID: 27881431 DOI: 10.1093/bib/bbw104] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 12.5] [Reference Citation Analysis]
422 Ter Veer E, van Rijssen LB, Besselink MG, Mali RMA, Berlin JD, Boeck S, Bonnetain F, Chau I, Conroy T, Van Cutsem E, Deplanque G, Friess H, Glimelius B, Goldstein D, Herrmann R, Labianca R, Van Laethem JL, Macarulla T, van der Meer JHM, Neoptolemos JP, Okusaka T, O'Reilly EM, Pelzer U, Philip PA, van der Poel MJ, Reni M, Scheithauer W, Siveke JT, Verslype C, Busch OR, Wilmink JW, van Oijen MGH, van Laarhoven HWM. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncol 2018;19:e151-60. [PMID: 29508762 DOI: 10.1016/S1470-2045(18)30098-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 8.8] [Reference Citation Analysis]
423 Lei F, Xi X, Batra SK, Bronich TK. Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer. J Pharmacol Exp Ther 2019;370:682-94. [PMID: 30796131 DOI: 10.1124/jpet.118.255786] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
424 Liu S, Qin Z, Xu J, Zeng J, Chen J, Niu L, Xu M. Irreversible electroporation combined with chemotherapy for unresectable pancreatic carcinoma: a prospective cohort study. Onco Targets Ther. 2019;12:1341-1350. [PMID: 30863100 DOI: 10.2147/ott.s186721] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
425 Spano C, Grisendi G, Golinelli G, Rossignoli F, Prapa M, Bestagno M, Candini O, Petrachi T, Recchia A, Miselli F, Rovesti G, Orsi G, Maiorana A, Manni P, Veronesi E, Piccinno MS, Murgia A, Pinelli M, Horwitz EM, Cascinu S, Conte P, Dominici M. Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer. Sci Rep 2019;9:1788. [PMID: 30742129 DOI: 10.1038/s41598-018-37433-6] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 9.0] [Reference Citation Analysis]
426 Gergely PA, Murnyák B, Bencze J, Kurucz A, Varjas T, Gombos K, Hortobágyi T. Tyrosine Kinase Inhibitor Imatinib Mesylate Alters DMBA-Induced Early Onco/Suppressor Gene Expression with Tissue-Specificity in Mice. Biomed Res Int 2019;2019:8670398. [PMID: 30882001 DOI: 10.1155/2019/8670398] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
427 Ning Z, Xie J, Chen Q, Zhang C, Xu L, Song L, Meng Z. HIFU is safe, effective, and feasible in pancreatic cancer patients: a monocentric retrospective study among 523 patients. Onco Targets Ther 2019;12:1021-9. [PMID: 30774386 DOI: 10.2147/OTT.S185424] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
428 Péron J, Giai J, Maucort-Boulch D, Buyse M. The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma. Pancreas 2019;48:275-80. [PMID: 30629024 DOI: 10.1097/MPA.0000000000001234] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
429 Zukas AM, Schiff D. Neurological complications of new chemotherapy agents. Neuro Oncol 2018;20:24-36. [PMID: 28992326 DOI: 10.1093/neuonc/nox115] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
430 Tong M, Wang J, Zhang H, Xing H, Wang Y, Fang Y, Pan H, Li D. Efficacy and safety of gemcitabine plus anti-angiogenesis therapy for advanced pancreatic cancer: a systematic review and meta-analysis of clinical randomized phase III trials. J Cancer 2019;10:968-78. [PMID: 30854103 DOI: 10.7150/jca.26672] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
431 Halfdanarson TR, Foster NR, Kim GP, Meyers JP, Smyrk TC, McCullough AE, Ames MM, Jaffe JP, Alberts SR. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance). Oncologist 2019;24:589-e160. [PMID: 30679315 DOI: 10.1634/theoncologist.2018-0878] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
432 Xu F, Sun Y, Yang SZ, Zhou T, Jhala N, McDonald J, Chen Y. Cytoplasmic PARP-1 promotes pancreatic cancer tumorigenesis and resistance. Int J Cancer 2019;145:474-83. [PMID: 30614530 DOI: 10.1002/ijc.32108] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
433 Cerullo M, Gani F, Chen SY, Canner JK, Herman JM, Laheru D, Pawlik TM. Assessing the Financial Burden Associated With Treatment Options for Resectable Pancreatic Cancer. Ann Surg 2018;267:544-51. [PMID: 27787294 DOI: 10.1097/SLA.0000000000002069] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
434 Uzunparmak B, Sahin IH. Pancreatic cancer microenvironment: a current dilemma. Clin Transl Med 2019;8:2. [PMID: 30645701 DOI: 10.1186/s40169-019-0221-1] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 12.0] [Reference Citation Analysis]
435 Chang CF, Huang PW, Chen JS, Chen YY, Lu CH, Chang PH, Hung YS, Chou WC. Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic Model. Cancers (Basel) 2019;11:E57. [PMID: 30634387 DOI: 10.3390/cancers11010057] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
436 Lasala R, Santoleri F, Romagnoli A, Musicco F, Costantini A. Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe. Eur J Clin Pharmacol 2019;75:697-706. [PMID: 30617511 DOI: 10.1007/s00228-018-02621-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
437 Zhu SK, Xu T, Wang R. Prospects and challenges of immunotherapy for pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2019; 27(1): 6-12 [DOI: 10.11569/wcjd.v27.i1.6] [Reference Citation Analysis]
438 Blomstrand H, Scheibling U, Bratthäll C, Green H, Elander NO. Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer. BMC Cancer 2019;19:40. [PMID: 30621618 DOI: 10.1186/s12885-018-5244-2] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 9.8] [Reference Citation Analysis]
439 Vogl UM, Andalibi H, Klaus A, Vormittag L, Schima W, Heinrich B, Kafka A, Winkler T, Öhler L. Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter? BMC Cancer 2019;19:28. [PMID: 30621630 DOI: 10.1186/s12885-018-5240-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 9.3] [Reference Citation Analysis]
440 Sushma P, Nagaraju GP. Pancreatic Cancer Resistance to Gemcitabine. Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy 2019. [DOI: 10.1016/b978-0-12-817661-0.00004-4] [Reference Citation Analysis]
441 Tillu H, Bramhachari PV. Genetic manipulations with chemotherapy in pancreatic cancer. Theranostic Approach for Pancreatic Cancer 2019. [DOI: 10.1016/b978-0-12-819457-7.00007-4] [Reference Citation Analysis]
442 Arshad A, Dennison A. Acute Pancreatitis, Chronic Pancreatitis and Pancreatic Neoplasms. Gastroenterology For General Surgeons 2019. [DOI: 10.1007/978-3-319-92768-8_10] [Reference Citation Analysis]
443 Rashid MU, Hussain I, Jehanzeb S, Ullah W, Ali S, Jain AG, Kumar R, Khetpal N, Ahmad S. Pancreatic Cancer and Possible Therapeutic Options. Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy 2019. [DOI: 10.1016/b978-0-12-817661-0.00005-6] [Reference Citation Analysis]
444 王 君. Research Progress on the Treatment of Pancreatic Cancer. ACM 2019;09:638-644. [DOI: 10.12677/acm.2019.95096] [Reference Citation Analysis]
445 Nakamura K, Akahori T, Nagai M, Nishiwada S, Nakagawa K, Ikeda N, Sho M. New Perspective in Pancreatic Cancer. Alcoholic/Non-Alcoholic Digestive Diseases 2019. [DOI: 10.1007/978-981-13-1465-0_13] [Reference Citation Analysis]
446 Hackert T, Wüsten L, Büchler MW. Anti-angiogenics in Pancreatic Cancer Therapy. Tumor Angiogenesis 2019. [DOI: 10.1007/978-3-319-33673-2_18] [Reference Citation Analysis]
447 Deperalta DK, Frakes J, Mahipal A, Saeed N, Almhanna K, Kim R, Anaya DA. Multidisciplinary Management of Liver, Pancreatic, and Gastric Malignancies in Older Adults. Geriatric Oncology 2019. [DOI: 10.1007/978-3-319-44870-1_28-1] [Reference Citation Analysis]
448 Gyawali B. Causes, Consequences, and Control of High Cancer Drug Prices. Cancer and Society 2019. [DOI: 10.1007/978-3-030-05855-5_4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
449 Javed MA, Beyer G, Le N, Vinci A, Wong H, Palmer D, Morgan RD, Lamarca A, Hubner RA, Valle JW, Alam S, Chowdhury S, Ma YT, Archibugi L, Capurso G, Maisonneuve P, Neesse A, Sund M, Schober M, Krug S. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. Pancreatology 2019;19:97-104. [PMID: 30529068 DOI: 10.1016/j.pan.2018.10.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
450 Diab M, Hamid MS, Mohammad RM, Philip PA, Azmi AS. Novel Targeted Treatment Approaches in Pancreatic Cancer. Textbook of Gastrointestinal Oncology 2019. [DOI: 10.1007/978-3-030-18890-0_27] [Reference Citation Analysis]
451 Rybak A, Zarzecki M, Golabiewska E, Niechoda A, Holownia A. Sialidase Attenuates Epidermal Growth Factor Response and Abolishes Antiproliferative Effects of Erlotinib in A549Alveolar Epithelial Cells. Adv Exp Med Biol 2019;1153:55-61. [PMID: 30729434 DOI: 10.1007/5584_2018_329] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
452 Stevenson MA, Patel SH, Ahmad SA. Resectable and Borderline Resectable Pancreatic Cancer. Textbook of Gastrointestinal Oncology 2019. [DOI: 10.1007/978-3-030-18890-0_14] [Reference Citation Analysis]
453 Jain AG, Wazir M, Zafar H, Zhou J, Khanal K, Khan AK, Ahmad S. Epidermal growth factor receptor role in pancreatic cancer. Theranostic Approach for Pancreatic Cancer 2019. [DOI: 10.1016/b978-0-12-819457-7.00015-3] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
454 Akce M, El-rayes BF, Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA. Novel Strategies on the Horizon for Metastatic Pancreatic Cancer Management. Oncology & Hematology Review (US) 2019;15:27. [DOI: 10.17925/ohr.2019.15.1.27] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
455 Kitasato K, Kano N, Azuma M, Kawakami H, Murata I, Ikota M, Ohta T, Kobayashi Y, Tsuruta Y. A Case of Pancreatic Head Cancer with a Hepatic Metastasis that Showed Complete Response to Administration of Gemcitabine + Nab-Paclitaxel Therapy. JJCS 2019;44:113-119. [DOI: 10.4030/jjcs.44.113] [Reference Citation Analysis]
456 Tesfaye A, Philip PA. Treatment of Advanced Pancreatic Carcinoma. Textbook of Gastrointestinal Oncology 2019. [DOI: 10.1007/978-3-030-18890-0_15] [Reference Citation Analysis]
457 Khan AK, Jain AG, Afridi S, Wazir M, Rao JS, Ahmad S. Latest developments in chemotherapy for metastatic pancreatic cancer. Theranostic Approach for Pancreatic Cancer 2019. [DOI: 10.1016/b978-0-12-819457-7.00006-2] [Reference Citation Analysis]
458 Antoniou G, Koutsounas I, Kountourakis P, Pontas C, De Mello RA. Pancreatic Cancer. International Manual of Oncology Practice 2019. [DOI: 10.1007/978-3-030-16245-0_21] [Reference Citation Analysis]
459 Masu T, Atsukawa M, Nakatsuka K, Shimizu M, Miura D, Arai T, Harimoto H, Kondo C, Kaneko K, Futagami S, Kawamoto C, Takahashi H, Iwakiri K. Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression. PLoS One 2018;13:e0200664. [PMID: 30596643 DOI: 10.1371/journal.pone.0200664] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
460 Pothuraju R, Rachagani S, Junker WM, Chaudhary S, Saraswathi V, Kaur S, Batra SK. Pancreatic cancer associated with obesity and diabetes: an alternative approach for its targeting. J Exp Clin Cancer Res. 2018;37:319. [PMID: 30567565 DOI: 10.1186/s13046-018-0963-4] [Cited by in Crossref: 50] [Cited by in F6Publishing: 57] [Article Influence: 10.0] [Reference Citation Analysis]
461 Wang X, Wu X, Zhang Z, Ma C, Wu T, Tang S, Zeng Z, Huang S, Gong C, Yuan C, Zhang L, Feng Y, Huang B, Liu W, Zhang B, Shen Y, Luo W, Wang X, Liu B, Lei Y, Ye Z, Zhao L, Cao D, Yang L, Chen X, Haydon RC, Luu HH, Peng B, Liu X, He TC. Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway. Sci Rep 2018;8:17914. [PMID: 30559409 DOI: 10.1038/s41598-018-36214-5] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
462 Chawla SP, Bruckner H, Morse MA, Assudani N, Hall FL, Gordon EM. A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer. Mol Ther Oncolytics 2019;12:56-67. [PMID: 30705966 DOI: 10.1016/j.omto.2018.12.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
463 Thomas NA, Abraham RG, Dedi B, Krucher NA. Targeting retinoblastoma protein phosphorylation in combination with EGFR inhibition in pancreatic cancer cells. Int J Oncol 2019;54:527-36. [PMID: 30535494 DOI: 10.3892/ijo.2018.4658] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
464 Park S, Kim D, Wu G, Jung H, Park JA, Kwon HJ, Lee Y. A peptide-CpG-DNA-liposome complex vaccine targeting TM4SF5 suppresses growth of pancreatic cancer in a mouse allograft model. Onco Targets Ther 2018;11:8655-72. [PMID: 30584324 DOI: 10.2147/OTT.S186606] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
465 Wisniewski M, Placide PA, Granier S, Al Shatti Y, Al Qalaf S, Bouattour M, Lamuraglia M, Hammel P. Adjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma: is there a role for erlotinib?-review of the open label phase III trial CONKO 005. Hepatobiliary Surg Nutr 2018;7:399-402. [PMID: 30498718 DOI: 10.21037/hbsn.2018.08.03] [Reference Citation Analysis]
466 Neuzillet C, Gaujoux S, Williet N, Bachet JB, Bauguion L, Colson Durand L, Conroy T, Dahan L, Gilabert M, Huguet F, Marthey L, Meilleroux J, de Mestier L, Napoléon B, Portales F, Sa Cunha A, Schwarz L, Taieb J, Chibaudel B, Bouché O, Hammel P; Thésaurus National de Cancérologie Digestive (TNCD), Société Nationale Française de Gastroentérologie (SNFGE), Fédération Francophone de Cancérologie Digestive (FFCD), Groupe Coopérateur multidisciplinaire en Oncologie (GERCOR), Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER), Société Française de Chirurgie Digestive (SFCD), Société Française d’Endoscopie Digestive (SFED), Société Française de Radiothérapie Oncologique (SFRO), Association de Chirurgie Hépato-Bilio-Pancréatique et Transplantation (ACHBT), Association Française de Chirurgie (AFC). Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Dig Liver Dis 2018;50:1257-71. [PMID: 30219670 DOI: 10.1016/j.dld.2018.08.008] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 14.2] [Reference Citation Analysis]
467 Zhou Y, Liu H, Xue R, Tang W, Zhang S. BH3 Mimetic ABT-199 Enhances the Sensitivity of Gemcitabine in Pancreatic Cancer in vitro and in vivo. Dig Dis Sci 2018;63:3367-75. [PMID: 30155839 DOI: 10.1007/s10620-018-5253-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
468 Ormanns S. Personalisierte Krebsmedizin. Pathologe 2018;39:221-224. [DOI: 10.1007/s00292-018-0539-2] [Reference Citation Analysis]
469 Ogden JR, Xie H, Ma WW, Hubbard JM. The Management of Older Adults with Pancreatic Adenocarcinoma. Geriatrics (Basel) 2018;3:E85. [PMID: 31011120 DOI: 10.3390/geriatrics3040085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
470 Sun J, Jiang W, Tian D, Guo Q, Shen Z. Icotinib inhibits the proliferation of hepatocellular carcinoma cells in vitro and in vivo dependently on EGFR activation and PDL1 expression. Onco Targets Ther 2018;11:8227-37. [PMID: 30538492 DOI: 10.2147/OTT.S179844] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
471 Wang YN, Lee HH, Hung MC. A novel ligand-receptor relationship between families of ribonucleases and receptor tyrosine kinases. J Biomed Sci 2018;25:83. [PMID: 30449278 DOI: 10.1186/s12929-018-0484-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
472 Chen J, Chen L, Yu J, Xu Y, Wang X, Zeng Z, Liu N, Xu F, Yang S. Meta‑analysis of current chemotherapy regimens in advanced pancreatic cancer to prolong survival and reduce treatment‑associated toxicities. Mol Med Rep 2019;19:477-89. [PMID: 30431091 DOI: 10.3892/mmr.2018.9638] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
473 Kang H, Jo JH, Lee HS, Chung MJ, Bang S, Park SW, Song SY, Park JY. Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. World J Gastrointest Oncol 2018; 10(11): 421-430 [PMID: 30487953 DOI: 10.4251/wjgo.v10.i11.421] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
474 Abendroth A, Noureddine R, Abramczyk M, Paul A, Gerken G, Schmid KW, Markus P, Schumacher B, Wiesweg M, Köhler J, Markus M, Mende B, Dechêne A, Schuler M, Kasper S. Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols. J Cancer Res Clin Oncol 2019;145:445-55. [PMID: 30430229 DOI: 10.1007/s00432-018-2789-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
475 Parkin A, Man J, Chou A, Nagrial AM, Samra J, Gill AJ, Timpson P, Pajic M. The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. Diseases 2018;6:E103. [PMID: 30428574 DOI: 10.3390/diseases6040103] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
476 Türeci Ӧ, Mitnacht-Kraus R, Wöll S, Yamada T, Sahin U. Characterization of zolbetuximab in pancreatic cancer models. Oncoimmunology 2019;8:e1523096. [PMID: 30546962 DOI: 10.1080/2162402X.2018.1523096] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
477 Klaiber U, Leonhardt C, Strobel O, Tjaden C, Hackert T, Neoptolemos JP. Neoadjuvant and adjuvant chemotherapy in pancreatic cancer. Langenbecks Arch Surg 2018;403:917-32. [DOI: 10.1007/s00423-018-1724-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 8.6] [Reference Citation Analysis]
478 von Figura G, Reichert M. Pankreaskarzinom – neue Konzepte? Gastroenterologe 2018;13:450-454. [DOI: 10.1007/s11377-018-0300-7] [Reference Citation Analysis]
479 Salem Y, Yacov N, Propheta-Meiran O, Breitbart E, Mendel I. Newly characterized motile sperm domain-containing protein 2 promotes human breast cancer metastasis. Int J Cancer 2019;144:125-35. [PMID: 29978511 DOI: 10.1002/ijc.31665] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
480 Kim HJ, Lee SY, Kim DS, Kang EJ, Kim JS, Choi YJ, Oh SC, Seo JH, Kim JS. Inflammatory markers as prognostic indicators in pancreatic cancer patients who underwent gemcitabine-based palliative chemotherapy. Korean J Intern Med. 2020;35:171-184. [PMID: 30360017 DOI: 10.3904/kjim.2018.076] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
481 Chen H, He R, Shi X, Zhou M, Zhao C, Zhang H, Qin R. Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone. BMC Cancer 2018;18:1034. [PMID: 30352573 DOI: 10.1186/s12885-018-4948-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
482 Kim MK, Yee J, Cho YS, Jang HW, Han JM, Gwak HS. Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study. BMC Cancer 2018;18:988. [PMID: 30326853 DOI: 10.1186/s12885-018-4891-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
483 Hong S, Fang Z, Jung HY, Yoon JH, Hong SS, Maeng HJ. Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties. Molecules 2018;23:E2608. [PMID: 30314360 DOI: 10.3390/molecules23102608] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
484 Kannaiyan R, Mahadevan D. A comprehensive review of protein kinase inhibitors for cancer therapy. Expert Rev Anticancer Ther 2018;18:1249-70. [PMID: 30259761 DOI: 10.1080/14737140.2018.1527688] [Cited by in Crossref: 105] [Cited by in F6Publishing: 92] [Article Influence: 21.0] [Reference Citation Analysis]
485 Zeng M, Feng Q, Lu M, Zhou J, Yang Z, Tang J. Predictive role of skin rash in advanced pancreatic cancer patients treated with gemcitabine plus erlotinib: a systematic review and meta-analysis. Onco Targets Ther 2018;11:6633-46. [PMID: 30349297 DOI: 10.2147/OTT.S168418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
486 Hegewisch-Becker S, Aldaoud A, Wolf T, Krammer-Steiner B, Linde H, Scheiner-Sparna R, Hamm D, Jänicke M, Marschner N; TPK-Group (Tumour Registry Pancreatic Cancer). Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma. Int J Cancer 2019;144:981-90. [PMID: 30006989 DOI: 10.1002/ijc.31751] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
487 Olsen JR, Murphy JD, Huguet F, Hallemeier CL, Apisarnthanarax S, Jabbour SK. Gastrointestinal Cancers—Carving Out the Optimal Local Therapies in the Gastrointestinal Tract. International Journal of Radiation Oncology*Biology*Physics 2018;102:233-242. [DOI: 10.1016/j.ijrobp.2018.05.026] [Reference Citation Analysis]
488 Chang JS, Chen LT, Shan YS, Chu PY, Tsai CR, Tsai HJ. The incidence and survival of pancreatic cancer by histology, including rare subtypes: a nation-wide cancer registry-based study from Taiwan. Cancer Med 2018;7:5775-88. [PMID: 30264519 DOI: 10.1002/cam4.1795] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
489 Gerhart J, Thévenin AF, Bloch E, King KE, Thévenin D. Inhibiting Epidermal Growth Factor Receptor Dimerization and Signaling Through Targeted Delivery of a Juxtamembrane Domain Peptide Mimic. ACS Chem Biol 2018;13:2623-32. [PMID: 30133245 DOI: 10.1021/acschembio.8b00555] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
490 Stroese AJ, Ullerich H, Koehler G, Raetzel V, Senninger N, Dhayat SA. Circulating microRNA-99 family as liquid biopsy marker in pancreatic adenocarcinoma. J Cancer Res Clin Oncol 2018;144:2377-90. [PMID: 30225540 DOI: 10.1007/s00432-018-2749-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
491 Ramos MC, Genilloud O, Reyes F, Vicente F. Drug Discovery from Natural Products for Pancreatic Cancer. Advances in Pancreatic Cancer 2018. [DOI: 10.5772/intechopen.76399] [Reference Citation Analysis]
492 Waters AM, Der CJ. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med. 2018;8. [PMID: 29229669 DOI: 10.1101/cshperspect.a031435] [Cited by in Crossref: 354] [Cited by in F6Publishing: 392] [Article Influence: 70.8] [Reference Citation Analysis]
493 Tiwari A, Kumar L. Pancreatic ductal adenocarcinoma: Role of chemotherapy & future perspectives. Indian J Med Res 2018;148:254-7. [PMID: 30425214 DOI: 10.4103/ijmr.IJMR_615_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
494 Ko AH. Moving from late to early stage disease: lessons learned from erlotinib in pancreatic cancer. Hepatobiliary Surg Nutr 2018;7:406-8. [PMID: 30498720 DOI: 10.21037/hbsn.2018.06.02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
495 Brunner M, Grützmann R, Weber GF. Palliative Konzepte beim Pankreaskarzinom. Chirurg 2018;89:737-750. [DOI: 10.1007/s00104-018-0696-0] [Reference Citation Analysis]
496 Zolghadri Y, Fazeli M. Comparison of anticancer effects of everolimus-gemcitabine combination with gemcitabine on pancreatic cancer using Rgs16 biomarker evaluation. Comp Clin Pathol 2018;27:1113-1117. [DOI: 10.1007/s00580-018-2706-5] [Reference Citation Analysis]
497 Hayashi H, Tanishima S, Fujii K, Mori R, Okamura Y, Yanagita E, Matsuoka R, Amano T, Kinoshita I, Komatsu Y, Dosaka-Akita H, Nishihara H. Genomic testing for pancreatic cancer in clinical practice as real-world evidence. Pancreatology 2018;18:647-54. [PMID: 30055942 DOI: 10.1016/j.pan.2018.07.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
498 Wolfe AR, Williams TM. Altering the response to radiation: radiosensitizers and targeted therapies in pancreatic ductal adenocarcinoma: preclinical and emerging clinical evidence. Ann Pancreat Cancer 2018;1:26. [PMID: 32656528 DOI: 10.21037/apc.2018.08.02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
499 Oria VO, Bronsert P, Thomsen AR, Föll MC, Zamboglou C, Hannibal L, Behringer S, Biniossek ML, Schreiber C, Grosu AL, Bolm L, Rades D, Keck T, Werner M, Wellner UF, Schilling O. Proteome Profiling of Primary Pancreatic Ductal Adenocarcinomas Undergoing Additive Chemoradiation Link ALDH1A1 to Early Local Recurrence and Chemoradiation Resistance. Transl Oncol 2018;11:1307-22. [PMID: 30172883 DOI: 10.1016/j.tranon.2018.08.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
500 Deshmukh SK, Tyagi N, Khan MA, Srivastava SK, Al-Ghadhban A, Dugger K, Carter JE, Singh S, Singh AP. Gemcitabine treatment promotes immunosuppressive microenvironment in pancreatic tumors by supporting the infiltration, growth, and polarization of macrophages. Sci Rep 2018;8:12000. [PMID: 30097594 DOI: 10.1038/s41598-018-30437-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 6.8] [Reference Citation Analysis]
501 Lo JH, Hao L, Muzumdar MD, Raghavan S, Kwon EJ, Pulver EM, Hsu F, Aguirre AJ, Wolpin BM, Fuchs CS, Hahn WC, Jacks T, Bhatia SN. iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer. Mol Cancer Ther 2018;17:2377-88. [PMID: 30097486 DOI: 10.1158/1535-7163.MCT-17-1090] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
502 Bruera G, Massacese S, Candria S, Galvano A, Manetta R, Giordano AV, Carducci S, Di Sibio A, Ciacco E, Russo A, Ricevuto E; Oncology Network ASL1 Abruzzo, Italy. Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study. Oncotarget 2018;9:31861-76. [PMID: 30159128 DOI: 10.18632/oncotarget.25870] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
503 Skelton WP 4th, Parekh H, Starr JS, Trevino J, Cioffi J, Hughes S, George TJ Jr. Clinical Factors as a Component of the Personalized Treatment Approach to Advanced Pancreatic Cancer: a Systematic Literature Review. J Gastrointest Cancer 2018;49:1-8. [PMID: 29110227 DOI: 10.1007/s12029-017-0021-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
504 Adamska A, Falasca M. ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward? World J Gastroenterol 2018; 24(29): 3222-3238 [PMID: 30090003 DOI: 10.3748/wjg.v24.i29.3222] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 60] [Article Influence: 11.4] [Reference Citation Analysis]
505 Yegya-Raman N, Shah MM, Grandhi MS, Poplin E, August DA, Kennedy TJ, Malhotra U, Spencer KR, Carpizo DR, Jabbour SK. Adjuvant therapeutic strategies for resectable pancreatic adenocarcinoma. Ann Pancreat Cancer 2018;1:20. [PMID: 30687847 DOI: 10.21037/apc.2018.07.05] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
506 Hua J, Shi S, Liang D, Liang C, Meng Q, Zhang B, Ni Q, Xu J, Yu X. Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining? Onco Targets Ther 2018;11:4591-608. [PMID: 30122951 DOI: 10.2147/OTT.S166405] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
507 Cai W, Ratnayake R, Gerber MH, Chen QY, Yu Y, Derendorf H, Trevino JG, Luesch H. Development of apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent and its preliminary evaluation in an orthotopic patient-derived xenograft (PDX) model. Invest New Drugs 2019;37:364-74. [PMID: 30073464 DOI: 10.1007/s10637-018-0647-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
508 Drubay V, Skrypek N, Cordiez L, Vasseur R, Schulz C, Boukrout N, Duchêne B, Coppin L, Van Seuningen I, Jonckheere N. TGF-βRII Knock-down in Pancreatic Cancer Cells Promotes Tumor Growth and Gemcitabine Resistance. Importance of STAT3 Phosphorylation on S727. Cancers (Basel) 2018;10:E254. [PMID: 30065235 DOI: 10.3390/cancers10080254] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
509 Jiang H, Xu M, Li L, Grierson P, Dodhiawala P, Highkin M, Zhang D, Li Q, Wang-Gillam A, Lim KH. Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models. Mol Cancer Ther 2018;17:2144-55. [PMID: 30065098 DOI: 10.1158/1535-7163.MCT-17-1142] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
510 Dittrich C, Königsberg R, Mittlböck M, Geissler K, Sahmanovic-Hrgovcic A, Pleiner-Duxneuner J, Czejka M, Buchner P. Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial. Invest New Drugs 2019;37:127-38. [PMID: 29998365 DOI: 10.1007/s10637-018-0639-0] [Reference Citation Analysis]
511 Yoshizawa N, Yamada R, Sakuno T, Inoue H, Miura H, Takeuchi T, Nakamura M, Hamada Y, Katsurahara M, Tanaka K, Horiki N, Takei Y. Comparison of endoscopic ultrasound-guided fine-needle aspiration and biopsy with 22-gauge and 25-gauge needles for the "precision medicine" of pancreatic cancer: A retrospective study. Medicine (Baltimore) 2018;97:e11096. [PMID: 29901627 DOI: 10.1097/MD.0000000000011096] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
512 Wang L, Cheng CS, Chen L, Chen Z. Benefit from the inclusion of surgery in the treatment of patients with stage III pancreatic cancer: a propensity-adjusted, population-based SEER analysis. Cancer Manag Res 2018;10:1907-18. [PMID: 30013397 DOI: 10.2147/CMAR.S167103] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
513 Mohammad AA. Advanced pancreatic cancer: The standard of care and new opportunities. Oncol Rev 2018;12:370. [PMID: 30344961 DOI: 10.4081/oncol.2018.370] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
514 Westphalen CB, Heinemann V. Neue Ansätze in der Therapie des metastasierten Pankreaskarzinoms. Im Focus Onkologie 2018;21:62-64. [DOI: 10.1007/s15015-018-4103-y] [Reference Citation Analysis]
515 Bhuyan DJ, Vuong QV, Chalmers AC, Bowyer MC, Scarlett CJ. An Array of Bioactive Compounds From Australian Eucalypts and Their Relevance in Pancreatic Cancer Therapeutics. Pancreas 2018;47:690-707. [PMID: 29894418 DOI: 10.1097/MPA.0000000000001074] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
516 Drubay V, Skrypek N, Cordiez L, Vasseur R, Schulz C, Boukrout N, Duchêne B, Coppin L, Seuningen IV, Jonckheere N. TGF-βRII knock-down promotes tumor growth and chemoresistance to gemcitabine of pancreatic cancer cells via phosphorylation of STAT3.. [DOI: 10.1101/352963] [Reference Citation Analysis]
517 Vitellius C, Fizanne L, Menager-Tabourel E, Nader J, Baize N, Laly M, Lermite E, Bertrais S, Caroli-Bosc FX. The combination of everolimus and zoledronic acid increase the efficacy of gemcitabine in a mouse model of pancreatic adenocarcinoma. Oncotarget 2018;9:28069-82. [PMID: 29963262 DOI: 10.18632/oncotarget.25560] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
518 Tong H, Fan Z, Liu B, Lu T. The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis. Sci Rep. 2018;8:8666. [PMID: 29875415 DOI: 10.1038/s41598-018-26811-9] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 7.4] [Reference Citation Analysis]
519 . Treatments That Block Proteins Involved in Cell Communication. A Beginner's Guide to Targeted Cancer Treatments 2018. [DOI: 10.1002/9781119126843.ch3] [Reference Citation Analysis]
520 Sinn M, Stein A. Personalisierte Therapie von gastrointestinalen Malignomen. Info Onkol 2018;21:37-43. [DOI: 10.1007/s15004-018-6136-y] [Reference Citation Analysis]
521 Cintas C, Douché T, Therville N, Arcucci S, Ramos-Delgado F, Basset C, Thibault B, Guillermet-Guibert J. Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics. Cancers (Basel) 2018;10:E174. [PMID: 29865155 DOI: 10.3390/cancers10060174] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
522 . Targeted Treatments for Common Solid Tumors. A Beginner's Guide to Targeted Cancer Treatments 2018. [DOI: 10.1002/9781119126843.ch6] [Reference Citation Analysis]
523 Cardin DB, Goff LW, Chan E, Whisenant JG, Dan Ayers G, Takebe N, Arlinghaus LR, Yankeelov TE, Berlin J, Merchant N. Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial. Invest New Drugs 2018;36:442-50. [PMID: 28990119 DOI: 10.1007/s10637-017-0519-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
524 Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol 2018;15:333-48. [PMID: 29717230 DOI: 10.1038/s41575-018-0005-x] [Cited by in Crossref: 506] [Cited by in F6Publishing: 506] [Article Influence: 101.2] [Reference Citation Analysis]
525 Abdel-Wahab R, Varadhachary GR, Bhosale PR, Wang X, Fogelman DR, Shroff RT, Overman MJ, Wolff RA, Javle M. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. J Hematol Oncol 2018;11:71. [PMID: 29843755 DOI: 10.1186/s13045-018-0616-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
526 Saito K, Isayama H, Sakamoto Y, Nakai Y, Ishigaki K, Tanaka M, Watadani T, Arita J, Takahara N, Mizuno S, Kogure H, Ijichi H, Tateishi K, Tada M, Hasegawa K, Fukayama M, Kokudo N, Koike K. A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer. Med Oncol. 2018;35:100. [PMID: 29846849 DOI: 10.1007/s12032-018-1158-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
527 Hirooka Y, Kasuya H, Ishikawa T, Kawashima H, Ohno E, Villalobos IB, Naoe Y, Ichinose T, Koyama N, Tanaka M, Kodera Y, Goto H. A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer. BMC Cancer 2018;18:596. [PMID: 29801474 DOI: 10.1186/s12885-018-4453-z] [Cited by in Crossref: 69] [Cited by in F6Publishing: 76] [Article Influence: 13.8] [Reference Citation Analysis]
528 Jakubison BL, Schweickert PG, Moser SE, Yang Y, Gao H, Scully K, Itkin-Ansari P, Liu Y, Konieczny SF. Induced PTF1a expression in pancreatic ductal adenocarcinoma cells activates acinar gene networks, reduces tumorigenic properties, and sensitizes cells to gemcitabine treatment. Mol Oncol. 2018;12:1104-1124. [PMID: 29719936 DOI: 10.1002/1878-0261.12314] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
529 Chu M, Wang T, Sun A, Chen Y. Nimesulide inhibits proliferation and induces apoptosis of pancreatic cancer cells by enhancing expression of PTEN. Exp Ther Med 2018;16:370-6. [PMID: 29896263 DOI: 10.3892/etm.2018.6191] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
530 Li T, Kang G, Wang T, Huang H. Tumor angiogenesis and anti-angiogenic gene therapy for cancer. Oncol Lett 2018;16:687-702. [PMID: 29963134 DOI: 10.3892/ol.2018.8733] [Cited by in Crossref: 57] [Cited by in F6Publishing: 85] [Article Influence: 11.4] [Reference Citation Analysis]
531 Saletti P, Zaniboni A. Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospects. J Gastrointest Oncol 2018;9:377-89. [PMID: 29755778 DOI: 10.21037/jgo.2018.01.12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
532 Todaka A, Mizuno N, Ozaka M, Ueno H, Kobayashi S, Uesugi K, Kobayashi N, Hayashi H, Sudo K, Okano N, Horita Y, Kamei K, Yukisawa S, Nakamori S, Yachi Y, Henmi T, Kobayashi M, Boku N, Mori K, Fukutomi A. Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan. Pancreas 2018;47:631-6. [PMID: 29683973 DOI: 10.1097/MPA.0000000000001049] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
533 Sato Y, Ueno H, Ioka T, Ohkawa S, Ikeda M, Shimamura T, Tsuji A, Tsuchiya Y, Furuse J, Ishii H, Furuya K, Iguchi H, Saito Y, Kaniwa N, Sawada JI, Sakamoto H, Sekine A, Okusaka T, Yoshida T; GEST. SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1. Pancreas 2018;47:637-42. [PMID: 29683977 DOI: 10.1097/MPA.0000000000001052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
534 Martín AM, Hidalgo M, Alvarez R, Arrazubi V, Martínez-Galán J, Salgado M, Macarulla T, Carrato A. From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer. J Cancer 2018;9:1978-88. [PMID: 29896283 DOI: 10.7150/jca.23716] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
535 Sheahan AV, Biankin AV, Parish CR, Khachigian LM. Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review. Oncotarget 2018;9:21613-27. [PMID: 29765563 DOI: 10.18632/oncotarget.25085] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
536 Tummers WS, Miller SE, Teraphongphom NT, Gomez A, Steinberg I, Huland DM, Hong S, Kothapalli SR, Hasan A, Ertsey R, Bonsing BA, Vahrmeijer AL, Swijnenburg RJ, Longacre TA, Fisher GA, Gambhir SS, Poultsides GA, Rosenthal EL. Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging. Ann Surg Oncol 2018;25:1880-8. [PMID: 29667116 DOI: 10.1245/s10434-018-6453-2] [Cited by in Crossref: 95] [Cited by in F6Publishing: 101] [Article Influence: 19.0] [Reference Citation Analysis]
537 Dorjee P, Long ZW. A mixed treatment comparison of toxicity of gemcitabine combined with different targeted drugs in the treatment of advanced or metastatic pancreatic cancer. Cancer Biol Ther 2018;19:497-506. [PMID: 29658816 DOI: 10.1080/15384047.2018.1433503] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
538 Arias-Pinilla GA, Dalgleish AG, Mudan S, Bagwan I, Walker AJ, Modjtahedi H. Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer. Oncotarget 2018;9:19994-20007. [PMID: 29731998 DOI: 10.18632/oncotarget.25017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
539 Hall BR, Cannon A, Atri P, Wichman CS, Smith LM, Ganti AK, Are C, Sasson AR, Kumar S, Batra SK. Advanced pancreatic cancer: a meta-analysis of clinical trials over thirty years. Oncotarget 2018;9:19396-405. [PMID: 29721211 DOI: 10.18632/oncotarget.25036] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
540 Deng C, Xiong J, Gu X, Chen X, Wu S, Wang Z, Wang D, Tu J, Xie J. Novel recombinant immunotoxin of EGFR specific nanobody fused with cucurmosin, construction and antitumor efficiency in vitro. Oncotarget 2017;8:38568-80. [PMID: 28445134 DOI: 10.18632/oncotarget.16930] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
541 Nishimura M, Hayashi M, Mizutani Y, Takenaka K, Imamura Y, Chayahara N, Toyoda M, Kiyota N, Mukohara T, Aikawa H, Fujiwara Y, Hamada A, Minami H. Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging. Oncotarget 2018;9:18540-7. [PMID: 29719624 DOI: 10.18632/oncotarget.24928] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
542 Kang J, Hwang I, Yoo C, Kim KP, Jeong JH, Chang HM, Lee SS, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Hong SM, Shin SH, Hwang DW, Song KB, Lee JH, Kim SC, Ryoo BY. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Invest New Drugs. 2018;36:732-741. [PMID: 29616439 DOI: 10.1007/s10637-018-0598-5] [Cited by in Crossref: 73] [Cited by in F6Publishing: 67] [Article Influence: 14.6] [Reference Citation Analysis]
543 Strijker M, Gerritsen A, van Hilst J, Bijlsma MF, Bonsing BA, Brosens LA, Bruno MJ, van Dam RM, Dijk F, van Eijck CH, Farina Sarasqueta A, Fockens P, Gerhards MF, Groot Koerkamp B, van der Harst E, de Hingh IH, van Hooft JE, Huysentruyt CJ, Kazemier G, Klaase JM, van Laarhoven CJ, van Laarhoven HW, Liem MS, de Meijer VE, van Rijssen LB, van Santvoort HC, Suker M, Verhagen JH, Verheij J, Verspaget HW, Wennink RA, Wilmink JW, Molenaar IQ, Boermeester MA, Busch OR, Besselink MG; Dutch Pancreatitis Study Group and Dutch Pancreatic Cancer Group. The Dutch Pancreas Biobank Within the Parelsnoer Institute: A Nationwide Biobank of Pancreatic and Periampullary Diseases. Pancreas 2018;47:495-501. [PMID: 29521943 DOI: 10.1097/MPA.0000000000001018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
544 Di B, Pan B, Ge L, Ma J, Wu Y, Guo T. Targeted agents for patients with advanced/metastatic pancreatic cancer: A protocol for systematic review and network meta-analysis. Medicine (Baltimore) 2018;97:e0115. [PMID: 29595634 DOI: 10.1097/MD.0000000000010115] [Reference Citation Analysis]
545 Manegold P, Lai KKY, Wu Y, Teo JL, Lenz HJ, Genyk YS, Pandol SJ, Wu K, Lin DP, Chen Y, Nguyen C, Zhao Y, Kahn M. Differentiation Therapy Targeting the β-Catenin/CBP Interaction in Pancreatic Cancer. Cancers (Basel) 2018;10:E95. [PMID: 29596326 DOI: 10.3390/cancers10040095] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 5.6] [Reference Citation Analysis]
546 Wang YN, Lee HH, Chou CK, Yang WH, Wei Y, Chen CT, Yao J, Hsu JL, Zhu C, Ying H, Ye Y, Wang WJ, Lim SO, Xia W, Ko HW, Liu X, Liu CG, Wu X, Wang H, Li D, Prakash LR, Katz MH, Kang Y, Kim M, Fleming JB, Fogelman D, Javle M, Maitra A, Hung MC. Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Cancer Cell 2018;33:752-769.e8. [PMID: 29606349 DOI: 10.1016/j.ccell.2018.02.012] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
547 Zhu J, Ji Y, Yu Y, Jin Y, Zhang X, Zhou J, Chen Y. Knockdown of serine/threonine protein phosphatase 5 enhances gemcitabine sensitivity by promoting apoptosis in pancreatic cancer cells in vitro. Oncol Lett 2018;15:8761-9. [PMID: 29805615 DOI: 10.3892/ol.2018.8363] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
548 Chin V, Nagrial A, Sjoquist K, O'Connor CA, Chantrill L, Biankin AV, Scholten RJ, Yip D. Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database Syst Rev 2018;3:CD011044. [PMID: 29557103 DOI: 10.1002/14651858.CD011044.pub2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 56] [Article Influence: 7.0] [Reference Citation Analysis]
549 Cheng XB, Sato N, Kohi S, Koga A, Hirata K. 4-Methylumbelliferone inhibits enhanced hyaluronan synthesis and cell migration in pancreatic cancer cells in response to tumor-stromal interactions. Oncol Lett 2018;15:6297-301. [PMID: 29725394 DOI: 10.3892/ol.2018.8147] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
550 Felsenstein M, Hruban RH, Wood LD. New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis. Adv Anat Pathol 2018;25:131-42. [PMID: 28914620 DOI: 10.1097/PAP.0000000000000172] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 5.6] [Reference Citation Analysis]
551 Uccello M, Moschetta M, Mak G, Alam T, Henriquez CM, Arkenau HT. Towards an optimal treatment algorithm for metastatic pancreatic ductal adenocarcinoma (PDA). Curr Oncol 2018;25:e90-4. [PMID: 29507500 DOI: 10.3747/co.25.3708] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
552 Yang L, Yang G, Ding Y, Dai Y, Xu S, Guo Q, Xie A, Hu G. Inhibition of PI3K/AKT Signaling Pathway Radiosensitizes Pancreatic Cancer Cells with ARID1A Deficiency in Vitro. J Cancer 2018;9:890-900. [PMID: 29581767 DOI: 10.7150/jca.21306] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
553 Bobrov E, Skobeleva N, Restifo D, Beglyarova N, Cai KQ, Handorf E, Campbell K, Proia DA, Khazak V, Golemis EA, Astsaturov I. Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models. Oncotarget 2017;8:4399-409. [PMID: 27779106 DOI: 10.18632/oncotarget.12642] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
554 Péron J, Roy P, Conroy T, Desseigne F, Ychou M, Gourgou-Bourgade S, Stanbury T, Roche L, Ozenne B, Buyse M. An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma. Oncotarget 2016;7:82953-60. [PMID: 27765912 DOI: 10.18632/oncotarget.12761] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
555 Dong Q, Li C, Che X, Qu J, Fan Y, Li X, Li Y, Wang Q, Liu Y, Yang X, Qu X. MicroRNA-891b is an independent prognostic factor of pancreatic cancer by targeting Cbl-b to suppress the growth of pancreatic cancer cells. Oncotarget 2016;7:82338-53. [PMID: 27494897 DOI: 10.18632/oncotarget.11001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
556 Wu S, Fu L. Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells. Mol Cancer 2018;17:25. [PMID: 29455646 DOI: 10.1186/s12943-018-0775-3] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 13.4] [Reference Citation Analysis]
557 Chu QD, Borazanci E, Kim RH, Sangster G. Adenocarcinoma of the Pancreas. The American Cancer Society's Oncology in Practice 2018. [DOI: 10.1002/9781118592168.ch6] [Reference Citation Analysis]
558 Bernard V, Maitra A. Targeted Therapies for Pancreatic Cancer. The Pancreas 2018. [DOI: 10.1002/9781119188421.ch115] [Reference Citation Analysis]
559 Faluyi OO, Chatterjee M, Palmer DH. Palliative Chemotherapy for Advanced Pancreatic Cancer. The Pancreas 2018. [DOI: 10.1002/9781119188421.ch116] [Reference Citation Analysis]
560 Yu IS, Cheung WY. A Contemporary Review of the Treatment Landscape and the Role of Predictive and Prognostic Biomarkers in Pancreatic Adenocarcinoma. Can J Gastroenterol Hepatol 2018;2018:1863535. [PMID: 29623263 DOI: 10.1155/2018/1863535] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
561 Xu BQ, Fu ZG, Meng Y, Wu XQ, Wu B, Xu L, Jiang JL, Li L, Chen ZN. Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling. Oncotarget 2016;7:62177-93. [PMID: 27556697 DOI: 10.18632/oncotarget.11405] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
562 Comito F, Grassi E, Poerio A, Freier E, Calculli L, Zompatori M, Ricci C, Casadei R, Di Marco M. Organizing pneumonia after pancreatic cancer treatment with nab-paclitaxel and gemcitabine: a case report. BJR Case Rep 2018;4:20170086. [PMID: 30363157 DOI: 10.1259/bjrcr.20170086] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
563 Rosenberg A, Mahalingam D. Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response. J Gastrointest Oncol. 2018;9:143-159. [PMID: 29564181 DOI: 10.21037/jgo.2018.01.13] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
564 Kieler M, Unseld M, Bianconi D, Prager G. Challenges and Perspectives for Immunotherapy in Adenocarcinoma of the Pancreas: The Cancer Immunity Cycle. Pancreas 2018;47:142-57. [PMID: 29346215 DOI: 10.1097/MPA.0000000000000970] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
565 Palacio S, Hosein PJ, Reis I, Akunyili II, Ernani V, Pollack T, Macintyre J, Restrepo MH, Merchan JR, Rocha Lima CM. The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma. J Gastrointest Oncol 2018;9:135-9. [PMID: 29564179 DOI: 10.21037/jgo.2017.10.12] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
566 Amanam I, Chung V. Targeted Therapies for Pancreatic Cancer. Cancers (Basel) 2018;10:E36. [PMID: 29382159 DOI: 10.3390/cancers10020036] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 11.4] [Reference Citation Analysis]
567 Berry W, Lundy J, Croagh D, Jenkins BJ. Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer. Cancers (Basel) 2018;10:E35. [PMID: 29382047 DOI: 10.3390/cancers10020035] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
568 Smigiel JM, Parameswaran N, Jackson MW. Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics. Cancers (Basel) 2018;10:E14. [PMID: 29320425 DOI: 10.3390/cancers10010014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
569 Qiu J, Yang G, Feng M, Zheng S, Cao Z, You L, Zheng L, Zhang T, Zhao Y. Extracellular vesicles as mediators of the progression and chemoresistance of pancreatic cancer and their potential clinical applications. Mol Cancer. 2018;17:2. [PMID: 29304816 DOI: 10.1186/s12943-017-0755-z] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 9.0] [Reference Citation Analysis]
570 Li JA, Song C, Rong Y, Kuang T, Wang D, Xu X, Yuan J, Luo K, Qin B, Nowsheen S, Lou Z, Lou W. Chk1 inhibitor SCH 900776 enhances the antitumor activity of MLN4924 on pancreatic cancer. Cell Cycle 2018;17:191-9. [PMID: 29157102 DOI: 10.1080/15384101.2017.1405194] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
571 Dukleska K, Yeo CJ, Pishvaian MJ, Brody JR. Precision Medicine Based on Next Generation Sequencing and Master Controllers. Pancreatic Cancer 2018. [DOI: 10.1007/978-1-4939-6631-8_71-1] [Reference Citation Analysis]
572 Malla S, Gangishetti U. Tyrosine Kinase Inhibitors and Their Clinical Prospective in Pancreatic Cancer. Role of Tyrosine Kinases in Gastrointestinal Malignancies 2018. [DOI: 10.1007/978-981-13-1486-5_5] [Reference Citation Analysis]
573 Sümbül AT, Özyılkan Ö. Hepatotoxicity and Hepatic Dysfunction. The MASCC Textbook of Cancer Supportive Care and Survivorship 2018. [DOI: 10.1007/978-3-319-90990-5_30] [Reference Citation Analysis]
574 Vijayvergia N, Cohen SJ. Cytotoxic Therapy in Advanced Pancreatic Cancer: Where We Are and Where We Are Headed. Current and Emerging Therapies in Pancreatic Cancer 2018. [DOI: 10.1007/978-3-319-58256-6_11] [Reference Citation Analysis]
575 Shaib WL, El-rayes BF. Molecularly Targeted Therapies in Pancreatic Cancer. Current and Emerging Therapies in Pancreatic Cancer 2018. [DOI: 10.1007/978-3-319-58256-6_12] [Reference Citation Analysis]
576 Dev R, Javle M. Palliative Management of Pancreatic Cancer. Pancreatic Cancer 2018. [DOI: 10.1007/978-1-4939-7193-0_33] [Reference Citation Analysis]
577 Iovanna J, Bian B, Bigonnet M, Dusetti N. Differential Therapy Based on Tumor Heterogeneity in Pancreatic Cancer. Pancreatic Cancer 2018. [DOI: 10.1007/978-1-4939-7193-0_94] [Reference Citation Analysis]
578 Dukleska K, Yeo CJ, Pishvaian MJ, Brody JR. Precision Medicine Based on Next-Generation Sequencing and Master Controllers. Pancreatic Cancer 2018. [DOI: 10.1007/978-1-4939-7193-0_71] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
579 Neoptolemos JP, Cunningham D, Sclafani F, Ghaneh P. Adjuvant Chemotherapy in Pancreatic Cancer. Pancreatic Cancer 2018. [DOI: 10.1007/978-1-4939-7193-0_43] [Reference Citation Analysis]
580 Fukutomi A. Treatment strategy for unresectable pancreatic cancer. Journal of the Japan Pancreas Society 2018;33:37-47. [DOI: 10.2958/suizo.33.37] [Reference Citation Analysis]
581 Bhaskar LVKS, Saikrishna L. Drug Resistance Against Tyrosine Kinase Inhibitor in Gastrointestinal Malignancies. Role of Tyrosine Kinases in Gastrointestinal Malignancies 2018. [DOI: 10.1007/978-981-13-1486-5_14] [Reference Citation Analysis]
582 Williams M, Lomberk G, Urrutia R. EGFR (ErbB) Signaling Pathways in Pancreatic Cancer Pathogenesis. Pancreatic Cancer 2018. [DOI: 10.1007/978-1-4939-7193-0_15] [Reference Citation Analysis]
583 Forst DA, Wen PY. Neurological Complications of Targeted Therapies. Cancer Neurology in Clinical Practice 2018. [DOI: 10.1007/978-3-319-57901-6_16] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
584 Le UM, Ngo D, Nguyen TM, Nguyen QT, Ton J. Enhanced Selective Cytotoxicity in Pancreatic Cancer Cells Using EGF-Conjugated Liposome-Encapsulated Curcumin. 6th International Conference on the Development of Biomedical Engineering in Vietnam (BME6) 2018. [DOI: 10.1007/978-981-10-4361-1_36] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
585 Steins M, Thomas M, Geißler M. Erlotinib. Recent Results Cancer Res 2018;211:1-17. [PMID: 30069756 DOI: 10.1007/978-3-319-91442-8_1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
586 Major-Elechi BT, Novotny PJ, Singh JA, Bonner JA, Dueck AC, Sargent DJ, Grothey A, Sloan JA. Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance). Int J Stat Med Res 2018;7:137-46. [PMID: 31396297 DOI: 10.6000/1929-6029.2018.07.04.4] [Reference Citation Analysis]
587 Koyama N. DLI Induced by Molecular Target Antineoplastic Drug: What Are the Characteristics of DLI in Molecular Target Antineoplastic Drugs? Respiratory Disease Series: Diagnostic Tools and Disease Managements 2018. [DOI: 10.1007/978-981-10-4466-3_11] [Reference Citation Analysis]
588 Golombek T, Lordick F. Stellenwert der systemischen Chemotherapie bei fortgeschrittener peritonealer Metastasierung. Peritoneale Tumoren und Metastasen 2018. [DOI: 10.1007/978-3-662-54500-3_26] [Reference Citation Analysis]
589 Tanaka S. Molecular Analysis for Therapeutic Targets of Pancreatic Cancer. Molecular Diagnosis and Targeting for Thoracic and Gastrointestinal Malignancy 2018. [DOI: 10.1007/978-981-10-6469-2_8] [Reference Citation Analysis]
590 Barreto SG. Pancreatic Cancer. Surgical Diseases of the Pancreas and Biliary Tree 2018. [DOI: 10.1007/978-981-10-8755-4_16] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
591 Härtel N, Rückert F. Pankreaskarzinom beim alten und geriatrischen Patienten. Geriatrische Onkologie 2018. [DOI: 10.1007/978-3-662-48727-3_26] [Reference Citation Analysis]
592 Mukhund V, Alam A, Nagaraju GP. EGFR and Cytoplasmic Kinase Src Targeting in Pancreatic Cancer. Role of Tyrosine Kinases in Gastrointestinal Malignancies 2018. [DOI: 10.1007/978-981-13-1486-5_8] [Reference Citation Analysis]
593 Sclafani F, Cunningham D, Okines A, Ratnayake G, Chau I. Chemotherapy for Advanced Pancreatic Cancer. Pancreatic Cancer 2018. [DOI: 10.1007/978-1-4939-7193-0_37] [Reference Citation Analysis]
594 Wei F, Shin D, Cai X. Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis. Int J Clin Oncol 2018;23:443-51. [PMID: 29289981 DOI: 10.1007/s10147-017-1231-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
595 Palmer AC, Sorger PK. Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy. Cell. 2017;171:1678-1691.e13. [PMID: 29245013 DOI: 10.1016/j.cell.2017.11.009] [Cited by in Crossref: 323] [Cited by in F6Publishing: 341] [Article Influence: 53.8] [Reference Citation Analysis]
596 Tesfaye AA, Kamgar M, Azmi A, Philip PA. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. Expert Rev Anticancer Ther. 2018;18:131-148. [PMID: 29254387 DOI: 10.1080/14737140.2018.1417844] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
597 Zhou Y, Huang J, Yu X, Jiang X, Shi Y, Weng Y, Kuai Y, Lei L, Ren G, Feng X, Zhong G, Liu Q, Pan H, Zhang X, Zhou R, Lu C. LITAF is a potential tumor suppressor in pancreatic cancer. Oncotarget 2018;9:3131-42. [PMID: 29423035 DOI: 10.18632/oncotarget.23220] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
598 Polireddy K, Dong R, Reed G, Yu J, Chen P, Williamson S, Violet PC, Pessetto Z, Godwin AK, Fan F, Levine M, Drisko JA, Chen Q. High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis: Mechanisms and a Phase I/IIa study. Sci Rep 2017;7:17188. [PMID: 29215048 DOI: 10.1038/s41598-017-17568-8] [Cited by in Crossref: 65] [Cited by in F6Publishing: 70] [Article Influence: 10.8] [Reference Citation Analysis]
599 Berger AK, Haag GM, Ehmann M, Byl A, Jäger D, Springfeld C. Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient. BMC Gastroenterol 2017;17:143. [PMID: 29207968 DOI: 10.1186/s12876-017-0709-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
600 Ubezio P, Falcetta F, Carrassa L, Lupi M. Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer. Oncotarget 2016;7:15492-506. [PMID: 26909860 DOI: 10.18632/oncotarget.7491] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
601 Khan K, Cunningham D, Peckitt C, Barton S, Tait D, Hawkins M, Watkins D, Starling N, Rao S, Begum R, Thomas J, Oates J, Guzzardo V, Fassan M, Braconi C, Chau I. miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial. Oncotarget 2016;7:12672-81. [PMID: 26862857 DOI: 10.18632/oncotarget.7208] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 5.2] [Reference Citation Analysis]
602 Wegner CS, Hauge A, Gaustad JV, Andersen LMK, Simonsen TG, Galappathi K, Rofstad EK. Dynamic contrast-enhanced MRI of the microenvironment of pancreatic adenocarcinoma xenografts. Acta Oncol 2017;56:1754-62. [PMID: 28661213 DOI: 10.1080/0284186X.2017.1343494] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
603 Furuse J, Gemma A, Ichikawa W, Okusaka T, Seki A, Ishii T. Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis. Jpn J Clin Oncol 2017;47:832-9. [PMID: 28541474 DOI: 10.1093/jjco/hyx075] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
604 Chen L, Ma C, Bian Y, Shao C, Wang T, Li J, Chong X, Su L, Lu J. Aberrant expression of STYK1 and E-cadherin confer a poor prognosis for pancreatic cancer patients. Oncotarget 2017;8:111333-45. [PMID: 29340057 DOI: 10.18632/oncotarget.22794] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
605 Puri A, Chang JC, Kundranda M. Screening for Pancreatic Cancer: Current Status and Future Directions. EMJ 2017. [DOI: 10.33590/emj/10313242] [Reference Citation Analysis]
606 Mo J, Lin M, He B, Tan K, Jin C, Jiang H, Pan X, Lin W. Recombinant human adenovirus-p53 improves the outcome of mid-late stage pancreatic cancer via arterial infusion. Oncol Lett 2017;14:6829-32. [PMID: 29181104 DOI: 10.3892/ol.2017.7058] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
607 Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. J Am Coll Cardiol 2017;70:2536-51. [PMID: 29145954 DOI: 10.1016/j.jacc.2017.09.1096] [Cited by in Crossref: 205] [Cited by in F6Publishing: 227] [Article Influence: 34.2] [Reference Citation Analysis]
608 Hu X, Wang D, Tong Y, Tong L, Wang X, Zhu L, Xie H, Li S, Yang Y, Xu Y. Design, Synthesis, and Evaluation of Ribose-Modified Anilinopyrimidine Derivatives as EGFR Tyrosine Kinase Inhibitors. Front Chem 2017;5:101. [PMID: 29250520 DOI: 10.3389/fchem.2017.00101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
609 Huang CY, Ju DT, Chang CF, Muralidhar Reddy P, Velmurugan BK. A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer. Biomedicine (Taipei). 2017;7:23. [PMID: 29130448 DOI: 10.1051/bmdcn/2017070423] [Cited by in Crossref: 222] [Cited by in F6Publishing: 234] [Article Influence: 37.0] [Reference Citation Analysis]
610 Hammam K, Saez-Ayala M, Rebuffet E, Gros L, Lopez S, Hajem B, Humbert M, Baudelet E, Audebert S, Betzi S, Lugari A, Combes S, Letard S, Casteran N, Mansfield C, Moussy A, De Sepulveda P, Morelli X, Dubreuil P. Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology. Nat Commun 2017;8:1420. [PMID: 29127277 DOI: 10.1038/s41467-017-01582-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
611 Li CM, Liu ZC, Bao YT, Sun XD, Wang LL. Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: A case report and literature review. World J Gastroenterol 2017; 23(41): 7478-7488 [PMID: 29151702 DOI: 10.3748/wjg.v23.i41.7478] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
612 Tischer B, Bilang M, Kraemer M, Ronga P, Lacouture ME. A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies. Support Care Cancer 2018;26:1169-79. [PMID: 29116406 DOI: 10.1007/s00520-017-3938-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
613 Ko AH. Clinical Management. Cancer J 2017;23:355-361. [DOI: 10.1097/ppo.0000000000000294] [Reference Citation Analysis]
614 Kim M, Chin YW, Lee EJ. α, γ-Mangostins Induce Autophagy and Show Synergistic Effect with Gemcitabine in Pancreatic Cancer Cell Lines. Biomol Ther (Seoul) 2017;25:609-17. [PMID: 28822990 DOI: 10.4062/biomolther.2017.074] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
615 Van Laethem JL, Riess H, Jassem J, Haas M, Martens UM, Weekes C, Peeters M, Ross P, Bridgewater J, Melichar B, Cascinu S, Saramak P, Michl P, Van Brummelen D, Zaniboni A, Schmiegel W, Dueland S, Giurescu M, Garosi VL, Roth K, Schulz A, Seidel H, Rajagopalan P, Teufel M, Childs BH. Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. Target Oncol 2017;12:97-109. [PMID: 27975152 DOI: 10.1007/s11523-016-0469-y] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
616 Huguet F, Fernet M, Giocanti N, Favaudon V, Larsen AK. Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status. Target Oncol 2016;11:371-81. [PMID: 26668065 DOI: 10.1007/s11523-015-0403-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
617 Jing W, Song N, Liu Y, Qu X, Hou K, Yang X, Che X. DNA methyltransferase 3a modulates chemosensitivity to gemcitabine and oxaliplatin via CHK1 and AKT in p53‑deficient pancreatic cancer cells. Mol Med Rep 2018;17:117-24. [PMID: 29115606 DOI: 10.3892/mmr.2017.7923] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
618 Wu Q, Tian Y, Zhang J, Zhang H, Gu F, Lu Y, Zou S, Chen Y, Sun P, Xu M, Sun X, Xia C, Chi H, Ying Zhu A, Tang D, Wang D. Functions of pancreatic stellate cell-derived soluble factors in the microenvironment of pancreatic ductal carcinoma. Oncotarget 2017;8:102721-38. [PMID: 29254283 DOI: 10.18632/oncotarget.21970] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
619 Sato S, Nakamura T, Katagiri T, Tsuchikawa T, Kushibiki T, Hontani K, Takahashi M, Inoko K, Takano H, Abe H, Takeuchi S, Ono M, Kuwabara S, Umemoto K, Suzuki T, Sato O, Nakamura Y, Hirano S. Molecular targeting of cell-permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferation. Oncotarget 2017;8:113662-72. [PMID: 29371937 DOI: 10.18632/oncotarget.21939] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
620 Nalbantoglu S, Abu-Asab M, Tan M, Zhang X, Cai L, Amri H. Study of Clinical Survival and Gene Expression in a Sample of Pancreatic Ductal Adenocarcinoma by Parsimony Phylogenetic Analysis. OMICS 2016;20:442-7. [PMID: 27428255 DOI: 10.1089/omi.2016.0059] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
621 Muñoz AR, Chakravarthy D, Gong J, Halff GA, Ghosh R, Kumar AP. Pancreatic cancer: Current status and Challenges. Curr Pharmacol Rep 2017;3:396-408. [PMID: 29404265 DOI: 10.1007/s40495-017-0112-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
622 Chung KH, Ryu JK, Son JH, Lee JW, Jang DK, Lee SH, Kim YT. Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy.Gut Liver. 2017;11:298-305. [PMID: 27965478 DOI: 10.5009/gnl16307] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
623 Cao F, Li J, Li A, Li F. Prognostic significance of positive peritoneal cytology in resectable pancreatic cancer: a systemic review and meta-analysis. Oncotarget 2017;8:15004-13. [PMID: 28122342 DOI: 10.18632/oncotarget.14745] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
624 Shi Y, Zhang S, Han Q, Li J, Yan H, Lv Y, Shi H, Liu R, Dai G. Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial. Oncotarget 2017;8:92401-10. [PMID: 29190925 DOI: 10.18632/oncotarget.21359] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
625 Nguyen AH, Elliott IA, Wu N, Matsumura C, Vogelauer M, Attar N, Dann A, Ghukasyan R, Toste PA, Patel SG, Williams JL, Li L, Dawson DW, Radu C, Kurdistani SK, Donahue TR. Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts. Oncotarget 2017;8:19074-88. [PMID: 27894105 DOI: 10.18632/oncotarget.13572] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
626 Thillai K, Lam H, Sarker D, Wells CM. Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer? Oncotarget 2017;8:14173-91. [PMID: 27845911 DOI: 10.18632/oncotarget.13309] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
627 Saung MT, Zheng L. Current Standards of Chemotherapy for Pancreatic Cancer. Clin Ther 2017;39:2125-34. [PMID: 28939405 DOI: 10.1016/j.clinthera.2017.08.015] [Cited by in Crossref: 48] [Cited by in F6Publishing: 59] [Article Influence: 8.0] [Reference Citation Analysis]
628 Bhargava C, Dürkop H, Zhao X, Weng A, Melzig MF, Fuchs H. Targeted dianthin is a powerful toxin to treat pancreatic carcinoma when applied in combination with the glycosylated triterpene SO1861. Mol Oncol 2017;11:1527-43. [PMID: 28755527 DOI: 10.1002/1878-0261.12115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
629 Averett C, Bhardwaj A, Arora S, Srivastava SK, Khan MA, Ahmad A, Singh S, Carter JE, Khushman M, Singh AP. Honokiol suppresses pancreatic tumor growth, metastasis and desmoplasia by interfering with tumor-stromal cross-talk. Carcinogenesis 2016;37:1052-61. [PMID: 27609457 DOI: 10.1093/carcin/bgw096] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
630 Kim TH, Shin S, Kim S, Bulitta JB, Weon KY, Joo SH, Ma E, Yoo SD, Park GY, Kwon DR, Jeong SW, Lee DY, Shin BS. Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine. Molecules 2017;22:E1515. [PMID: 28891960 DOI: 10.3390/molecules22091515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
631 Ruess DA, Görgülü K, Wörmann SM, Algül H. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. Drugs Aging 2017;34:331-57. [PMID: 28349415 DOI: 10.1007/s40266-017-0453-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
632 Kieler M, Unseld M, Bianconi D, Prager GW. Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer. Memo 2017;10:136-40. [PMID: 28989542 DOI: 10.1007/s12254-017-0352-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
633 Ishigaki K, Nakai Y, Isayama H, Saito K, Hamada T, Takahara N, Mizuno S, Mohri D, Kogure H, Matsubara S, Yamamoto N, Tada M, Koike K. Thromboembolisms in Advanced Pancreatic Cancer: A Retrospective Analysis of 475 Patients. Pancreas 2017;46:1069-75. [PMID: 28787333 DOI: 10.1097/MPA.0000000000000889] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
634 Chen K, Qian W, Li J, Jiang Z, Cheng L, Yan B, Cao J, Sun L, Zhou C, Lei M, Duan W, Ma J, Ma Q, Ma Z. Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1-dependent pathway. Mol Oncol 2017;11:1475-92. [PMID: 28783244 DOI: 10.1002/1878-0261.12116] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 8.3] [Reference Citation Analysis]
635 Beg MS, Gupta A, Stewart T, Rethorst CD. Promise of Wearable Physical Activity Monitors in Oncology Practice. J Oncol Pract 2017;13:82-9. [PMID: 28387544 DOI: 10.1200/JOP.2016.016857] [Cited by in Crossref: 53] [Cited by in F6Publishing: 58] [Article Influence: 8.8] [Reference Citation Analysis]
636 Li Y, Xie P, Lu L, Wang J, Diao L, Liu Z, Guo F, He Y, Liu Y, Huang Q, Liang H, Li D, He F. An integrated bioinformatics platform for investigating the human E3 ubiquitin ligase-substrate interaction network. Nat Commun 2017;8:347. [PMID: 28839186 DOI: 10.1038/s41467-017-00299-9] [Cited by in Crossref: 71] [Cited by in F6Publishing: 81] [Article Influence: 11.8] [Reference Citation Analysis]
637 Li D, Wang J, Zhou J, Zhan S, Huang Y, Wang F, Zhang Z, Zhu D, Zhao H, Li D, Chen G, Zhu X, Zhao X. B7-H3 combats apoptosis induced by chemotherapy by delivering signals to pancreatic cancer cells. Oncotarget 2017;8:74856-68. [PMID: 29088829 DOI: 10.18632/oncotarget.20421] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
638 Wang T, Zhuang Z, Zhang P, Wang Y, Mu L, Jin H, Zhou L, Ma X, Liang R, Yuan Y. Effect of arenobufagin on human pancreatic carcinoma cells. Oncol Lett 2017;14:4971-6. [PMID: 29085509 DOI: 10.3892/ol.2017.6798] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
639 Tartari F, Conti A, Cerqueti R. Assessing the relationship between toxicity and economic cost of oncological target agents: A systematic review of clinical trials. PLoS One 2017;12:e0183639. [PMID: 28829823 DOI: 10.1371/journal.pone.0183639] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
640 Connor AA, Denroche RE, Jang GH, Timms L, Kalimuthu SN, Selander I, McPherson T, Wilson GW, Chan-Seng-Yue MA, Borozan I, Ferretti V, Grant RC, Lungu IM, Costello E, Greenhalf W, Palmer D, Ghaneh P, Neoptolemos JP, Buchler M, Petersen G, Thayer S, Hollingsworth MA, Sherker A, Durocher D, Dhani N, Hedley D, Serra S, Pollett A, Roehrl MHA, Bavi P, Bartlett JMS, Cleary S, Wilson JM, Alexandrov LB, Moore M, Wouters BG, McPherson JD, Notta F, Stein LD, Gallinger S. Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. JAMA Oncol 2017;3:774-83. [PMID: 27768182 DOI: 10.1001/jamaoncol.2016.3916] [Cited by in Crossref: 167] [Cited by in F6Publishing: 175] [Article Influence: 27.8] [Reference Citation Analysis]
641 Adamo P, Cowley CM, Neal CP, Mistry V, Page K, Dennison AR, Isherwood J, Hastings R, Luo J, Moore DA, Howard PJ, Miguel ML, Pritchard C, Manson M, Shaw JA. Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer. Oncotarget 2017;8:87221-33. [PMID: 29152076 DOI: 10.18632/oncotarget.20250] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
642 Xia G, Wang H, Song Z, Meng Q, Huang X, Huang X. Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2). J Exp Clin Cancer Res 2017;36:107. [PMID: 28797284 DOI: 10.1186/s13046-017-0579-0] [Cited by in Crossref: 42] [Cited by in F6Publishing: 48] [Article Influence: 7.0] [Reference Citation Analysis]
643 Lambert A, Gavoille C, Conroy T. Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions. Therap Adv Gastroenterol 2017;10:631-45. [PMID: 28835777 DOI: 10.1177/1756283X17713879] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
644 Ota K, Harada T, Otsubo K, Fujii A, Tsuchiya Y, Tanaka K, Okamoto I, Nakanishi Y. Visualization and quantitation of epidermal growth factor receptor homodimerization and activation with a proximity ligation assay. Oncotarget 2017;8:72127-32. [PMID: 29069773 DOI: 10.18632/oncotarget.19552] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
645 Burtness B, Powell M, Catalano P, Berlin J, Liles DK, Chapman AE, Mitchell E, Benson AB. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study. Am J Clin Oncol 2016;39:340-5. [PMID: 24685886 DOI: 10.1097/COC.0000000000000068] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
646 Kiesewetter B, Raderer M, Prager GW, Fuereder T, Marosi C, Preusser M, Krainer M, Locker GJ, Brodowicz T, Zielinski CC. The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna. ESMO Open 2017;2:e000166. [PMID: 28761758 DOI: 10.1136/esmoopen-2017-000166] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
647 Lau SC, Cheung WY. Evolving treatment landscape for early and advanced pancreatic cancer. World J Gastrointest Oncol 2017; 9(7): 281-292 [PMID: 28808501 DOI: 10.4251/wjgo.v9.i7.281] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
648 Moutinho-Ribeiro P, Coelho R, Giovannini M, Macedo G. Pancreatic cancer screening: Still a delusion? Pancreatology 2017;17:754-65. [PMID: 28739291 DOI: 10.1016/j.pan.2017.07.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
649 Fountzilas C, Chhatrala R, Khushalani N, Tan W, LeVea C, Hutson A, Tucker C, Ma WW, Warren G, Boland P, Iyer R. A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent. Cancer Chemother Pharmacol 2017;80:497-505. [PMID: 28702772 DOI: 10.1007/s00280-017-3375-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
650 Borsoi C, Leonard F, Lee Y, Zaid M, Elganainy D, Alexander JF, Kai M, Liu YT, Kang Y, Liu X, Koay EJ, Ferrari M, Godin B, Yokoi K. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. Cancer Lett 2017;403:296-304. [PMID: 28687352 DOI: 10.1016/j.canlet.2017.06.026] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
651 Schwartzberg LS, Arena FP, Bienvenu BJ, Kaplan EH, Camacho LH, Campos LT, Waymack JP, Tagliaferri MA, Chen MM, Li D. A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic Cancer. J Cancer 2017;8:1872-83. [PMID: 28819385 DOI: 10.7150/jca.15407] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
652 Go KL, Delitto D, Judge SM, Gerber MH, George TJ Jr, Behrns KE, Hughes SJ, Judge AR, Trevino JG. Orthotopic Patient-Derived Pancreatic Cancer Xenografts Engraft Into the Pancreatic Parenchyma, Metastasize, and Induce Muscle Wasting to Recapitulate the Human Disease. Pancreas 2017;46:813-9. [PMID: 28609371 DOI: 10.1097/MPA.0000000000000843] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
653 Levy MJ, Alberts SR, Bamlet WR, Burch PA, Farnell MB, Gleeson FC, Haddock MG, Kendrick ML, Oberg AL, Petersen GM, Takahashi N, Chari ST. EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer. Gastrointest Endosc 2017;86:161-9. [PMID: 27889543 DOI: 10.1016/j.gie.2016.11.014] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
654 Rahman FAU, Ali S, Saif MW. Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer. Therap Adv Gastroenterol 2017;10:563-72. [PMID: 28804517 DOI: 10.1177/1756283X17705328] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
655 Lee HS, Park SW. Systemic Chemotherapy in Advanced Pancreatic Cancer. Gut Liver 2016;10:340-7. [PMID: 27114434 DOI: 10.5009/gnl15465] [Cited by in Crossref: 33] [Cited by in F6Publishing: 47] [Article Influence: 5.5] [Reference Citation Analysis]
656 Adamska A, Domenichini A, Falasca M. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int J Mol Sci. 2017;18. [PMID: 28640192 DOI: 10.3390/ijms18071338] [Cited by in Crossref: 287] [Cited by in F6Publishing: 308] [Article Influence: 47.8] [Reference Citation Analysis]
657 Muñoz Martín AJ, Adeva J, Martínez-Galán J, Reina JJ, Hidalgo M. Pancreatic ductal adenocarcinoma: metastatic disease. Clin Transl Oncol 2017;19:1423-9. [PMID: 28623515 DOI: 10.1007/s12094-017-1690-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
658 Moravec R, Divi R, Verma M. Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression. World J Gastrointest Oncol 2017; 9(6): 235-250 [PMID: 28656074 DOI: 10.4251/wjgo.v9.i6.235] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
659 Zhu C, Ling W, Zhang J, Gao H, Shen K, Ma X. Safety and efficacy evaluation of pertuzumab in patients with solid tumors. Medicine (Baltimore) 2017;96:e6870. [PMID: 28514302 DOI: 10.1097/MD.0000000000006870] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
660 Hang J, Xue P, Yang H, Li S, Chen D, Zhu L, Huang W, Ren S, Zhu Y, Wang L. Pretreatment C-reactive protein to albumin ratio for predicting overall survival in advanced pancreatic cancer patients. Sci Rep 2017;7:2993. [PMID: 28592881 DOI: 10.1038/s41598-017-03153-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
661 Pimienta M, Edderkaoui M, Wang R, Pandol S. The Potential for Circulating Tumor Cells in Pancreatic Cancer Management. Front Physiol 2017;8:381. [PMID: 28626429 DOI: 10.3389/fphys.2017.00381] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
662 Muranaka T, Kuwatani M, Komatsu Y, Sawada K, Nakatsumi H, Kawamoto Y, Yuki S, Kubota Y, Kubo K, Kawahata S. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. J Gastrointest Oncol. 2017;8:566-571. [PMID: 28736643 DOI: 10.21037/jgo.2017.02.02] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 8.3] [Reference Citation Analysis]
663 Au TH, Wang K, Stenehjem D, Garrido-Laguna I. Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. J Gastrointest Oncol 2017;8:387-404. [PMID: 28736627 DOI: 10.21037/jgo.2017.01.04] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
664 Nguyen KT, Kalyan A, Beasley HS, Singhi AD, Sun W, Zeh HJ, Normolle D, Bahary N. Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer-retrospective analysis of response. J Gastrointest Oncol 2017;8:556-65. [PMID: 28736642 DOI: 10.21037/jgo.2017.01.23] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
665 Khalafalla FG, Khan MW. Inflammation and Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Fighting Against Multiple Opponents. Cancer Growth Metastasis. 2017;10:1179064417709287. [PMID: 28579826 DOI: 10.1177/1179064417709287] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
666 Wong MH, Xue A, Baxter RC, Pavlakis N, Smith RC. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma. Neoplasia 2016;18:425-35. [PMID: 27435925 DOI: 10.1016/j.neo.2016.06.001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
667 Palta M, Willett CG, Czito BG. Pancreatic Cancer. Clinical Radiation Oncology 2017. [DOI: 10.1002/9781119341154.ch22] [Reference Citation Analysis]
668 Hamada C, Okusaka T, Ikari T, Isayama H, Furuse J, Ishii H, Nakai Y, Imai S, Okamura S. Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data. Br J Cancer 2017;116:1544-50. [PMID: 28472821 DOI: 10.1038/bjc.2017.128] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
669 Talwar V, Pradeep Babu K, Raina S. An overall review of targeted therapy in solid cancers. Current Medicine Research and Practice 2017;7:99-105. [DOI: 10.1016/j.cmrp.2017.04.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
670 Haas M, Ormanns S, Baechmann S, Remold A, Kruger S, Westphalen CB, Siveke JT, Wenzel P, Schlitter AM, Esposito I, Quietzsch D, Clemens MR, Kettner E, Laubender RP, Jung A, Kirchner T, Boeck S, Heinemann V. Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer. Br J Cancer 2017;116:1462-9. [PMID: 28449008 DOI: 10.1038/bjc.2017.115] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
671 Chiramel J, Backen AC, Pihlak R, Lamarca A, Frizziero M, Tariq NU, Hubner RA, Valle JW, Amir E, McNamara MG. Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. Int J Mol Sci 2017;18:E909. [PMID: 28445400 DOI: 10.3390/ijms18050909] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
672 Braiteh F, Patel MB, Parisi M, Ni Q, Park S, Faria C. Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting. Cancer Manag Res 2017;9:141-8. [PMID: 28461766 DOI: 10.2147/CMAR.S126073] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
673 Chung V, McDonough S, Philip PA, Cardin D, Wang-Gillam A, Hui L, Tejani MA, Seery TE, Dy IA, Al Baghdadi T, Hendifar AE, Doyle LA, Lowy AM, Guthrie KA, Blanke CD, Hochster HS. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 2017;3:516-22. [PMID: 27978579 DOI: 10.1001/jamaoncol.2016.5383] [Cited by in Crossref: 102] [Cited by in F6Publishing: 110] [Article Influence: 17.0] [Reference Citation Analysis]
674 Infante JR, Cohen RB, Kim KB, Burris HA 3rd, Curt G, Emeribe U, Clemett D, Tomkinson HK, LoRusso PM. A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors. Invest New Drugs 2017;35:576-88. [PMID: 28424891 DOI: 10.1007/s10637-017-0459-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
675 Mehrotra S, Britten CD, Chin S, Garrett-Mayer E, Cloud CA, Li M, Scurti G, Salem ML, Nelson MH, Thomas MB, Paulos CM, Salazar AM, Nishimura MI, Rubinstein MP, Li Z, Cole DJ. Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. J Hematol Oncol 2017;10:82. [PMID: 28388966 DOI: 10.1186/s13045-017-0459-2] [Cited by in Crossref: 83] [Cited by in F6Publishing: 86] [Article Influence: 13.8] [Reference Citation Analysis]
676 Borazanci E, Dang CV, Robey RW, Bates SE, Chabot JA, Von Hoff DD. Pancreatic Cancer: “A Riddle Wrapped in a Mystery inside an Enigma”. Clinical Cancer Research 2017;23:1629-1637. [DOI: 10.1158/1078-0432.ccr-16-2070] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
677 Inoue K, Ohtsuka H, Tachikawa M, Motoi F, Shijo M, Douchi D, Kawasaki S, Kawaguchi K, Masuda K, Fukase K, Naitoh T, Katayose Y, Egawa S, Unno M, Terasaki T. MK2461, a Multitargeted Kinase Inhibitor, Suppresses the Progression of Pancreatic Cancer by Disrupting the Interaction Between Pancreatic Cancer Cells and Stellate Cells. Pancreas 2017;46:557-66. [PMID: 28196027 DOI: 10.1097/MPA.0000000000000778] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
678 Kaneda M, Obara H, Suzuki K, Takeuchi O, Takizawa A, Osaku M, Matsubara H, Kitagawa Y. Evaluation of Suppressive Effects of Tranilast on the Invasion/Metastasis Mechanism in a Murine Pancreatic Cancer Cell Line. Pancreas 2017;46:567-74. [PMID: 28196028 DOI: 10.1097/MPA.0000000000000779] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
679 Hwang DW, So KS, Kim SC, Park KM, Lee YJ, Kim SW, Choi CM, Rho JK, Choi YJ, Lee JC. Autophagy Induced by CX-4945, a Casein Kinase 2 Inhibitor, Enhances Apoptosis in Pancreatic Cancer Cell Lines. Pancreas 2017;46:575-81. [PMID: 28196025 DOI: 10.1097/MPA.0000000000000780] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
680 Lee S, Jang WJ, Choi B, Joo SH, Jeong CH. Comparative metabolomic analysis of HPAC cells following the acquisition of erlotinib resistance. Oncol Lett 2017;13:3437-44. [PMID: 28529573 DOI: 10.3892/ol.2017.5940] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
681 Hu H, Han T, Zhuo M, Wu LL, Yuan C, Wu L, Lei W, Jiao F, Wang LW. Elevated COX-2 Expression Promotes Angiogenesis Through EGFR/p38-MAPK/Sp1-Dependent Signalling in Pancreatic Cancer. Sci Rep 2017;7:470. [PMID: 28352075 DOI: 10.1038/s41598-017-00288-4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 6.2] [Reference Citation Analysis]
682 Knudsen ES, Vail P, Balaji U, Ngo H, Botros IW, Makarov V, Riaz N, Balachandran V, Leach S, Thompson DM. Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers. Clin Cancer Res. 2017;23:4429-4440. [PMID: 28348045 DOI: 10.1158/1078-0432.ccr-17-0162] [Cited by in Crossref: 113] [Cited by in F6Publishing: 118] [Article Influence: 18.8] [Reference Citation Analysis]
683 Hagiwara Y, Ohashi Y, Okusaka T, Ueno H, Ioka T, Boku N, Egawa S, Hatori T, Furuse J, Mizumoto K, Ohkawa S, Yamaguchi T, Yamao K, Funakoshi A, Cheng AL, Kihara K, Sato A, Tanaka M. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study. ESMO Open 2017;2:e000151. [PMID: 28761731 DOI: 10.1136/esmoopen-2016-000151] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
684 Chabu C, Li DM, Xu T. EGFR/ARF6 regulation of Hh signalling stimulates oncogenic Ras tumour overgrowth. Nat Commun 2017;8:14688. [PMID: 28281543 DOI: 10.1038/ncomms14688] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
685 Kudo D, Suto A, Hakamada K. The Development of a Novel Therapeutic Strategy to Target Hyaluronan in the Extracellular Matrix of Pancreatic Ductal Adenocarcinoma. Int J Mol Sci 2017;18:E600. [PMID: 28282922 DOI: 10.3390/ijms18030600] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
686 Ellenrieder V, König A, Seufferlein T. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma. Digestion 2016;94:44-9. [PMID: 27438590 DOI: 10.1159/000447739] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
687 Blaszak M, El-Masri M, Hirmiz K, Mathews J, Omar A, Elfiki T, Gupta R, Hamm C, Kanjeekal S, Kay A, Kulkarni S, Ghafoor A. Survival of patients with pancreatic cancer treated with varied modalities: A single-centre study. Mol Clin Oncol 2017;6:583-8. [PMID: 28413673 DOI: 10.3892/mco.2017.1179] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
688 Kipps E, Young K, Starling N. Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy. Ther Adv Med Oncol 2017;9:159-70. [PMID: 28344661 DOI: 10.1177/1758834016688816] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
689 Ottaiano A, Capozzi M, De Divitiis C, De Stefano A, Botti G, Avallone A, Tafuto S. Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials. Acta Oncol 2017;56:377-83. [PMID: 28256961 DOI: 10.1080/0284186X.2017.1288922] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
690 Saito T, Hirano K, Isayama H, Nakai Y, Saito K, Umefune G, Akiyama D, Watanabe T, Takagi K, Hamada T, Takahara N, Uchino R, Mizuno S, Kogure H, Matsubara S, Yamamoto N, Tada M, Koike K. The Role of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer: A Prospective Cohort Study. Pancreas 2017;46:341-6. [PMID: 28099252 DOI: 10.1097/MPA.0000000000000767] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
691 Hayashi H, Kohno T, Ueno H, Hiraoka N, Kondo S, Saito M, Shimada Y, Ichikawa H, Kato M, Shibata T, Morizane C, Sakamoto Y, Shimada K, Komatsu Y, Sakamoto N, Okusaka T. Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer. Pancreas 2017;46:335-40. [PMID: 28099251 DOI: 10.1097/MPA.0000000000000760] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 9.7] [Reference Citation Analysis]
692 Apisarnthanarax S, Chia-hsien Cheng J, Jabbour SK, Liauw SL, Murphy JD, Chang DT. Pancreatic, Rectal, and Liver Cancers: Out With the Old, In With the New. International Journal of Radiation Oncology*Biology*Physics 2017;97:643-650. [DOI: 10.1016/j.ijrobp.2016.09.021] [Reference Citation Analysis]
693 Panwar N, Song P, Yang C, Yong K, Tjin SC. An optofluidic approach for gold nanoprobes based-cancer theranostics. SPIE Proceedings 2017. [DOI: 10.1117/12.2251366] [Reference Citation Analysis]
694 Shindo Y, Hazama S, Suzuki N, Iguchi H, Uesugi K, Tanaka H, Aruga A, Hatori T, Ishizaki H, Umeda Y, Fujiwara T, Ikemoto T, Shimada M, Yoshimatsu K, Takenouchi H, Matsui H, Kanekiyo S, Iida M, Koki Y, Arima H, Furukawa H, Ueno T, Yoshino S, Fujita T, Kawakami Y, Nakamura Y, Oka M, Nagano H. Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. J Exp Clin Cancer Res 2017;36:36. [PMID: 28241889 DOI: 10.1186/s13046-017-0509-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
695 Smoot RL, Hallemeier CL, Mcwilliams RR, Truty MJ. Pancreas. TNM Online 2017. [DOI: 10.1002/9780471420194.tnmm60] [Reference Citation Analysis]
696 Kasuga A, Hamamoto Y, Takeuchi A, Kawasaki K, Suzuki T, Hirata K, Sukawa Y, Takaishi H, Kanai T. Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy. Cancer Chemother Pharmacol 2017;79:595-602. [PMID: 28236000 DOI: 10.1007/s00280-017-3263-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
697 Berndsen RH, Weiss A, Abdul UK, Wong TJ, Meraldi P, Griffioen AW, Dyson PJ, Nowak-Sliwinska P. Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity. Sci Rep 2017;7:43005. [PMID: 28223694 DOI: 10.1038/srep43005] [Cited by in Crossref: 81] [Cited by in F6Publishing: 83] [Article Influence: 13.5] [Reference Citation Analysis]
698 Lee HS, Chung MJ, Park JY, Bang S, Park SW, Kim HG, Noh MH, Lee SH, Kim YT, Kim HJ, Kim CD, Lee DK, Cho KB, Cho CM, Moon JH, Kim DU, Kang DH, Cheon YK, Choi HS, Kim TH, Kim JK, Moon J, Shin HJ, Song SY; Korean Society of Gastrointestinal Cancer. A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea. Medicine (Baltimore) 2017;96:e5702. [PMID: 28072706 DOI: 10.1097/MD.0000000000005702] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
699 Okusaka T, Miyakawa H, Fujii H, Nakamori S, Satoh T, Hamamoto Y, Ito T, Maguchi H, Matsumoto S, Ueno H, Ioka T, Boku N, Egawa S, Hatori T, Furuse J, Mizumoto K, Ohkawa S, Yamaguchi T, Yamao K, Funakoshi A, Chen JS, Cheng AL, Sato A, Ohashi Y, Tanaka M; GEST group. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer. J Cancer Res Clin Oncol 2017;143:1053-9. [PMID: 28210843 DOI: 10.1007/s00432-017-2349-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
700 Chen L, Chen C, Yen Y, Tam KW. Chemotherapy for advanced biliary tract carcinoma: A meta-analysis of randomized controlled trials. Medicine (Baltimore) 2016;95:e4584. [PMID: 27537589 DOI: 10.1097/MD.0000000000004584] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
701 Tabernero J, Kunzmann V, Scheithauer W, Reni M, Shiansong Li J, Ferrara S, Djazouli K. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial. Onco Targets Ther 2017;10:591-6. [PMID: 28203092 DOI: 10.2147/OTT.S124097] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
702 Patel GK, Khan MA, Bhardwaj A, Srivastava SK, Zubair H, Patton MC, Singh S, Khushman M, Singh AP. Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK. Br J Cancer. 2017;116:609-619. [PMID: 28152544 DOI: 10.1038/bjc.2017.18] [Cited by in Crossref: 161] [Cited by in F6Publishing: 170] [Article Influence: 26.8] [Reference Citation Analysis]
703 Thota R, Maitra A, Berlin JD. Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer? Pancreas 2017;46:143-50. [PMID: 28085753 DOI: 10.1097/MPA.0000000000000753] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
704 Lee HS, Park SB, Kim SA, Kwon SK, Cha H, Lee DY, Ro S, Cho JM, Song SY. A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance. Sci Rep 2017;7:41615. [PMID: 28134290 DOI: 10.1038/srep41615] [Cited by in Crossref: 46] [Cited by in F6Publishing: 52] [Article Influence: 7.7] [Reference Citation Analysis]
705 Słotwiński R, Słotwińska SM. Dysregulation of signaling pathways associated with innate antibacterial immunity in patients with pancreatic cancer. Cent Eur J Immunol 2016;41:404-18. [PMID: 28450804 DOI: 10.5114/ceji.2016.65140] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
706 Fasano M, Della Corte CM, Vicidomini G, Scotti V, Rambaldi PF, Fiorelli A, Accardo M, De Vita F, Santini M, Ciardiello F, Morgillo F. Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review. Oncol Lett 2016;12:4505-9. [PMID: 28105159 DOI: 10.3892/ol.2016.5279] [Reference Citation Analysis]
707 Ali R, Wendt MK. The paradoxical functions of EGFR during breast cancer progression. Signal Transduct Target Ther 2017;2:16042. [PMID: 28435746 DOI: 10.1038/sigtrans.2016.42] [Cited by in Crossref: 61] [Cited by in F6Publishing: 64] [Article Influence: 10.2] [Reference Citation Analysis]
708 Schneeweis C, Wirth M, Saur D, Reichert M, Schneider G. Oncogenic KRAS and the EGFR loop in pancreatic carcinogenesis-A connection to licensing nodes. Small GTPases 2018;9:457-64. [PMID: 27880072 DOI: 10.1080/21541248.2016.1262935] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
709 Kyrochristos ID, Glantzounis GK, Ziogas DE, Gizas I, Schizas D, Lykoudis EG, Felekouras E, Machairas A, Katsios C, Liakakos T, Cho WC, Roukos DH. From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers. Int J Mol Sci 2017;18:E180. [PMID: 28106782 DOI: 10.3390/ijms18010180] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
710 Ullenhag GJ, Mozaffari F, Broberg M, Mellstedt H, Liljefors M. Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer. PLoS One 2017;12:e0169736. [PMID: 28099502 DOI: 10.1371/journal.pone.0169736] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
711 Hashim YM, Vangveravong S, Sankpal NV, Binder PS, Liu J, Goedegebuure SP, Mach RH, Spitzer D, Hawkins WG. The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer. J Exp Clin Cancer Res 2017;36:14. [PMID: 28095907 DOI: 10.1186/s13046-016-0470-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
712 Ioka T, Komatsu Y, Mizuno N, Tsuji A, Ohkawa S, Tanaka M, Iguchi H, Ishiguro A, Kitano M, Satoh T, Yamaguchi T, Takeda K, Kida M, Eguchi K, Ito T, Munakata M, Itoi T, Furuse J, Hamada C, Sakata Y. Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer 2017;116:464-71. [PMID: 28081543 DOI: 10.1038/bjc.2016.436] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
713 Chen Z, Ramalingam S, Shin DM. Biological Principles and Clinical Application of EGFR Inhibitors in Cancer. The Molecular Basis of Human Cancer 2017. [DOI: 10.1007/978-1-59745-458-2_37] [Reference Citation Analysis]
714 Tridente G. Gefitinib. Adverse Events and Oncotargeted Kinase Inhibitors 2017. [DOI: 10.1016/b978-0-12-809400-6.00006-8] [Reference Citation Analysis]
715 Iovanna J, Bian B, Bigonnet M, Dusetti N. Differential Therapy Based on Tumor Heterogeneity in Pancreatic Cancer. Pancreatic Cancer 2017. [DOI: 10.1007/978-1-4939-6631-8_94-1] [Reference Citation Analysis]
716 Peretti U, Zanon S, Michele R. The personalized medicine for pancreatic ductal adenocarcinoma patients: The oncologist perspective. Endosc Ultrasound 2017;6:S66-8. [PMID: 29387692 DOI: 10.4103/eus.eus_62_17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
717 Chiang N, Chen L. Chemotherapy in the Management of Pancreatic Cancer. Pancreatic Cancer 2017. [DOI: 10.1007/978-3-662-47181-4_37] [Reference Citation Analysis]
718 Lim K. K-Ras. Cancer Therapeutic Targets 2017. [DOI: 10.1007/978-1-4419-0717-2_73] [Reference Citation Analysis]
719 Tsunoda T. Development of Hypoxia: Activated Cytotoxic Prodrug. Innovation of Diagnosis and Treatment for Pancreatic Cancer 2017. [DOI: 10.1007/978-981-10-2486-3_17] [Reference Citation Analysis]
720 Ooi M, Phan A, Nguyen NQ. Future role of endoscopic ultrasound in personalized management of pancreatic cancer. Endosc Ultrasound 2017;6:300-7. [PMID: 29063873 DOI: 10.4103/eus.eus_84_17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
721 Halloran CM, Oldfield FE, Neoptolemos JP. Chemotherapy and radiotherapy for pancreatic cancer. Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set 2017. [DOI: 10.1016/b978-0-323-34062-5.00068-6] [Reference Citation Analysis]
722 Dev R, Javle M. Palliative Management of Pancreatic Cancer. Pancreatic Cancer 2017. [DOI: 10.1007/978-1-4939-6631-8_33-3] [Reference Citation Analysis]
723 Hackert T, Wüsten L, Büchler MW. Anti-Angiogenics in Pancreatic Cancer Therapy. Tumor Angiogenesis 2017. [DOI: 10.1007/978-3-319-31215-6_18-1] [Reference Citation Analysis]
724 Mathis G. Palliative Onkologie – Möglichkeiten und Herausforderungen. Palliativmedizin 2017. [DOI: 10.1007/978-3-662-49039-6_6] [Reference Citation Analysis]
725 Suga T, Shimada M, Maekawa M, Suzuki H, Mori M, Okazaki T, Inoue A, Yamaguchi H, Mano N. A Rapid and Simple UHPLC-UV Method for Quantitative Determination of Erlotinib and Its Active Metabolite OSI-420 in Human Serum, and Its Application in a Non-Small Cell Lung Cancer Patient. CHROMATOGRAPHY 2017;38:95-100. [DOI: 10.15583/jpchrom.2017.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
726 Sclafani F, Cunningham D, Okines A, Ratnayake G, Chau I. Chemotherapy for Advanced Pancreatic Cancer. Pancreatic Cancer 2017. [DOI: 10.1007/978-1-4939-6631-8_37-3] [Reference Citation Analysis]
727 Miyata T, Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, Uemura S, Uesaka K. Pathological Complete Response after S-1 Therapy for an Unresectable Pancreatic Head Cancer with Liver Metastasis. Jpn J Gastroenterol Surg, Nihon Shokaki Geka Gakkai zasshi 2017;50:461-468. [DOI: 10.5833/jjgs.2016.0122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
728 Tridente G. Erlotinib. Adverse Events and Oncotargeted Kinase Inhibitors 2017. [DOI: 10.1016/b978-0-12-809400-6.00007-x] [Reference Citation Analysis]
729 Weiner LM, Wu C. EGFR, Immunology. Cancer Therapeutic Targets 2017. [DOI: 10.1007/978-1-4419-0717-2_27] [Reference Citation Analysis]
730 Williams M, Lomberk G, Urrutia R. EGFR (ErbB) Signaling Pathways in Pancreatic Cancer Pathogenesis. Pancreatic Cancer 2017. [DOI: 10.1007/978-1-4939-6631-8_15-2] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
731 Zhu SK. Role of precision medicine in pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2016; 24(36): 4752-4758 [DOI: 10.11569/wcjd.v24.i36.4752] [Reference Citation Analysis]
732 Buanes TA. Updated therapeutic outcome for patients with periampullary and pancreatic cancer related to recent translational research. World J Gastroenterol 2016; 22(48): 10502-10511 [PMID: 28082802 DOI: 10.3748/wjg.v22.i48.10502] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
733 Bossé D, Ng T, Ahmad C, Alfakeeh A, Alruzug I, Biagi J, Brierley J, Chaudhury P, Cleary S, Colwell B, Cripps C, Dawson LA, Dorreen M, Ferland E, Galiatsatos P, Girard S, Gray S, Halwani F, Kopek N, Mahmud A, Martel G, Robillard L, Samson B, Seal M, Siddiqui J, Sideris L, Snow S, Thirwell M, Vickers M, Goodwin R, Goel R, Hsu T, Tsvetkova E, Ward B, Asmis T. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016. Curr Oncol 2016;23:e605-14. [PMID: 28050151 DOI: 10.3747/co.23.3394] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
734 Suzuki N, Hazama S, Iguchi H, Uesugi K, Tanaka H, Hirakawa K, Aruga A, Hatori T, Ishizaki H, Umeda Y, Fujiwara T, Ikemoto T, Shimada M, Yoshimatsu K, Shimizu R, Hayashi H, Sakata K, Takenouchi H, Matsui H, Shindo Y, Iida M, Koki Y, Arima H, Furukawa H, Ueno T, Yoshino S, Nakamura Y, Oka M, Nagano H. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Cancer Sci 2017;108:73-80. [PMID: 27783849 DOI: 10.1111/cas.13113] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 5.7] [Reference Citation Analysis]
735 Moon do C, Lee HS, Lee YI, Chung MJ, Park JY, Park SW, Song SY, Chung JB, Bang S. Concomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer. Yonsei Med J 2016;57:1124-30. [PMID: 27401642 DOI: 10.3349/ymj.2016.57.5.1124] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
736 Khan MA, Srivastava SK, Bhardwaj A, Singh S, Arora S, Zubair H, Carter JE, Singh AP. Gemcitabine triggers angiogenesis-promoting molecular signals in pancreatic cancer cells: Therapeutic implications. Oncotarget 2015;6:39140-50. [PMID: 25970774 DOI: 10.18632/oncotarget.3784] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
737 Topham JT, Marra MA. Sequencing Strategies to Guide Decision Making in Cancer Treatment. PLoS Med 2016;13:e1002189. [PMID: 27923042 DOI: 10.1371/journal.pmed.1002189] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
738 Yang SH, Guo JC, Yeh KH, Tien YW, Cheng AL, Kuo SH. Association of radiotherapy with favorable prognosis in daily clinical practice for treatment of locally advanced and metastatic pancreatic cancer. J Gastroenterol Hepatol 2016;31:2004-12. [PMID: 27059987 DOI: 10.1111/jgh.13395] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
739 Sukharamwala P, Hennessey D, Wood T, Singh S, Ryan C, Rosemurgy A. Molecular profiles in foregut oncology. Cancer Genet 2016;209:537-53. [PMID: 27887938 DOI: 10.1016/j.cancergen.2016.09.008] [Reference Citation Analysis]
740 Bellon E, Gebauer F, Tachezy M, Izbicki JR, Bockhorn M. Pancreatic cancer and liver metastases: state of the art. Updates Surg 2016;68:247-51. [PMID: 27832445 DOI: 10.1007/s13304-016-0407-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
741 Gao Y, Zhu Y, Yuan Z. Circulating Tumor Cells and Circulating Tumor DNA Provide New Insights into Pancreatic Cancer. Int J Med Sci 2016;13:902-13. [PMID: 27994495 DOI: 10.7150/ijms.16734] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
742 Hanoun N, Gayral M, Pointreau A, Buscail L, Cordelier P. Initial Characterization of Integrase-Defective Lentiviral Vectors for Pancreatic Cancer Gene Therapy. Hum Gene Ther. 2016;27:184-192. [PMID: 26731312 DOI: 10.1089/hum.2015.151] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
743 Wang Z, Liu Y, Zhang Y, Shang Y, Gao Q. MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer. Oncotarget. 2016;7:4760-4769. [PMID: 26716894 DOI: 10.18632/oncotarget.6734] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 6.3] [Reference Citation Analysis]
744 Ahn DH, Krishna K, Blazer M, Reardon J, Wei L, Wu C, Ciombor KK, Noonan AM, Mikhail S, Bekaii-Saab T. A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis. Ther Adv Med Oncol. 2017;9:75-82. [PMID: 28203300 DOI: 10.1177/1758834016676011] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
745 Farrell JJ, Moughan J, Wong JL, Regine WF, Schaefer P, Benson AB 3rd, Macdonald JS, Liu X, Yen Y, Lai R, Zheng Z, Bepler G, Guha C, Elsaleh H. Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach. Pancreas 2016;45:1485-93. [PMID: 27748721 DOI: 10.1097/MPA.0000000000000710] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
746 Nowara E, Huszno J. Masitinib plus gemcitabine for personalized treatment of PDAC patients with overexpression of ACOX1. Expert Review of Precision Medicine and Drug Development 2016;1:479-485. [DOI: 10.1080/23808993.2016.1257911] [Reference Citation Analysis]
747 Karjalainen E, Repasky GA. Molecular Changes During Acute Myeloid Leukemia (AML) Evolution and Identification of Novel Treatment Strategies Through Molecular Stratification. Prog Mol Biol Transl Sci 2016;144:383-436. [PMID: 27865463 DOI: 10.1016/bs.pmbts.2016.09.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
748 Vogel A, Römmler-Zehrer J, Li JS, McGovern D, Romano A, Stahl M. Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT). BMC Cancer 2016;16:817. [PMID: 27769210 DOI: 10.1186/s12885-016-2798-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
749 Polireddy K, Dong R, McDonald PR, Wang T, Luke B, Chen P, Broward M, Roy A, Chen Q. Targeting Epithelial-Mesenchymal Transition for Identification of Inhibitors for Pancreatic Cancer Cell Invasion and Tumor Spheres Formation. PLoS One 2016;11:e0164811. [PMID: 27764163 DOI: 10.1371/journal.pone.0164811] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
750 Vijayvergia N, Cohen SJ. Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer? J Gastrointest Oncol 2016;7:727-37. [PMID: 27747087 DOI: 10.21037/jgo.2016.08.01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
751 Budzyńska A, Nowakowska-Duława E, Marek T, Hartleb M. Comparison of patency and cost-effectiveness of self-expandable metal and plastic stents used for malignant biliary strictures: a Polish single-center study. Eur J Gastroenterol Hepatol 2016;28:1223-8. [PMID: 27455079 DOI: 10.1097/MEG.0000000000000699] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
752 Zhu AX, Kang YK, Rosmorduc O, Evans TR, Santoro A, Ross P, Gane E, Vogel A, Jeffers M, Meinhardt G, Peña CE. Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial. Clin Cancer Res 2016;22:4870-9. [PMID: 27220960 DOI: 10.1158/1078-0432.CCR-15-2883] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
753 Jorand R, Biswas S, Wakefield DL, Tobin SJ, Golfetto O, Hilton K, Ko M, Ramos JW, Small AR, Chu P, Singh G, Jovanovic-Talisman T. Molecular signatures of mu opioid receptor and somatostatin receptor 2 in pancreatic cancer. Mol Biol Cell 2016;27:3659-72. [PMID: 27682590 DOI: 10.1091/mbc.E16-06-0427] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
754 Akinleye A, Iragavarapu C, Furqan M, Cang S, Liu D. Novel agents for advanced pancreatic cancer. Oncotarget 2015;6:39521-37. [PMID: 26369833 DOI: 10.18632/oncotarget.3999] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
755 Varghese AM, Lowery MA, Yu KH, O'Reilly EM. Current management and future directions in metastatic pancreatic adenocarcinoma. Cancer 2016;122:3765-75. [PMID: 27649047 DOI: 10.1002/cncr.30342] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
756 Ocana A, Ethier JL, Díez-González L, Corrales-Sánchez V, Srikanthan A, Gascón-Escribano MJ, Templeton AJ, Vera-Badillo F, Seruga B, Niraula S, Pandiella A, Amir E. Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. Oncotarget 2015;6:39538-49. [PMID: 26446908 DOI: 10.18632/oncotarget.5946] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
757 Liu X, Pitarresi JR, Cuitiño MC, Kladney RD, Woelke SA, Sizemore GM, Nayak SG, Egriboz O, Schweickert PG, Yu L, Trela S, Schilling DJ, Halloran SK, Li M, Dutta S, Fernandez SA, Rosol TJ, Lesinski GB, Shakya R, Ludwig T, Konieczny SF, Leone G, Wu J, Ostrowski MC. Genetic ablation of Smoothened in pancreatic fibroblasts increases acinar-ductal metaplasia. Genes Dev 2016;30:1943-55. [PMID: 27633013 DOI: 10.1101/gad.283499.116] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 5.7] [Reference Citation Analysis]
758 Hao J, Yang X, Ding XL, Guo LM, Zhu CH, Ji W, Zhou T, Wu XZ. Paeoniflorin Potentiates the Inhibitory Effects of Erlotinib in Pancreatic Cancer Cell Lines by Reducing ErbB3 Phosphorylation. Sci Rep 2016;6:32809. [PMID: 27609096 DOI: 10.1038/srep32809] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
759 Muckenhuber A, Babitzki G, Thomas M, Hölzlwimmer G, Zajac M, Jesinghaus M, Bergmann F, Werner J, Stenzinger A, Weichert W. Profiling of cMET and HER Family Receptor Expression in Pancreatic Ductal Adenocarcinomas and Corresponding Lymph Node Metastasis to Assess Relevant Pathways for Targeted Therapies: Looking at the Soil Before Planting the Seed. Pancreas 2016;45:1167-74. [PMID: 26825865 DOI: 10.1097/MPA.0000000000000604] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
760 Saluja AK, Dudeja V, Banerjee S. Evolution of novel therapeutic options for pancreatic cancer. Curr Opin Gastroenterol 2016;32:401-7. [PMID: 27454027 DOI: 10.1097/MOG.0000000000000298] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
761 Yabar CS, Winter JM. Pancreatic Cancer: A Review. Gastroenterol Clin North Am 2016;45:429-45. [PMID: 27546841 DOI: 10.1016/j.gtc.2016.04.003] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 9.0] [Reference Citation Analysis]
762 Faloppi L, Bianconi M, Giampieri R, Sobrero A, Labianca R, Ferrari D, Barni S, Aitini E, Zaniboni A, Boni C, Caprioni F, Mosconi S, Fanello S, Berardi R, Bittoni A, Andrikou K, Cinquini M, Torri V, Scartozzi M, Cascinu S; Italian Group for the Study of Digestive Tract Cancer (GISCAD). The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. Oncotarget 2015;6:35087-94. [PMID: 26397228 DOI: 10.18632/oncotarget.5197] [Cited by in Crossref: 33] [Cited by in F6Publishing: 38] [Article Influence: 4.7] [Reference Citation Analysis]
763 Vickers MM, Lee C, Tu D, Wheatley-Price P, Parulekar W, Brundage MD, Moore MJ, Au H, O'Callaghan CJ, Jonker DJ, Ringash J, Goldstein D. Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3. Pancreatology 2016;16:1106-12. [PMID: 27600995 DOI: 10.1016/j.pan.2016.08.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
764 Rao CV, Janakiram NB, Madka V, Devarkonda V, Brewer M, Biddick L, Lightfoot S, Steele VE, Mohammed A. Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma. Oncotarget 2015;6:33290-305. [PMID: 26429877 DOI: 10.18632/oncotarget.5396] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
765 Lewis AR, Valle JW, McNamara MG. Pancreatic cancer: Are "liquid biopsies" ready for prime-time? World J Gastroenterol 2016; 22(32): 7175-7185 [PMID: 27621566 DOI: 10.3748/wjg.v22.i32.7175] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
766 Hsueh CT, Selim JH, Tsai JY, Hsueh CT. Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma. World J Gastroenterol 2016; 22(31): 7080-7090 [PMID: 27610018 DOI: 10.3748/wjg.v22.i31.7080] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
767 Caparello C, Meijer LL, Garajova I, Falcone A, Le Large TY, Funel N, Kazemier G, Peters GJ, Vasile E, Giovannetti E. FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. World J Gastroenterol 2016; 22(31): 6987-7005 [PMID: 27610011 DOI: 10.3748/wjg.v22.i31.6987] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 55] [Article Influence: 7.6] [Reference Citation Analysis]
768 Au M, Emeto TI, Power J, Vangaveti VN, Lai HC. Emerging Therapeutic Potential of Nanoparticles in Pancreatic Cancer: A Systematic Review of Clinical Trials. Biomedicines 2016;4:E20. [PMID: 28536387 DOI: 10.3390/biomedicines4030020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
769 Adiseshaiah PP, Crist RM, Hook SS, McNeil SE. Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat Rev Clin Oncol 2016;13:750-65. [PMID: 27531700 DOI: 10.1038/nrclinonc.2016.119] [Cited by in Crossref: 136] [Cited by in F6Publishing: 147] [Article Influence: 19.4] [Reference Citation Analysis]
770 Axtner J, Steele M, Kröz M, Spahn G, Matthes H, Schad F. Health services research of integrative oncology in palliative care of patients with advanced pancreatic cancer. BMC Cancer. 2016;16:579. [PMID: 27485618 DOI: 10.1186/s12885-016-2594-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
771 Bliss LA, Eskander MF, Kent TS, Watkins AA, de Geus SW, Storino A, Ng SC, Callery MP, Moser AJ, Tseng JF. Early surgical bypass versus endoscopic stent placement in pancreatic cancer. HPB (Oxford) 2016;18:671-7. [PMID: 27485061 DOI: 10.1016/j.hpb.2016.05.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
772 Liu X, Yang X, Zhou G, Chen Y, Li C, Wang X. Gemcitabine-Based Regional Intra-Arterial Infusion Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma. Medicine (Baltimore) 2016;95:e3098. [PMID: 26986149 DOI: 10.1097/MD.0000000000003098] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
773 Nakamura T, Katagiri T, Sato S, Kushibiki T, Hontani K, Tsuchikawa T, Hirano S, Nakamura Y. Overexpression of C16orf74 is involved in aggressive pancreatic cancers. Oncotarget 2017;8:50460-75. [PMID: 28881575 DOI: 10.18632/oncotarget.10912] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [